UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscalyearendedDecember 31, 20182020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number:000-1609139


INNERSCOPE HEARING TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

INNERSCOPE HEARING TECHNOLOGIES, INC.Nevada46-3096516
(Exact name of registrant as specified in its charter)

Nevada46-3096516
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
2151 Professional Drive, Second Floor
Roseville, CA95661
(Address of principal executive offices)(Zip Code)

(833) 788-0506
(916) 218-4100
(Registrant’s telephone number, including area code)

Securities registered under Section 12(b) of the Act:None

Securities registered pursuant to Section 12(g) of the Act:Common Stock, $0.0001 par value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesNo

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YesNo

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or has for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YesNoNo

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YesNo

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer ☐Accelerated filer ☐

Non-accelerated filer

Smaller reporting company
(Do not check if a smaller reporting company)Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YesNo

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter. $4,752,400.quarter was $4,752,400 as of September 30, 2019

The number of shares outstanding of the registrant’s $0.0001 par value Common Stock as of April 15, 2019,of August 22, 2022, 2022, was 151,737,305 7,662,715,566shares.

 
 

 

Table of Contents

PART IPage
Item 1Business4
Item 1ARisk Factors106
Item 1BUnresolved Staff Comments2315
Item 2Properties2315
Item 3Legal Proceedings2416
Item 4Mine Safety Disclosures2416
PART II
Item 5Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities2417
Item 6Selected Financial Data2717
Item 7Management’s Discussion and Analysis of Financial Condition and Results of Operations2718
Item 7AQuantitative and Qualitative Disclosures About Market Risk3722
Item 8Financial Statements and Supplementary Data3722
Item 9Changes in and Disagreements with Accountants on Accounting and Financial Disclosure3722
Item 9AControls and Procedures3722
Item 9BOther Information3923
PART III
Item 10Directors, Executive Officers and Corporate Governance3924
Item 11Executive Compensation4326
Item 12Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters4427
Item 13Certain Relationships and Related Transactions, and Director Independence4528
Item 14Principal Accountant Fees and Services4628
PART IV
Item 15Exhibits and Financial Statement Schedules4728
Signatures5031

 2 

 

FORWARD-LOOKING STATEMENTS

 

This report contains forward-looking statements. The Securities and Exchange Commission (the “SEC”) encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This report and other written and oral statements that we make from time to time contain such forward-looking statements that set out anticipated results based on management’s plans and assumptions regarding future events or performance. We have tried, wherever possible, to identify such statements by using words such as “project”, “believe”, “anticipate”, “plan”, “expect”, “estimate”, “intend”, “should”, “would”, “could”, or “may”, or other such words, verbs in the future tense and words and phrases that convey similar meaning and uncertainty of future events or outcomes to identify these forward–looking statements. There are a number of important factors beyond our control that could cause actual results to differ materially from the results anticipated by these forward–looking statements. While we make these forward–looking statements based on various factors and using numerous assumptions, you have no assurance the factors and assumptions will prove to be materially accurate when the events they anticipate actually occur in the future. Factors that could cause our actual results of operations and financial condition to differ materially are discussed in greater detail under Item 1A, “Risk Factors” of this annual report on Form 10-K.

 

The forward–looking statements are based upon our beliefs and assumptions using information available at the time we make these statements. We caution you not to place undue reliance on our forward–looking statements as (i) these statements are neither predictions nor guaranties of future events or circumstances, and (ii) the assumptions, beliefs, expectations, forecasts and projections about future events may differ materially from actual results. We undertake no obligation to publicly update any forward–looking statement to reflect developments occurring after the date of this report.

 

 3 

 

PARTI

PART I

 

ITEM 1. BUSINESS.

 

Company Overview

 

InnerScope Hearing Technologies, Inc. (“InnerScope” or the “Company”) is a Nevada Corporation incorporated June 15, 2012, with its principal place of business in Roseville, California.

 

On June 20, 2012, InnerScope acquired InnerScope Advertising Agency, LLC (“ILLC”), a commonly owned entity, to provide advertising/marketing services to the hearing device industry in accordance with an Acquisition and Plan of Share Exchange with ILLC.

 

On November 1, 2013, InnerScope acquired Intela-Hear, LLC (“Intela-Hear”), a commonly owned entity, with an Acquisition and Plan of Share Exchange with Intela-Hear.

 

On August 25, 2017, the Company changed its name to InnerScope Hearing Technologies, Inc.to better reflect the Company’sCompany's current direction as a hearing health technology driven company that manufactures, develops, distributes, and sells numerous innovative hearing health-related products, hearing treatments, and hearing solutions direct to consumer (DTC) with a scalable business to business (B2B) solution and business to consumer (and B2C) solution. Recently, themodel. The Company began offering its own line of FDA (Food and Drug Administration)registered Hearing Aids and its“Hearable” “Hearable”, and “Wearable” Personal Sound Amplifier Products (PSAPs).On July 5, 2018, the Company signed a supplier agreement as a direct shipped vendor ("DSV") for Walmart.com. The Company has been accepted as a Walmart.com USA, LLC (a wholly-owned subsidiary of Wal-Mart Stores, Inc.) supplier and will sell its FDA-Registered Hearing Aids and its PSAP to Walmart.com as the retailer for their Direct-To-Consumer online retail sale.

 

The Company is a manufacturer and a distributor/retailer of Direct-to-Consumer ("DTC") FDA (Food and Drug Administration) registered hearing aids, personal sound amplifier products (PSAPs), hearing-related treatment therapies, and doctor-formulated dietary hearing supplements (“Hearing Products”). The Company's mission is to improve the quality of life of the 70 million people in North America and the 1.5 billion people worldwide who suffer from hearing impairment and/or hearing-related issues. The management team of InnerScope is a technology driven company with scalable Business to Business (“BTB”)applying decades of industry experience and Business to Consumer (“BTC”) solutions. The Company offers a BTB SaaS based Patient Management System (PMS) software program, designed to improve operations and communication with patients. InnerScope also offers a Buying Group experience for audiology practice, enabling owners to lower product costs and increase their margins. The Company will compete in the DTC (Direct-to-Consumer) marketsbelieves it is well-positioned with its own lineinnovative in-store point-of-sale Free Self-Check Hearing Screening Kiosks ("Hearing Kiosks") to directly benefit when the Over-the-Counter (OTC) Hearing Aid Act (the "OTC Hearing Aid Law") (see below “Proposed Rule for OTC Category for Hearing Aids”) becomes enacted (expected in 4th quarter of “Hearables”, and “Wearables”, including APPs on the iOS and Android markets. The company also has opened 5 retail2022) (the OTC Hearing Aid Law allows OTC hearing device clinics andplans onusing management’s unique and successful talents on acquiring and opening additional audiological brick and mortar clinicsaids for mild to moderate hearing losses to be ownedsold in retail stores without a prescription or having to see a professional). The Hearing Kiosk is designed for the tens of millions of Americans with undetected/untreated mild-to-moderate hearing losses to treat themselves with the Company's easy, convenient, and operated by the company. affordable hearing products.

 

On September 10, 2018, the Company acquired all of the assets and assumed certain liabilities of Kathy L Amos Audiology (“Amos Audiology”) in exchange for 340,352 shares of common stock (the “Acquisition”). Amos Audiologyprovides retail hearing aid sales and audiological services in the East Bay area of San Francisco.

On November 22, 2021, the Company purchased Hearing Assist II, LLC. The Company acquired 100% interest in the entity for a total consideration of 591,209,963 common shares valued at $8,513,423 on the day of purchase. As part of the acquisition, the Company assumed assets in the amount of $15,713,000, consisting of trademarks, domains, customer lists, customer contracts, licenses, royalties, other contracts, and assumed liabilities in the amount of $7,199,678.

On September 30, 2021, the Company entered into an Asset Purchase agreement with iHear Medical, Inc. pursuant to which the Company received a number of intangible assets, equipment, customer database and inventory for total consideration of 400,000 preferred series C shares and a $1,000,000 convertible note, where preferred shares were valued at $666,667 on the day of purchase. As part of the acquisition, the Company assumed assets in the amount of $1,666,667, consisting of inventory, equipment, customer lists, patents and other technology-based intangibles.

 

We are dedicated to serving the retail hearing aid dispensing community and developing a program to contribute to various hearing aid focused charities.

 

InnerScope is an "emerging“emerging growth company"company” within the meaning of the federal securities laws. For as long as we are an emerging growth company, we will not be required to comply with the requirements that are applicable to other public companies that are not "emerging“emerging growth companies"companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, the reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and the exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We intend to take advantage of these reporting exemptions until we are no longer an emerging growth company.

 

InnerScope will continue to be an emerging growth company until the earliest to occuroccurrence of (1) the last day of the fiscal year during which we hadhave total annual gross revenues of at least $1 billion$1billion (as indexed for inflation), (2) the last day of the fiscal year following the fifth anniversary of the date of our initial public offering, (3)the date on which we have, during the previous three-year period, issued more than $1 billion in non-convertible debt and (4) the date on which we are deemed to be a “large accelerated filer,” as defined under the Securities Exchange Act of 1934, as amended (which we refer to as the “Exchange Act”).

 4 

 

InnerScope also qualifies as a “smaller reporting company” under Rule 12b-2 of the Securities Exchange Act of 1934, as amended, which is defined as a company with a public equity float of less than $75 million. To the extent that we remain a smaller reporting company at such time as we are no longer an emerging growth company, we will still have reduced disclosure requirements for our public filings, some of which are similar to those of an emerging growth company including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and the reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.

Our authorized capital stock currently consists of 490,000,00014,975,000,000 shares of common stock, and 25,000,000 shares of preferred stock. Our common stock is listed on The OTCQB under the symbol “INND.”

Our principal corporate headquarters areis located at 2151 Professional Drive, Second Floor, Roseville, CA. 95661. Our telephone number is (916) 218-4100. Our website address is www.innd.com. (The information contained on, or that can be accessed through, our website is not a part of this Annual Report on Form 10-K.)

 

Customers

Pursuant to a Marketing Agreement (cancelled August 5, 2016), the Company provided marketing programs to promote and sell hearing aid instruments and related devices to Moore Family Hearing Company (“MFHC”), an entity under common control, MFHC owned and operated retail hearing aid stores. Based on common control of MFHC and the Company, all transactions with MFHC are classified as related party transactions. The Company has offset the accounts receivable owed from MFHC for expenses of the Company that have been paid by MFHC. As a result of these payments, in addition to MFHC’s payments to the Company through December 31, 2016, the balance due to MFHC as of December 31, 2018, and 2017, was $22,548, which is included in Accounts payable, related party, on the consolidated balance sheet included herein.

In September 2016, the officers and directors of the Company formed a California Limited Liability Company (“LLC1”), for the purpose of acquiring commercial real estate and other business activities.On December 24, 2016, LLC1 acquired two retail stores from the buyer of the MFHC stores. On March 1, 2017, the Company entered into a twelve-month Marketing Agreement with each of the stores to provide telemarketing and design and marketing services for $2,500 per month per store, resulting in $60,000 and $50,000, respectively for the years ended December 31, 2018, and 2017. Additionally, for the years ended December 31, 2018, the Company invoiced LLC1 $20,226 for the Company’s production, printing and mailing services and $1,793 for sale of products. As of December 31, 2018, and December 31, 2017, LLC1 owes the Company $145,505 and $73,996, respectively.

On August 5, 2016, the Company along with Mark Moore (“Mark”, the Company’s Chairman of the Board), Matthew Moore (“Matthew”, the Company’s Chief Executive Officer) and Kim Moore (“Kim”, the Company’s Chief Financial Officer) entered into a Store Expansion Consulting Agreement (the “Expansion Agreement”) with a third party (the “Client”). Mark, Matthew and Kim are herein referred to collectively as the “Moores”. Pursuant to the Expansion Agreement, the Company and the Moores were responsible for all physical plant and marketing details for the Client’s new store openings during the initial term of six-months. The Expansion Agreement was cancelled on January 6, 2017. The Client has decided to do their own marketing in-house and eliminate this out-sourced contract and decided to open only one location and delay the opening of any other new stores.  For the year ended December 31, 2017, the Company recognized $100,000 of income for the one new store, opened in January 2017, and $160,000 in other income, net, for payments received for the Expansion Agreement pursuant to the cancellation. The Client also paid an additional $30,000 for the cancellation of the Store Expansion Agreement and a marketing agreement.

On August 5, 2016, the Company and the Moores also entered into a Consulting Agreement (the “Consulting Agreement”) with the same Client as the store Expansion Agreement. Under the Consulting Agreement, including the Non-Compete provision covering a ten-mile radius of any retail store, the Company and the Moores were to provide unlimited licensing of the Intela-Hear brand name, exclusive access to the Aware Aural Rehab Program within 10 miles of retail stores, exclusive territory of all services within 10 miles of retail stores and up to 40 hours per month of various consulting services. The Consulting Agreement continues until January 31, 2019, unless terminated for cause, as defined in the Consulting Agreement. On May 26, 2017, the Company and the Moores were named in an action filed by the Client, that included a demand that all monies paid pursuant to the Consulting Agreement be returned. On August 13, 2018, the Client, InnerScope and the Moores executed a Settlement Agreement.

5

Revenue GenerationBusiness Model

 

The Company's Hearing Products and its business model allow breaking through the persistent barriers that prevent access to effective hearing solutions. For example, the Company's recent acquisition of iHear Medical Inc., a DTC cloud-based hearing solution provider, gives access to over 40 patents and an FDA-registered manufacturing and R&D facility. In addition, the Company has begun to implementacquired HearingAssist, an industry encompassing revenue strategy, includingestablished leader in the current revenue model to other major sectors of the global hearing industry. The Company plans include generating revenues from 7 separate revenue streams. Each stream will generate revenue and be poised for growth, increasing the Company’s market penetration.

The 7 revenue streams are:

Patient Management System (PMS): a SaaS based software program which was created, designed and customized by and for audiologists, specifically to fill a much-needed clinical gap solved in other multidiscipline software programs. It allows audiological retail clinics to better manage their day-to-day operations through efficient clinical workflow, patient follow up, and logical organization of data.ThePMS software platform delivers a comprehensive business solution. Once the data is uploaded, the platform seamlessly integrates the needs of the audiologist, management, patient and marketing. The software also provides a link between an electronic medical record (EMR) system containing patient's medical history, all while seamlessly integrating the schedule and patient files of the clinics’ patient management platform. EMR systems are not designed for Audiology and the records are often not integrated. The Company’s PMS software solves that problem by linking the two platforms.

Buying Group:The Companywill create an exclusive Buying Group experience that management believes will permit hearing aid practices of all sizes to reduce their wholesale costs by aggregating their orders with other practices to obtain a lower per unit cost.

Direct-to-Consumer (DTC):The Company has begun the marketing and selling of products within the new emerging “Hearables” and “Wearables” markets in “Personal Sound Amplification Products” (PSAP’s) and the Over-the-Counter (OTC)direct-to-consumer hearing aid market created by the result of recently passed Congressional legislation, known as “The Hearing Aid Act of 2017”, which allows the purchase of hearing aids and related products without seeking a medical professional.The Company will continue to market and sell these products as well as invest in “Hearable” technology and has and will continue to create its own brands and technology in the PSAP and OTC hearing aids in the DTC markets.

APP Development:The Company plans on building apps for the iOS and Android markets that will be dedicated to serving the hearing impairment population around the world. The APPs will be developed to help the audiology and hearing aid retail practices that have joined the Buying Group or using theCompany’sPMS software, as well as APPs for the hearing-impaired consumer to use for a better hearing experience.

Advertising and Marketing: This division will be built on the Company’s current business and will include graphic artists, digital and print marketing experts, and telemarketers. This division will assist all divisions in helping to market and deployallproducts and services to practices and consumers, as well as assisting Buying Group members with advertising and marketing for their own practices. Whether the hearing aid dispensary is small, medium or large, we have previously shown an ability to increase the total revenue of our clients without increasing cost. There are over 14,000 retail hearing aid dispensing practices in the United States. The company operates in a highly competitive and growing industry. The proliferation of media channels, including the rapid development of interactive technologies and mediums, along with their integration within all offerings has fragmented consumer audiences, especially the 55+ age sector which is our clients’ primary targeted audience. These developments make it more complex for marketers to reach their target audiences in a cost-effective way, causing them to turn to marketing service providers for a customized mix of advertising and marketing communications services designed to make the best use of their total marketing expenditures. We provide a comprehensive range of services (including consulting services), grouped into four fundamental disciplines: advertising/marketing, customer relationship management, public relations and specialty communications.

Retail:The Companyplans to open a chain of Audiological and Hearing Aid Clinics throughout the United States and eventually abroad.

Research and Development (“R&D”): Management has been researching and developing products and solutions for the Business to Business (“BTB”) and Business to Consumer (“BTC”) hearing impaired markets for more than 3 decades. The R&D team which will be comprised of world renowned scientists, business professionals and industry leaders, will develop and deploy products.

6

Consulting Agreements

On August 9, 2018, the Company entered into a monthly Consulting Services Master Agreement (the “CSMA”), with a third party. The CSMA requires a two- month minimum and a 30- day termination notice. Pursuant to the CSMA, the Company is to compensate the consultant $12,500 per month by the issuancecustomer base of restricted shares of common stock, based on the average closing trading prices for the three days prior to each monthly payment.

On August 10, 2018, the Company entered into a one- year Consulting, Public Relations and Marketing Agreement (the “CPRM Agreement”),over 400,000. These acquisitions, combined with a third party, which can be cancelled by either partypartnership with Atlazo Inc., a 30- day notice to the other party. Pursuant to the terms of the CPTM Agreement the Company is to issue 100,000 shares of restricted common stock each month. The parties agreed to terminate the CPRM Agreement on October 23, 2018.

On August 15, 2018, the Company entered into a six-month Consulting Agreement (the “CA”), with a third party. Pursuant to the CA, the Company agreed to issue 2,500,000 shares of restricted common stock to the consultant.

On October 3, 2018, the Company entered into a Manufacturing Design and Marketing Agreement (the “Agreement”) with Zounds Hearing, Inc. a Delaware corporation (“Zounds”), whereby, Zounds as the Subcontractorsemiconductor innovator for next-generation AI smart devices, will provide design, technology, manufacturing and supply chain services toallow the Company to enabletake the Company to manufacture comparablelead position in the direct-to-consumer hearing aidssolutions market by selling innovated proprietary advanced hearing products through Walmart and related components and accessories to be sold under the Company’s exclusive brand names (the “Manufacturer’s Products”) through the Company’s various marketing and distribution channels. The Company will pay Zounds One Million ($1,000,000) (the “Technology Access Fee”). The Technology Access Fee, as amended will be paid in eight (8) installments of $75,000 each, in four- week intervals until $600,000 is paid and $400,000 is to be paid as Product Surcharges based on $200 per unit manufactured for up to the first 2,000 units. Once $400,000 of Product Surcharges are paid said per unit surcharge will be discontinued. As of December 31, 2018, the Company has paid $183,200 towards the Technology Access Fee and as of December 31, 2018, $816.800 is including in accounts payable and accrued expenses.other major Big Box retailers.

 

On October 10, 2018,The Company's full line of FDA-Registered Hearing Aids, PSAPs and Hearing Health products (“Hearing Products”) are currently available through multiple retail/wholesale channels: Walmart, Walmart.com, Walmart Canada, RiteAid.com, BestBuy.com, Amazon.com, Giant Eagle, Hy-Vee, Hartig Drug, Food City, and Cardinal Health dba RGH Enterprises Inc., which provides the Company executed an engagement letterCompany's products to FSAStore.com, HSAStore.com, and WellDeservedHealth.com. In addition, the Company's Hearing Products will soon be available with The Crone Law Group (“Crone”). Crone will provide certain SEC filing servicesmore major retailers and pharmacy chains for a fee of $2,500 per month. Additionally, the Company has agreed to issue Crone 500,000 shares of common stock. The Company valued the shares at $36,400, based on the market price of the common stock on the date of the agreement,in-store and is included in professional fees, as stock- based compensation for the year ended December 31, 2108.online purchases.

 

On October 31, 2018, the Company entered into a three-year Joint Development Agreement (the “JD Agreement”) and an Exclusive Distribution Agreement (the “ED Agreement”) with Erchonia Corporation (“Erchonia”). As part of the JD Agreement, the Company and Erchonia will conduct FDA clinical research and trials for the purposes of obtaining 510k FDA Clearances for devices, technologies, methods and techniques used in the treatment of hearing relating conditions and disorders such as Tinnitus, Sensorineural hearing Loss, dizziness and other disorders. The agreements give the Company the exclusive worldwide rights for all designs and any newly developed Erchonia 3LT lasers and related technologies and gives the Company the rights to license and distribute such products worldwide. Pursuant to the JD Agreement, the Company has agreed to issue 1,000,000 shares of common stock. The Company valued to the common stock to be issued at $60,000, based on the market price of the common stock on the date of the JD Agreement, to be amortized over the three-year term.

On December 7, 2018, the Company entered into a one- year consulting agreement (the “Media Consulting Agreement”) with a third- party consultant (the “Consultant”). The Consultant will provide communication and broadcast services, as well as strategic planning services. Pursuant to the Media Consulting Agreement, the Company has agreed to issue the Consultant 3,125,000 shares of restricted common stock. On December 7, 2018, the Company recorded 3,125,000 shares of common stock to be issued. The company valued the common stock to be issued at $125,000 based on the market price of the common stock on the date of the Media Consulting Agreement, to be amortized over the term of the agreement. The Company amortized $7,639 for the year ended December 31, 2018, and is included in Professional fees on the consolidated Statement of operations. As of December 31, 2018, there remains $117,361 of deferred stock compensation on the consolidated balance sheet, to be amortized in 2019.

7

On April 3, 2017, the Company entered into a one (1) year Financial Consulting Agreement (the “FC Agreement”), with a Consultant (the “FC Consultant”). Pursuant to the FC Agreement, the FC Consultant will assist the Company in its’ accounting and public company filing requirements and compliance. The Company has agreed to compensate the FC Consultant $4,500 per month and to issue 333,334 shares of restricted common stock of the Company. The Company valued the shares at $0.30 per share (the market price of the common stock on the date of the agreement) and will amortize the cost over the one-year life of the agreement, accordingly, the Company recorded stock compensation expense of $25,000 and $75,000 for the years ended December 31, 2018, and 2017, respectively., and there remains a $25,000 balance of deferred stock compensation (in the equity section of the balance sheet herein) that will be amortized over the remaining term of the agreement. The FC Consultant was previously providing services for the Company at the time of the Agreement but is not affiliated with the Company or its management.. For each of the years ended December 31, 2018, and 2017, the Company expensed fees to the FC Consultant of $54,000.

Effective December 1, 2017, the Company entered into a one-year Marketing Services Agreement (the “MSA”), with a third party. Pursuant to the terms of the MSA, the Company will receive consulting and advisory services regarding the implementation of marketing programs, including the design and creation of commercial websites and commercialization of products through social media or other marketing methods. The Company will pay consideration for the services of $5,000 cash and $5,000 of common stock each month. The Company will issue the number of shares of common stock equal to a twenty-five percent (25%) discount to the lowest closing price of the common stock for the five (5) last trading days of the common stock for that month. The parties agreed to terminate the services and contract effective June 30, 2018. For the year ended December 31, 2018, the Company recorded $30,000 of consulting expense and recorded $38,512 of stock-based compensation expense (pursuant to the terms of the MSA) from the issuance of 925,130 shares of common stock. On February 27, 2018, the Company issued 102,564 shares of common stock that were previously recorded as common stock to be issued.as of December 31, 2017.

On December 1, 2017, the Company entered into a three-month Consulting and Marketing Agreement (the “CMA”) with a third party. Pursuant to the terms of the CMA the Company compensated the third-party $15,000 per month in consideration for consulting services related to development of business plans, corporate strategy and marketing.

On December 8, 2017, the Company entered in a month to month contract regarding investor relation services with a third-party for $3,600 per month beginning January 1, 2018.

On August 5, 2016, the Company along with the Expansion Agreement as discussed above. Pursuant to the Expansion Agreement, the Company and the Moores were responsible for all physical plant and marketing details for new store openings during the initial term of six-months. The Expansion Agreement was cancelled on January 6, 2017. The Company’s client has decidedto do their own marketing in-house and eliminate this out-sourced contract and has decided to delay the opening of any new stores. For the year ending December 31, 2017, the Company has received and recognized $160,000 in other income, net, for payments received for the cancellation of the Expansion Agreement.

Also, on August 5, 2016, the Company and the Moores entered into a Consulting Agreement as discussed above with the same party as the store Expansion Agreement. On May 26, 2017, a complaint (the “Complaint”) was filed against the Company and the Moores, which includes a request for rescission of the Consulting Agreement. The Company filed a countersuit against this third party for breach of contract so that it may recover the amounts owed under the Consulting Agreement, however, effective January 1, 2017, the Company had not recognized revenue from the Consulting Agreement, and accordingly, $847,223 was classified as deferred revenue on the December 31, 2017, consolidated balance sheets presented herein. On August 13, 2018, the client, the Company and the Moores signed a Settlement Agreement, whereby, the Company received $450,000 andboth parties dismissing all claims against the other party with prejudice. Accordingly, the Company recognized Other income of $1,297,223 for the year ended December 31, 2018, comprised of the deferred revenues for amounts previously received and the $450,000 settlement amount.

8

Competition

 

We have numerous direct, indirect and partial competitors, many of which have valuable industry relationships and access to greater resources than we do. There is no assurance that we will be able to provide services that will be competitive in the marketplace, and even if competitive, that we will be able to earn a profit.

 

The numerous types of direct or indirect competitors that exist in the market today include, but may not be limited to, sales and marketing firms, marketing consultants, design services, ad agencies, media buying firms, internet marketing firms, online social media firms and others: Key competitors include Chicago Advertising & Marketing (CAM), a leader in direct marketing for the Hearing Aid Industry since 1995, Beeman Marketing, a marketing firm specializing in hearing care practitioners and audiologists since 2004, and Nutshell Marketing, a high quality direct response marketing firm specialized in targeting 55 and older age group.

The internet is fast becoming a major factor in the distribution of hearing aids inaids. In the U.S. Numerous smallnumerous companies are on the internet advertising hearing aids forat inexpensive prices. We compete directly with these internet companies which are similar to our business model, and to include Listen Lively, Audicus, and Eargo. In addition, the cheapest price,hearing device industry is controlled by 5 global manufacturers. These manufacturers are GN Store Nord, Sonova, Starkey Hearing Technologies, William Demant and WS Audiology, all of which have established products and substantially greater financial, sales and marketing, manufacturing and development resources than we possess. We also compete against traditional brick and mortar retail hearing clinics which primarily sells the largest5 global manufacturers products.

Intellectual Property

With our asset purchase of iHear Medical Inc. we acquired access rights and license to over 40 U.S. patents for hearing aid manufacturer, Sonova, which owns HearingPlanet, is most prominent among these online offerings. However, internet sales still requiretechnology. This includes 100% ownership to the participation of a local practitioner for testing and fitting. This limitsonly FDA-Cleared in-home hearing test, called the widespread geographic appeal of internet sales.

Our Buying Group plan faces competition from major retail distributors and/or networks, as there is presently rapid growth of manufacturer-owned retail stores. Major consolidation has taken place in the US market by the hearing aid manufacturers in the last few years, with almost every manufacturer participating in buying out other smaller manufacturers, resulting in many different brand labels controlled under the same parent company umbrella. This consolidation has allowed the manufacturers to increase and control more of their distribution by offering different levels in their product lines throughout their different brands.  This has also allowed the manufacturers to implement different price strategies for the same technology throughout their brands.  This consolidation has not only increased their market share but also increased their profit margins.

Technology and Development

We are equipped with three (3) G5 MacPros and one (1) iMac, which are up-to-date with the latest in software package from Adobe Creative Cloud and other graphic design software.iHearTest. We also utilize a large format printerhave numerous copyrights, trademarks, and a production color printer to handle all proofing needs. All design and client information is held on a cloud computing network, which allows all designers and customer relation associates to access all design and customer files from on-site and off-site, to improve productivity and decrease lag time. Files are encrypted and password protected to make sure files are securely stored.

Intellectual Property

We have copyrights on all materials that are created or modified by any designers, which includes all conceptual and final artwork. Over the years, we have developed proprietary processes in how we manage our marketing programs; these processes are not protected by any patents but, to the extent possible, are covered by non-disclosureinventions assignment agreements executed with clients, consultants and employees. In the future we may utilize the services of contract developers, consultants, and/or third party personnel. Our success may depend in part upon our ability to preserve our trade secrets, obtain and maintain patent protection for our technologies, products and processes, and operate without infringing upon the proprietary right of other parties. However, we may rely on certain proprietary technologies, trade secrets, and know-how that are not patentable. Although we may take action to protect our unpatented trade secrets andintellectual property rights. We have two provisional patents filed that may not result in issued patents. We cannot be certain that any of the steps we have taken will prevent the misappropriation of our intellectual property, particularly in foreign countries where the laws may not protect our proprietary information,rights in part, bythese countries as fully as in the use of confidentiality agreements with our employees, consultants and certain of our contractors, we cannot guarantee that:United States.

(a)these agreements will not be breached;

(b)we would have adequate remedies for any breach; or

(c)our proprietary trade secrets and know-how will not otherwise become known or be independently developed or discovered by competitors.

Government Regulation.

We cannot guarantee that our actions will be sufficient to prevent imitation or duplication of either our products or services by others or prevent others from claiming violations of their trade secrets and proprietary rights.

9

Government Regulation.

We are subject to a limited variety of local, state, and federal regulations. Some of our products for example are registered with the FDA. U.S. Food and Drug Administration (the “FDA”), which regulates, among other things, the research, development, testing, design, manufacturing, approval, labeling, storage, recordkeeping, advertising, promotion and marketing, distribution, post approval monitoring and reporting and import and export of medical devices in the United States to assure the safety and effectiveness of medical products for their intended use. The U.S. Federal Trade Commission (the “FTC”) also regulates the advertising of our products in the United States. Further, we are subject to laws directed at preventing fraud and abuse, which subject our sales and marketing, training, and other practices to government scrutiny.

While we believe that our operations are in compliance with all applicable regulations, there can be no assurances that from time to time -to-time unintentional violations of such regulations will not occur. We are also subject to federal, state and local laws and regulation applied to businesses, such as payroll taxes on the state and federal levels. Our current business requires that we comply with state corporate filings, city or county business license and the necessary business liability insurance. The requirements of these regulations are minimal and do not cause any undue burden.

 

5

Internet

However, internet access and online services are not subject to direct regulation in the United States. Changes in the laws and regulations relating to the telecommunications and media industry, however, could impact our business. For example, the Federal Communications Commission could begin to regulate the Internet and online service industry, which could result in increased costs for us. The laws and regulations applicable to the Internet and to our services are evolving and unclear and could damage our business. There are currently few laws or regulations directly applicable to access to, or commerce on, the Internet. Due to the increasing popularity and use of the Internet, it is possible that laws and regulations may be adopted, covering issues such as user privacy, defamation, pricing, taxation, content regulation, quality of products and services, and intellectual property ownership and infringement. Such legislation could expose us to substantial liability as well as dampen the growth in use of the Internet, decrease the acceptance of the Internet as a communications and commercial medium, or require us to incur significant expenses in complying with any new regulations.

 

Regulation by the FDA

The FDA classifies hearing aids hearing aids as medical devices. In the United States, the Federal Food, Drug, and Cosmetic Act (the “FDCA”), as well as FDA regulations and other federal and state statutes and regulations, govern, among other things, medical device design and development, preclinical and clinical testing, device safety, premarket clearance and approval, establishment registration and device listing, manufacturing, labeling, storage, record-keeping, advertising and promotion, sales and distribution, export and import, recalls and field safety corrective actions, and post-market surveillance, including complaint handling and medical device reporting of adverse events.

We currently market and in compliance with the FDA regulations for our hearing aid products.

Proposed Rule for OTC Category for Hearing Aids

The FDA Reauthorization Act of 2017 (“FDARA”), which was signed into law on August 18, 2017 (the “OTC Hearing Aid Act”) created a new category of over-the-counter (“OTC”) hearing aids that are intended to be available without supervision, prescription, or other order, involvement or intervention of a licensed practitioner. The language in FDARA is not self-implementing, which means that the OTC hearing aid category does not exist until there is effective regulation. On October 20, 2021, the FDA published a notice of proposed rulemaking to establish new regulatory categories for OTC and prescription hearing aids, among other things (the “Proposed Rule”). Under FDARA, the OTC hearing aid controls that are the subject of the rulemaking, if finalized, would preempt any state or local requirement specifically related to hearing products that would restrict or interfere with commercial activity involving OTC hearing aids. The comment period on the Proposed Rule, in which we participated in support of the Proposed Rule, ended on January 18, 2022, after which the FDA will review the comments. It is not clear whether the FDA will publish a final rule (the “Final Rule”), and whether the Final Rule will differ significantly from the Proposed Rule. However, if the FDA publishes a Final Rule, it would become effective 60 days after publication.

Under the Proposed Rule, devices that require 510(k) clearance to be compliant with the rule requirements would need to be cleared by the effective date of the Final Rule in order to continue to be marketed. For all other currently marketed devices, the proposed compliance date is 180 days after the effective date of the Final Rule (240 days after the publication of the Final Rule). Hearing aids under existing regulations at 21 CFR 874.330 and 874.3305, both of which are exempt from 510(k) premarket review.

Debt and Recent Events

 

Capital Raising

During the year ended 20182020 and through April 15, 2019,July 30, 2022, we incurred an aggregate of $1,961,133 and $1,296,003$300,117 of convertible indebtedness, respectively, at variable conversion rates. An aggregate of $1,277.108 and $2,337,436$3,286,270 was outstanding as of December 31, 2018 and April 15, 2019, respectively,2020, convertible into approximately 75,600,0004,650,000,000 shares of our common stock as of the date hereof. All of these financings were private transactions with accredited investors pursuant to Regulation D of Rule 506 or other exemptions from the registration requirements of the Securities Act.

 

Retail Establishments

Our retail establishment presence has grown significantly during late 2018 and early 2019. Since September 2018 through the date of filing of this Report we opened and entered into property leases for, five new retail clinic facilities. Additional detailed information relating to these facilities is provided in our “Description of Properties” section below.

Employees

 

As of March 31, 2019,June 24, 2022 we have 1924 full-time employees.

 

 

ITEM 1A – RISK FACTORS

 

You should carefully consider the risks described below, as well as other information provided to you in this document, including information in the section of this document entitled “Forward-Looking Statements.” The risks and uncertainties described below are not the only ones facing the Company. If any of the following risks actually occur, the Company’s business, financial condition or results of operations could be materially adversely affected.

 

Investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. Our business, financial condition, and/or results of operation may be materially adversely affected by the nature and impact of these risks. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

 

 106 

 

Risks Related to Our Business and Our Industry

Our independent auditors have expressed substantial doubt about our ability to continue as a going concern.

We incurred a net losslosses of $4,585,117$4,953,692 and $1,913,332$7,924,339 for the years ending December 31, 2018,2020, and 2017,2019, respectively. Because of the operating losses, negative cash flows from operations and working capital deficit, in their report on our financial statements for the year ended December 31, 2018,2020, our independent auditors included an explanatory paragraph regarding their substantial doubt about our ability to continue as a going concern. We are dependent therefore in raising additional capital in order to fund our operations. We may continue to experience net operating losses in the foreseeable future. Our ability to continue as a going concern is subject to our ability to generate a profit and/or obtain necessary funding from outside sources, including obtaining additional funding from the sale of our securities, increasing sales, or obtaining loanloans from various financial institutions where possible. Our continued net operating losses increase the difficulty in meeting such goals and there can be no assurances that such methods will prove successful.

We are dependent on raising additional capital. If we are unable to raise additional capital, we may not be able to achieve our business plan and you could lose your investment.

We are dependent on raising outside capital to fill our operational and expansion needs. We currently raise this debt through private debt or equity financings, as well as obtainobtaining credit from vendors to be able to fully execute our business plan. Any additional capital raised through the sale of equity may dilute your ownership interest. We may not be able to raise additional funds on favorable terms, or at all. If we are unable to obtain additional funds or credit from our vendors, we will be unable to execute our business plan and you could lose your investment. Management estimates we will need approximately $2,500,000 to fully implement, execute, market and launch our plans of multiple revenue streams in 2019.2021. During 20192021 we raised approximately $1,073,000$3,074,00 by the issuance of $1,296,000 of convertible notes.

 

Our Directors and Officers hold 900,000 Shares of our Series B Preferred Shares which gives them voting control of the Company and therefore effective control of the Company.

 

As the holders of the Series B Preferred Stock, our current officers and directors ( the(the Moores) will have 1,000 votes per each share of the 900,000 shares of Series B Preferred that they own, constituting 900,000,000 votes, on any matter submitted to the holders of the common stock of the Company, effectively giving the holders voting control of the Company, as there are only 151,737,3053,628,422,042 shares of the Company’s common stock currently issued and outstanding. In addition to the voting power held via the Series B Preferred, our officers and directors are also the holderholders of 57,060,000 shares of the Company’s common stock representing 37.6%0.0157% of the issued and outstanding shares of the Company’s common stock. As a result of the issuance of the preferred, the holders total voting percentage, including their common stock, is now 91%99%. This leaves our outside shareholders with no control over our business and operations, and any investors in our Company should be aware of this risk.

 

Our management team has limited experience managing a public company, and regulatory compliance may divert its attention from the day-to-day management of our business.

 

Our management team has limited experience managing a public company, and regulatory compliance may divert its attention from the day-to-day management of our business. Some of the individuals who now constitute our management team have limited experience managing a publicly traded company and limited experience complying with the increasingly complex laws pertaining to public companies. Our management team may not successfully or efficiently manage our continued transition to a public company that will be subject to significant regulatory oversight and reporting obligations under the federal securities laws. In particular, these new obligations will require substantial attention from our senior management and could divert their attention away from the day-to-day management of our business, which could materially and adversely impact our business operations.

 

Sales concentrations for the year ended December 31, 20182020 and 2017.2019.

For the year ended December 31, 2108,2020, one customer accounted for 25.2%28% of our business and is a related party.business. For the year ended December 31, 2017, four2019, three customers accounted for approximately 75%11% of our business, of which one (18.3%), was a related party. In August 2016, we entered into a 30- month Consulting Agreement with an unaffiliated party, as well as a Store Expansion Agreement and Marketing Agreement. The Store Expansion Agreement and Marketing Agreement were subsequently cancelled. The unaffiliated party represented approximately 27.6% of our revenues for the year ended December 31, 2017.business.

11

 

A significant part of our business plan depends on marketing of our products and services, which may not be accepted in the marketplace.

Our industry is extremely competitive and we have yet to attain any significant market share. In order to achieve successful operations, we will depend on effective marketing to gain a significantly larger market share. We do not engage independent sales representatives. We do not employ a marketing agency. Employing a greater number of marketing personnel or a marketing agency would require greater financial resources than we currently possess. Furthermore, our ability to attract independent sales representatives may be limited without greater name recognition, an advertising campaign and market penetration. Unless we are able to address these limitations in our marketing capabilities, you may expect our revenues to be limited and we may have difficulty staying in business. And under such circumstances, our stock would not gain in value.

 

We operate in and plan to expand into extremely competitive environments, which will make it difficult for us to achieve market recognition and revenues.

We operate in an extremely competitive environment and the markets for our products and services are characterized by rapidly changing technologies, frequent new product introductions, short product life cycles and evolving industry standards. Our success depends, in substantial part, on the timely and successful introduction of our new products and services and thereafter upgrades of our products and services to comply with emerging industry standards and to address competing technological and product developments by our competitors. We may focus our resources on technologies that do not become widely accepted, are not timely released or are not commercially viable. In addition, our products may contain defects or errors that are detected only after deployment. If our products are not competitive or do not work properly, our business could suffer and our financial performance could be negatively impacted. You have no assurance that our new products and services, which we intend to be a significant part or our business, will be accepted in the marketplace. If our products and services do not achieve market acceptance, our revenues will be significantly below the level we anticipate.

7

 

We are an early-stage company with an unproven business model and our business may not become profitable.

 

We are an early-stage company with a limited operating history upon which you can evaluate our business. We have very limited historical financial data. As a result of these factors, the revenue and income potential of our business is unproven, and we have only a limited operating history upon which to base an evaluation of our current business and future prospects. Because of our limited operating history and because the health care industry is rapidly evolving, we have limited insight into trends that may emerge and affect our business. We may make errors in predicting and reacting to relevant business trends, which could harm our business. Early-stage companies in new and rapidly evolving markets such as ours frequently encounter risks, uncertainties, and difficulties, including those described in this section. We may not be able to successfully address any or all of these risks. Failure to adequately address such risks could cause our business, financial condition, results of operations and prospects to suffer.

 

Our revenues are highly susceptible to declines as a result of unfavorable economic conditions.

Economic downturns could affect the hearing aid industry more severely than other industries, and the recovery of the hearing aid industry could lag behind that of the economy generally. In the past, some clients have responded to weakening economic conditions by reducing their purchases of hearing aids in general and marketing budgets specifically, which include discretionary components that are easier to reduce in the short term than other operating expenses. This pattern may recur in the future. A decrease in our revenue could pose a challenge to our cash generation from operations.

 

12

Our financial condition could be adversely affected if our available liquidity is insufficient.

If our business is significantly adversely affected by further deterioration in the economic environment or otherwise, it could lead us to seek new or additional sources of liquidity to fund our needs. Currently, for a non-investment-grade company such as ours, the capital markets are challenging, with limited available financing and at higher costs than in recent years. There can be no guaranteeguarantees that we would be able to access any new sources of liquidity on commercially reasonable terms or at all.

 

We may lose or fail to attract and retain key employees and management personnel.

Our employees, including creative, research, media and account specialists, and their skills and relationships with clients, are among our most important assets. An important aspect of our competitiveness is our ability to attract and retain key employees and management personnel. Our ability to do so is influenced by a variety of factors, including the compensation we award, and could be adversely affected by our financial or market performance.

 

We currently have only a small management team and staff, which could limit our ability to effectively seize market opportunities and grow our business.

Our operations are subject to all of the risks inherent in a growing business enterprise, including the likelihood of operating losses. As a smaller company with a limited operating history, our success will depend, among other factors, upon how we manage the problems, expenses, difficulties, complications and delays frequently encountered in connection with the growth of a new business, products and channels of distribution, and current and future development. In addition, as a company with a limited operating history and only a small management team and staff to grow the business and manage the risks inherent in a growing business enterprise, these factors could limit our ability to effectively seize market opportunities and grow.

We are subject to regulations and other governmental scrutiny that could restrict our activities or negatively impact our revenues.

Our marketing sector is subject to government regulation and other governmental action, both domestic and foreign. There has been an increasing tendency on the part of advertisers and consumer groups to challenge advertising through legislation, regulation, the courts or otherwise. For example, challenges have been made in the courts on the grounds that the advertising is false and deceptive or injurious to public welfare. Through the years, there has been a continuing expansion of specific rules, prohibitions, media restrictions, labeling disclosures and warning requirements with respect to the advertising for certain products. Representatives within government bodies, both domestic and foreign, continue to initiate proposals to ban the advertising of specific products and to impose taxes on or deny deductions for advertising, which, if successful, may have an adverse effect on advertising expenditures and consequently our revenues.

 

We are be subject to the periodic reporting requirements of Section 15(d) of the Exchange Act that requires us to incur audit fees and legal fees in connection with the preparation of such reports. These additional costs could reduce or eliminate our ability to earn a profit.

 

We are subject to the periodic reporting requirements of Section 15(d) of the Exchange Act that requires us to incur audit fees and legal fees in connection with the preparation of such reports. These additional accounting, audit, legal, printing, public relations and other costs could reduce or eliminate our ability to earn a profit. We are required to file periodic reports with the SEC pursuant to the Exchange Act and the rules and regulations promulgated thereunder. In order to comply with these requirements, our independent registered public accounting firm will have to review our financial statements on a quarterly basis and audit our financial statements on an annual basis. Moreover, our legal counsel will have to review and assist in the preparation of such reports. The incurrence of such costs constitutes an expense to our operations and thus have a negative effect on our ability to meet our overhead requirements and earn a profit. We are also continually exposed to potential risks resulting from any new requirements under Section 404 of the Sarbanes-Oxley Act of 2002. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock, could drop significantly

 138 

 

If we experience significant fluctuations in our rate of anticipated growth and fail to balance our expenses with our revenue forecasts, our results could be harmed.

Due to our evolving business model, the unpredictability of new markets that we intend to enter, and the unpredictability of future general economic and financial market conditions, we may not be able to accurately forecast our rate of growth. We plan our expense levels and investment on estimates of future revenue and future anticipated rate of growth. As a result, we expect that our revenues, operating results and cash flows may fluctuate significantly on a quarterly basis

 

We may in the future be sued by third parties for alleged infringement of their proprietary rights.

The software and Internet industries are characterized by the existence of a large number of patents, trademarks and copyrights and by frequent litigation based on allegations of infringement or other violations of intellectual property rights. We may receive in the future communications from third parties claiming that we have infringed the intellectual property rights of others. We may in the future be sued by third parties for alleged infringement of their proprietary rights. Our technologies may not be able to withstand any third-party claims against their use. The outcome of any litigation is inherently uncertain. Any intellectual property claims, whether with or without merit, could be time-consuming and expensive to resolve, could divert management attention from executing our business plan and could require us to change our technology, change our business practices and/or pay monetary damages or enter into short- or long-term royalty or licensing agreements which may not be available in the future at the same terms or at all.

 

We rely on third-party computer hardware and software that may be difficult to replace or which could cause errors or failures of our service.

We will rely on computer hardware purchased or leased and software licensed from third parties in order to offer our proposed service, including database software from Oracle Corporation and an open source -source content management system. This hardware and software may not continue to be available at reasonable prices or on commercially reasonable terms, or at all. Any loss of the right to use any of this hardware or software could significantly increase our expenses and otherwise result in delays in the provisioning of our service until equivalent technology is either developed by us, or, if available, is identified, obtained and integrated, which could harm our business. Any errors or defects in third-party hardware or software could result in errors or a failure of our service which could harm our business.

Our business could be adversely affected if our customers are not satisfied with their purchase through us or the implementation and customization services provided by third party Service Providers.

Our business will depend on our ability to satisfy our potential customers. If a customer is not satisfied with the quality of the product or service, the customer's dissatisfaction could damage our ability to obtain additional or future orders from that customer. In addition, potential negative publicity related to our customer relationships, regardless of its accuracy, may further damage our business by affecting our ability to compete for new business with prospective customers.

 

We are dependent on our CEO and outsourced consultants, and the loss of one or more of these individuals could harm our business and prevent us from implementing our business plan in a timely manner.

Our success depends substantially upon the continued services of our executive officers and other key members of management, particularly our CEO, Matthew Moore. We do not maintain key person life insurance policies on our CEO. The loss of the services of our CEO could seriously harm our business.

 

Our CEO is also an Officer or a managing member of Moore Family Hearing Company Inc., Moore Holdings, LLC and Value Hearing, LLC, and we have entered into transactions with these entities.

14

Our future growth may be dependent, in part, on our distribution arrangements directly with retailers and regional retail accounts. If we are unable to establish and maintain these arrangements, our results of operations and financial condition could be adversely affected.

Our future growth may be dependent in part on our distribution arrangements directly with retailers and regional retail accounts. If we are unable to establish and maintain these arrangements, our results of operations and financial condition could be adversely affected. We currently have distribution arrangements with a few regional retail accounts to distribute our products directly through their venues; however, there are several risks associated with this distribution strategy. First, we do not have long-term agreements in place with any of these accounts and thus, the arrangements are terminable at any time by these retailers or us. Accordingly, we may not be able to maintain continuing relationships with any of these national accounts. A decision by any of these retailers, or any other large retail accounts we may obtain, to decrease the amount purchased from us or to cease carrying our products could have a material adverse effect on our reputation, financial condition or results of operations. In addition, we may not be able to establish additional distribution arrangements with other national retailers. In addition, our dependence on large regional retail chains may result in pressure on us to reduce our pricing to them or seek significant product discounts. In general, our margins are lower on our sales to these customers because of these pressures. Any increase in our costs for these retailers to carry our product, reduction in price, or demand for product discounts could have a material adverse effect on our profit margin.

 

9

Our ability to grow our business may depend on developing a positive brand reputation and member loyalty.

Establishing and maintaining a positive brand reputation and nurturing member loyalty is critical to attracting new customers. We expect to expend reasonable but limited resources to develop, maintain and enhance our brand in the near future. In addition, nurturing customer loyalty will depend on our ability to provide a high-quality, user experience. If we are unable to maintain and enhance our brand reputation and customer satisfaction, our ability to attract new customers will be harmed.

 

Investors may lose their entire investment if we fail to reach profitability.

 

We commenced business in 2006. We have no demonstrable operations record from which you can evaluate the business and its prospects. Our prospects must be considered in light of the risks, uncertainties, expenses and difficulties frequently encountered by companies in their early stages of development. We cannot guarantee that we will be successful in accomplishing our objectives. To date, we have incurred losses and will continue to do so in the foreseeable future. Investors should therefore be aware that they may lose their entire investment in the securities.

We have limited protection of our intellectual property.

Our business prospects do not rely upon company-owned patented technologies. Our business prospects will depend largely on our ability to service and support customers and deliver services and solutions. There can be no assurance that we will be able to adequately protect our trade secrets. In the event competitors independently develop or otherwise obtain access to our know-how, concepts or trade secrets, we may be adversely affected.

Litigation or legal proceedings could expose us to significant liabilities and damage our reputation.

Litigation or legal proceedings could expose us to significant liabilities and damage our reputation.

 

Litigation or legal proceedings could expose us to significant liabilities and damage our reputation.

15

We may become party to litigation claims and legal proceedings. Litigation involves significant risks, uncertainties and costs, including distracting of management’s attention away from our current business operations. We evaluate litigation claims and legal proceedings to assess the likelihood of unfavorable outcomes and to estimate, if possible, the amount of potential losses. Based on these assessments and estimates, we establish reserves and/or disclose the relevant litigation claims or legal proceedings, as appropriate. These assessments and estimates are based on the information available to management at the time and involve a significant amount of management judgment. We caution you that actual outcomes or losses may differ materially from those envisioned by our current assessments and estimates. Our policies and procedures require strict compliance by our employees and agents with all United States and local laws and regulations applicable to our business operations, including those prohibiting improper payments to government officials. Nonetheless, there can be no assurance that our policies and procedures will always ensure full compliance by our employees and agents with all applicable legal requirements. Improper conduct by our employees or agents could damage our reputation in the United States and internationally or lead to litigation or legal proceedings that could result in civil or criminal penalties, including substantial monetary fines, as well as disgorgement of profits.

 

Our business model is subject to change

We may elect from time to time to make pricing, service, hiring and marketing decisions that could increase our expenses, affect our revenues and impact our financial results. Moreover, because our expense levels in any given quarter are based, in part, on management’s expectations regarding future revenues, if revenues are below expectations, the effect on our operating results may be magnified by our inability to adjust spending in a timely manner to compensate for a shortfall in revenues. The extent to which expenses are not subsequently followed by increased revenues would harm our operating results and could seriously impair our business.

If we do not effectively manage changes in our business, these changes could place a significant strain on our management and operations.

To manage our growth successfully, we must continue to improve and expand our systems and infrastructure in a timely and efficient manner. Our controls, systems, procedures and resources may not be adequate to support a changing and growing company. If our management fails to respond effectively to changes and growth in our business, including acquisitions, this could have a material adverse effect on the Company’s business, financial condition, results of operations and future prospects.

 

As we attempt to expand our customer base through our marketing efforts, our new customers may use our products differently than our existing customers and, accordingly, our business model may not be as efficient at attracting and retaining new customers.

As we attempt to expand our customer base, our new customers may use our products differently than our existing customers. For example, a greater percentage of new customers may take advantage of the free trial period we offer but ultimately choose to use another form of marketing to reach their constituents. If our new customers are not as loyal as our existing customers, our attrition rate will increase and our customer referrals will decrease, which would have an adverse effect on our results of operations. In addition, as we seek to expand our customer base, we expect to increase our spending on sales and marketing activities in order to attract new customers, which will increase our operating costs. There can be no assurance that these sales and marketing efforts will be successful

 1610 

 

U.S. federal legislation entitled Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003 imposes certain obligations on the senders of commercial emails, which could minimize the effectiveness of our email marketing solution, and establishes financial penalties for non-compliance, which could increase the costs of our business.

 

Part of our marketing plan includes email advertising. U.S. federal legislation entitled Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003 imposes certain obligations on the senders of commercial emails, which could minimize the effectiveness of our email marketing solution, and establishes financial penalties for non-compliance, which could increase the costs of our business. In December 2003, Congress enacted Controlling the Assault of Non-SolicitedNon- Solicited Pornography and Marketing Act of 2003, or the CAN-SPAM Act, which establishes certain requirements for commercial email messages and specifies penalties for the transmission of commercial email messages that are intended to deceive the recipient as to source or content. The CAN-SPAM Act, among other things, obligates the sender of commercial emails to provide recipients with the ability to opt out of receiving future emails from the sender. In addition, some states have passed laws regulating commercial email practices that are significantly more punitive and difficult to comply with than the CAN-SPAM Act, particularly Utah and Michigan, which have enacted do-not-email registries listing minors who do not wish to receive unsolicited commercial email that markets certain covered content, such as adult or other harmful products. Some portions of these state laws may not be preempted by the CAN-SPAM Act. The ability of our customers’ constituents to opt out of receiving commercial emails may minimize the effectiveness of our email marketing solution. Moreover, non-compliance with the CAN-SPAM Act carries significant financial penalties. If we were found to be in violation of the CAN-SPAM Act, applicable state laws not preempted by the CAN-SPAM Act, or foreign laws regulating the distribution of commercial email, whether as a result of violations by our customers or if we were deemed to be directly subject to and in violation of these requirements, we could be required to pay penalties, which would adversely affect our financial performance and significantly harm our business. We also may be required to change one or more aspects of the way we operate our business, which could impair our ability to attract and retain customers or increase our operating costs.

 

Government regulation of the Internet, e-commerce and m-commerce is evolving, and unfavorable changes or failure by us to comply with these laws and regulations could substantially harm our business and results of operations.

Government regulation of the Internet, e-commerce and m-commerce is evolving, and unfavorable changes or failure by us to comply with these laws and regulations could substantially harm our business and results of operations. We are subject to general business regulations and laws as well as regulations and laws specifically governing the Internet, e-commerce and m-commerce in a number of jurisdictions around the world. Existing and future regulations and laws could impede the growth of the Internet, e-commerce, m-commerce or other online services. These regulations and laws may involve taxation, tariffs, privacy and data security, anti-spam, data protection, content, copyrights, distribution, electronic contracts, electronic communications and consumer protection. It is not clear how existing laws and regulations governing issues such as property ownership, sales and other taxes, libel and personal privacy apply to the Internet as the vast majority of these laws and regulations were adopted prior to the advent of the Internet and do not contemplate or address the unique issues raised by the Internet, e-commercee- commerce or m-commerce. It is possible that general business regulations and laws, or those specifically governing the Internet, e-commerce or m-commerce may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other rules or our practices. We cannot assure you that our practices have complied, comply or will comply fully with all such laws and regulations. Any failure, or perceived failure, by us to comply with any of these laws or regulations could result in damage to our reputation, a loss in business, and proceedings or actions against us by governmental entities or others. Any such proceeding or action could hurt our reputation, force us to spend significant resources in defense of these proceedings, distract our management, increase our costs of doing business, and cause consumers and retailers to decrease their use of our marketplace, and may result in the imposition of monetary liability. We may also be contractually liable to indemnify and hold harmless third parties from the costs or consequences of noncompliance with any such laws or regulations. In addition, it is possible that governments of one or more countries may seek to censor content available on our websites and mobile applications or may even attempt to completely block access to our marketplace. Adverse legal or regulatory developments could substantially harm our business. In particular, in the event that we are restricted, in whole or in part, from operating in one or more countries, our ability to retain or increase our customer base may be adversely affected and we may not be able to maintain or grow our net revenues as anticipatedanticipated.

 

17

Our business practices with respect to data and consumer protection could give rise to liabilities or reputational harm as a result of governmental regulation, legal requirements or industry standards relating to consumer privacy, data protection and consumer protection.

 

Our business practices with respect to data and consumer protection could give rise to liabilities or reputational harm as a result of governmental regulation, legal requirements or industry standards relating to consumer privacy, data protection and consumer protection. Federal, state and international laws and regulations govern the collection, use, retention, sharing and security of data that we collect. We strive to comply with all applicable laws, regulations, self-regulatory requirements and legal obligations relating to privacy, data protection and consumer protection, including those relating to the use of data for marketing purposes. It is possible, however, that these requirements may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other rules or our practices. We cannot assure you that our practices have complied, comply, or will comply fully with all such laws, regulations, requirements and obligations. Any failure, or perceived failure, by us to comply with federal, state or international laws or regulations, including laws and regulations regulating privacy, data security, marketing communications or consumer protection, or other policies, self-regulatory requirements or legal obligations could result in harm to our reputation, a loss in business, and proceedings or actions against us by governmental entities, consumers, retailers or others. We may also be contractually liable to indemnify and hold harmless performance marketing networks or other third parties from the costs or consequences of noncompliance with any laws, regulations, self-regulatory requirements or other legal obligations relating to privacy, data protection and consumer protection or any inadvertent or unauthorized use or disclosure of data that we store or handle as part of operating our business. Any such proceeding or action, and any related indemnification obligation, could hurt our reputation, force us to incur significant expenses in defense of these proceedings, distract our management, increase our costs of doing business and cause consumers and retailers to decrease their use of our marketplace, and may result in the imposition of monetary liability.

 

11

The Company may lose its status as an Emerging Growth Company.

 

Under Section 2(a)(19) of the Securities Act of 1933 and Section 3(a)(80) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), an Emerging Growth Company ("EGC") will lose its EGC status upon the earliest of:

 

the last day of the first fiscal year in which the company's annual gross revenues exceed $1 billion;
the date on which the company is deemed to be a large accelerated filer (as defined in Rule 12b-2 under the Exchange Act);
the date on which the company has, during the previous three-year period, issued more than $1 billion in non-convertible debt; and
the last day of the fiscal year in which the fifth anniversary of the company's first sale of equity securities pursuant to an effective registration statement occurs

Risks Related to Our Common Stock

 

We have raised capital through the use of convertible debt instruments that causes substantial dilution to our stockholders.

Because of the size of our Company and its status as a “penny stock” as well as the current economy and difficulties of companies our size experience in finding adequate sources of funding, we have been forced to raise capital through the issuance of convertible notes and other debt instruments. These debt instruments carry favorable conversion terms to their holders of up to 35% discounts to the market price of our common stock on conversion and in some cases provide for the immediate sale of our securities into the open market, which will cause dilution to our stockholders. As of December 31, 2018,2020, we had approximately $1,277,108$3,286,270 in convertible debt and potential convertible debt outstanding, with weighted average interest of approximately 8% and annual debt service of approximately $103,000.. The convertible debt is convertible into approximately 120,800,0004,650,854,286 shares of common stock at December 31, 2018.2020. This convertible debt balance as well as additional convertible debt we incur in the future will cause substantial dilution to our stockholders.

18

Because we are quoted on the OTCQBOTCPINK instead of an exchange or national quotation system, our investors may have a tougher time selling their stock or experience negative volatility on the market price of our common stock.

 

Our common stock is quoted on the OTCQB.OTCPINK. The OTCQBOTCPINK is often highly illiquid, in part because it does not have a national quotation system by which potential investors can follow the market price of shares except through information received and generated by a limited number of broker-dealers that make markets in particular stocks. There is a greater chance of volatility for securities that are quoted on the OTCQB as compared to a national exchange or quotation system. This volatility may be caused by a variety of factors, including the lack of readily available price quotations, the absence of consistent administrative supervision of bid and ask quotations, lower trading volume, and market conditions. Investors in our common stock may experience high fluctuations in the market price and volume of the trading market for our securities. These fluctuations, when they occur, have a negative effect on the market price for our securities. Accordingly, our stockholders may not be able to realize a fair price from their shares when they determine to sell them or may have to hold them for a substantial period of time until the market for our common stock improves.

Our stock is listed on the OTCQB,OTCPINK, if we fail to remain current on our reporting requirements, we could be removed from the OTCQBOTCPINK which would limit the ability of broker-dealers to sell our securities in the secondary market.

Companies trading on the OTCQB,OTCPINK, must be reporting issuers under Section 12 of the Securities Exchange Act of 1934, as amended, and must be current in their reports under Section 13, in order to maintain price quotation privileges on the OTCQB.OTCPINK. As a result, the market liquidity for our securities could be severely adversely affected by limiting the ability of broker-dealers to sell our securities and the ability of stockholders to sell their securities in the secondary market. In addition, we may be unable to get relisted on the OTCQB,OTCPINK, which may have an adverse material effect on the Company.

 

The Possible Sale of Shares of Common Stock by Our Selling Security Holders May Have a Significant Adverse Effect on the Market Price of Our Common Stock.

We have registered 906,000 shares of common stock with the U.S. Securities Exchange Commission. The security holders may sell some or all of their shares at anytime. In the event that the security holders sell some or all of their shares, the price of our common stock could decrease significantly.

 

Our ability to raise additional capital through the sale of our stock in a private placement may be harmed by these competing re-sales of our common stock by the selling security holders. Potential investors may not be interested in purchasing shares of our common stock if the selling security holders are selling their shares of common stock. The selling of stock by the security holders could be interpreted by potential investors as a lack of confidence in us and our ability to develop a stable market for our stock. The price of our common stock could fall if the selling security holders sell substantial amounts of our common stock. These sales may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate because the selling security holders may offer to sell their shares of common stock to potential investors for less than we do.

12

We are an ‘Emerging Growth Company” and we intend to take advantage of reduced disclosure and governance requirements applicable to Emerging Growth Companies, which could result in our stock being less attractive to investors.

We are an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012, which we refer to as the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We expect to take advantage of these reporting exemptions until we are no longer an emerging growth company, which in certain circumstances could be for up to five years.

 

19

The Company’s election to take advantage of the jobs act’s extended accounting transition period may not make its financial statements easily comparable to other companies.

Pursuant to the JOBS Act of 2012, as an emerging growth company the Company can elect to take advantage of the extended transition period for any new or revised accounting standards that may be issued by the Public Company Accounting Oversight Board ("PCAOB") or the Securities & Exchange Commission ("SEC"). The Company has elected take advantage of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the standard on the private company timeframe. This may make comparison of the Company's financial statements with any other public company which is not either an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible as possible different or revised standards may be used.

 

The Jobs Act will also allow the Company to postpone the date by which it must comply with certain laws and regulations intended to protect investors and reduce the amount of information provided in reports filed with the

 

The JOBS Act is intended to reduce the regulatory burden on “emerging growth companies. The Company meets the definition of an emerging growth company and so long as it qualifies as an “emerging growth company,” it will, among other things:

 

be exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that its independent registered public accounting firm provide an attestation report on the effectiveness of its internal control over financial reporting.
be exempt from the “say on pay” provisions (requiring a non-binding shareholder vote to approve compensation of certain executive officers) and the “say on golden parachute” provisions (requiring a non-binding shareholder vote to approve golden parachute arrangements for certain executive officers in connection with mergers and certain other business combinations) of the Dodd-Frank Act and certain disclosure requirements of the Dodd-Frank Act relating to compensation of its chief executive officer;
be permitted to omit the detailed compensation discussion and analysis from proxy statements and reports filed under the Securities Exchange Act of 1934 and instead provide a reduced level of disclosure concerning executive compensation; and
be exempt from any rules that may be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor’s report on the financial statements

The Company currently intends to take advantage of some or all of the reduced regulatory and reporting requirements that will be available to it so long as it qualifies as an “emerging growth company”.

 

As long as the Company qualifies as an Emerging Growth Company, the Company’s independent registered public accounting firm will not be required to attest to the effectiveness of the company’s internal control over financial reporting.

Because the Company has elected to take advantage of the extended time periods for compliance with new or revised accounting standards provided for under Section 102(b) of the JOBS Act, among other things, this means that the Company's independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of the Company's internal control over financial reporting so long as it qualifies as an emerging growth company, which may increase the risk that weaknesses or deficiencies in the internal control over financial reporting go undetected. Likewise, so long as it qualifies as an emerging growth company, the Company may elect not to provide certain information, including certain financial information and certain information regarding compensation of executive officers that would otherwise have been required to provide in filings with the SEC, which may make it more difficult for investors and securities analysts to evaluate the Company. As a result, investor confidence in the Company and the market price of its common stock may be adversely affected.

 

 2013 

 

The Penny Stock Rules Could Restrict the Ability of Broker-Dealers to Sell Our Shares.

The SEC has adopted penny stock regulations which apply to securities traded over-the-counter. These regulations generally define penny stock to be any equity security that has a market price of less than $5.00 per share or an equity security of an issuer with net tangible assets of less than $5,000,000 as indicated in audited financial statements, if the corporation has been in continuous operations for less than three years. Subject to certain limited exceptions, the rules for any transaction involving a penny stock require the delivery, prior to the transaction, of a risk disclosure document prepared by the SEC that contains certain information describing the nature and level of risk associated with investments in the penny stock market. The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Monthly account statements must be sent by the broker-dealerbroker- dealer disclosing the estimated market value of each penny stock held in the account or indicating that the estimated market value cannot be determined because of the unavailability of firm quotes. In addition, the rules impose additional sales practice requirements on broker-dealers who sell such securities to persons other than established customers and institutional accredited investors (generally institutions with assets in excess of $5,000,000). These practices require that, prior to the purchase, the broker-dealer determined that transactions in penny stocks were suitable for the purchaser and obtained the purchaser’s written consent to the transaction. If a market for our common stock does develop and our shares trade below $5.00 per share, it will be a penny stock. Consequently, the penny stock rules will likely restrict the ability of broker-dealers to sell our shares and will likely affect the ability of purchasers in the offering to sell our shares in the secondary market. Trading in our common stock will be subject to the “penny stock” rules. Due to the thinly traded market of these shares investors are at a much higher risk to lose all or part of their investment. Not only are these shares thinly traded but they are subject to higher fluctuations in price due to the instability of earnings of these smaller companies. As a result of the lack of a highly traded market in our shares investors are at risk of a lack of brokers who may be willing to trade in these shares.

 

We do not expect to pay dividends in the future; any return on investment may be limited to the value of our common stock.

We do not currently anticipate paying cash dividends in the foreseeable future. The payment of dividends on our common stock will depend on earnings, financial condition and other business and economic factors affecting it at such time as the board of directors may consider relevant. Our current intention is to apply net earnings, if any, in the foreseeable future to increasing our capital base and development and marketing efforts. There can be no assurance that the Company will ever have sufficient earnings to declare and pay dividends to the holders of our common stock, and in any event, a decision to declare and pay dividends is at the sole discretion of our board of directors. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if its stock price appreciates.

 

The market price of our common stock may be volatile and may decline in value.

The market price of our common stock has been and will likely continue to be highly volatile, as is the stock market in general, and the market for OTC Marketplace quoted stocks, in particular. Some of the factors that may materially affect the market price of our common stock are beyond our control, such as changes in financial estimates by industry and securities analysts, conditions or trends in the industry in which we operate or sales of our common stock. These factors may materially adversely affect the market price of our common stock, regardless of our performance. In addition, the public stock markets have experienced extreme price and trading volume volatility. This volatility has significantly affected the market prices of securities of many companies for reasons frequently unrelated to the operating performance of the specific companies. These broad market fluctuations may adversely affect the market price of our common stock.

 

Our stockholders may experience significant dilution if future equity offerings are used to fund operations or acquire complementary businesses.

If our future operations or acquisitions are financed through the issuance of equity securities, our stockholders could experience significant dilution. In addition, securities issued in connection with future financing activities or potential acquisitions may have rights and preferences senior to the rights and preferences of our common stock.

21

Our current management can exert significant influence over us and make decisions that are not in the best interests of all stockholders.

Our executive officers and directors (the Moores) beneficially own as a group approximately 91% of our outstanding voting shares, including our Series B Preferred Stock. As a result, these stockholders will be able to assert significant influence over all matters requiring stockholder approval, including the election and removal of directors and any change in control. In particular, this concentration of ownership of our outstanding shares of common stock could have the effect of delaying or preventing a change in control, or otherwise discouraging or preventing a potential acquirer from attempting to obtain control. This, in turn, could have a negative effect on the market price of our common stock. It could also prevent our stockholders from realizing a premium over the market prices for their shares of common stock. Moreover, the interests of the owners of this concentration of ownership may not always coincide with our interests or the interests of other stockholders and, accordingly, could cause us to enter into transactions or agreements that we would not otherwise consider.

 

We could issue additional “blank check” preferred stock without stockholder approval with the effect of diluting then current stockholder interests and impairing their voting rights, and provisions in our charter documents and under Nevada law could discourage a takeover that stockholders may consider favorable.

 

Our certificate of incorporation, as amended, provides that we may authorize and issue up to 25,000,000 shares of “blank check” preferred stock with designations, rights, and preferences as may be determined from time to time by our Board. Our Board has issued 900,000 of Series B Preferred, and is empowered, without stockholder approval, to issue one or more series of preferred stock with dividend, liquidation, conversion, voting, or other rights, which could dilute the interest of or impair the voting power of our holders of Common Stock. The issuance of a series of preferred stock could be used as a method of discouraging, delaying, or preventing a change in control. For example, it would be possible for our Board to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of our Company.

 

14

Investors who purchase shares of our common stock should be aware of the possibility of a total loss of their investment.

 

An investment in our common stock involves a substantial degree of risk. Before making an investment decision, you should give careful consideration to the risk factors described in this section in addition to the other information contained herein. The risk factors described herein, however, may not reflect all of the risks associated with our business or an investment in our common stock. You should invest in our Company only if you can afford to lose your entire investment.

 

The Financial Industry Regulatory Authority, or FINRA, sales practice requirements may also limit a stockholder's ability to buy and sell our stock.

 

In addition to the Penny Stock Rules described above, FINRA has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low-priced securities to their non-institutionalnon- institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer's financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low priced -priced securities will not be suitable for at least some customers. FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may limit your ability to buy and sell our stock and have an adverse effect on the market for our shares.

 

A significant amount of our issued and outstanding shares of common stock are restricted securities and may not be freely resold to the public. When the restriction on any or all of these shares is lifted, and the shares are sold in the open market, the price of our common stock could be adversely affected.

A significant amount of our issued and outstanding shares of common stock are "restricted securities" as defined under Rule 144 promulgated under the Securities Act of 1933, as amended, and may only be sold pursuant to an effective registration statement or an exemption from registration, if available. Although Rule 144 may not be immediately available to permit resale of such shares, once available, and given the number of shares that would no longer be restricted, sales of shares by our shareholders, whether pursuant to Rule 144 or otherwise, could have an immediate negative effect upon the price of our common stock.

 

 

22

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

Not applicable to a smaller reporting company.

ITEM 2. DESCRIPTION OF PROPERTY

Leases

 

Office Space

 

On April 1, 2013, the Company entered into a five- year sublease agreement with MFHC to sublease approximately 729 square feet of office space for $1,500 per month. The monthly rent reduced the amounts owed to the Company from MFHC for the marketing services provided to MFHC.

On February 1, 2017, the Company and MFHC terminated the above lease and the Company agreed to a month to month lease directly with the landlord for $8,436 per month. This lease was terminated June 15, 2017.Space

 

On June 14, 2017, the company entered into a five-year lease with LLC1 for approximately 6,944 square feet and a monthly rent of $12,000.$12,000.

 

Hearing Aid Retail Clinics

On June 14, 2017, the company entered into a five-year lease with LLC1 for approximately 6,944 square feet and a monthly rent of $12,000 with a related party (Note 7). Upon adoption of ASC 842, the Company recognized $434,504 of right-to-use assets as operating leases and operating lease obligations.

 

A significant portion of our business involves expansion in the form of retail clinics. The clinics involve leases or subleases.  

On September 10, 2018, pursuant to the Amos Audiology acquisition, the Company assumed a lease dated December 1, 2017, and expiring April 30, 2023, in Walnut Creek, California. Lease payments in the first year of the lease are $3, 988 per month and increase by 3% on December 1st of each new lease year. As of December 31, 2018, the Company was in arrears of $25,182 (including late fees) in lease payments and has agreed with the landlord to pay the arrears in seven monthly payments of $3,597 in addition to the monthly lease payments for January 2019 through July 2019. Settlement fees were fully paid during the year ending December 31, 2019.

 

On October 15, 2018, the Company entered into a lease to operate a retail hearing aid clinic in Roseville, California expiring December 31, 2023. Initial lease payments of $3,102 beginbegan on January 1, 2019 and increase by 3% on January 1st of each new lease year. Upon adoption of ASC 842, the Company recognized $160,623 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in November of 2020, therefore, a ROU asset loss was recognized in the amount of $106,419 during year ending December 31, 2020. No changes to operating lease liability have been made until the settlement has been reached.

On November 18, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Walnut Creek, expiring in October of 2022. Initial lease payments of $3,930 began on December 1, 2019 and increase by 3% on December 1 each new lease year. Upon adoption of ASC 842, the Company recognized $129,281 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in April of 2021.

 

15

On December 1, 2018, the Company entered into a lease to operate a retail hearing aid clinic in Sacramento, California expiring March 31, 2024. Initial lease payments of $3,002 beginbegan on April 1, 2019, and increase by 3.33% on April 1, 2020, and 2021, and by 3% on April 1, 2022. Upon adoption of ASC 842, the Company recognized $149,507 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in November of 2020, therefore, a ROU asset loss was recognized in the amount of $102,312 during year ending December 31, 2020. No changes to operating lease liability have been made until the settlement has been reached. Subsequent to year ending December 31, 2020, the Company reached the settlement where the Company agreed to make either one time payment of $44,000 or make fourteen monthly payments of $3,220.

 

On February 1, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Elk Grove, California expiring January 31, 2024. Initial lease payments of $2,307 beginbegan on February 1, 2019, and increase by an average of 2.6% on February 1,stof each new lease year. Upon adoption of ASC 842, the Company recognized $116,153 of right-to-use assets as operating leases and operating lease obligations. The Company terminated the lease in March of 2021 where the Company agreed to pay $23,911 in order to settle the lease.

On May 31, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Greenhaven, California expiring June 30, 2022. Initial lease payments of $1,450 began on July 1, 2019, and increase by 5% on July 1, each new lease year. Upon adoption of ASC 842, the Company recognized $48,512 of right-to-use assets as operating leases and operating lease obligations. The Company terminated the lease in November of 2020, therefore, a ROU asset loss was recognized in the amount of $27,041, during year ending December 31, 2020. No changes to operating lease liability have been made until the settlement has been reached. Subsequent to year ending December 31, 2021, the Company made a final payout of $6,000, upon which the lease was settled.

On April 15, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Pleasanton, California expiring April of 2024. Initial lease payments of $3,551 began on May 1, 2019 and increase by 3% on May 1 each new lease year. Upon adoption of ASC 842, the Company recognized $185,068 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in December of 2019, therefore, a ROU asset loss was recognized in the amount of $153,589 during year ending December 31, 2019. No changes to operating lease liability have been made until the settlement has been reached.

 

On February 1, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Fremont, California expiring February 28, 2021. Initial lease payments of $2,019 beginbegan on March 1, 2019 and increases by 3% on March 1, 2020. The Company terminated the lease in 2019 and agreed to make a payment of $4,038 in order to settle the lease.

 

On June 1, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Hayward, California expiring June of 2021. Initial lease payments of $1,816 began on June 1, 2019 and increase by 3% on June 1 each new lease year. Upon adoption of ASC 842, the Company recognized $34,486 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in December of 2019, therefore, a ROU asset loss was recognized in the amount of $14,348 during year ending December 31, 2019. No changes to operating lease liability have been made until the settlement has been reached.

23

ITEM 3. LEGAL PROCEEDINGS.

 

On May 26, 2017, Helix Hearing Care (California), Inc. a California corporation (“Helix”), filed a complaint (the “Complaint”)From time to time, claims are made against the InnerScope and the Moores,us in the Circuit Courtordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods.

However, as of the 11th Judicial Circuit in and for Miami-Dade County, Florida, that includes a rescissiondate of the Consulting Agreement and a demand that all monies paid pursuant to the Consulting Agreement be returned, on the basis that an injunction against certain Officers and Directors renders the Consulting Agreement impossible to perform. The Company had previously received $1,250,000 under the Consulting Agreement. InnerScope was not named as an enjoined party in such previous litigation, and the services contemplated under the Consulting Agreement are not within the scope of the injunction, thus InnerScopethis report, management believes the accusation by the third party is frivolousoutcome of currently identified potential claims and without merit, as well aslawsuits will not providing sufficient cause for the Agreement to be terminated. InnerScope and the Moores filed their Answer and Affirmative Defenses to the Complainthave a material adverse effect on June 27, 2017.  On the same date, InnerScope, the Moores, and MFHC filed a counterclaim. On February 27, 2018, the Counterclaim was amended to include four claims for breachour financial condition or results of contract, one claim for anticipatory breach of contract, one claim for negligent misrepresentation, and one claim for account stated. On August 13, 2018, Helix, the Company and the Moores signed a Settlement Agreement, whereby, the Company received $450,000,both parties dismissing all claims against the other party with prejudice and Matthew, Mark and Kimberly have been released from their covenant not to compete agreement signed in August 2016 with Helix.operations.

 

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

16

PARTII

 

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

The Company’s common stock began trading on February 14, 2017, on the over-the-counter market, and quoted on the OTCQB tier of the OTC Markets Group Inc. under the symbol “INND.”

 

(a) Market Information

(a)Market Information

 

The following table sets forth, for the periods indicated the high and low bid quotations for our common stock. These quotations represent inter-dealer quotations, without adjustment for retail markup, markdown, or commission and may not represent actual transactions.

 

Period High Low
Fiscal Year 2018        
First Quarter (January 1, 2018 – March 31, 2018) $0.13  $0.04 
Second Quarter (April 1, 2018 – June 30, 2018) $0.078  $0.013 
Third Quarter (July 1, 2018 – September 30, 2018) $0.108  $0.0065 
Fourth Quarter (October 1, 2018 – December 31, 2018) $0.0805  $0.0151 
         
Fiscal Year 2017        
First Quarter (January 1, 2017 – March 31, 2017) $0.30  $0.25 
Second Quarter (April 1, 2017 – June 30, 2017) $0.55  $0.30 
Third Quarter (July 1, 2017 - September 30, 2017) $0.39  $0.30 
Fourth Quarter (October 1, 2017 – December 31, 2017) $0.40  $.0535 
Period High Low
Fiscal Year 2020    
 First Quarter (January 1, 2020 – March 31, 2020)  $0.0289  $0.0013 
 Second Quarter (April 1, 2020 – June 30, 2020)  $0.0027  $0.0001 
 Third Quarter (July 1, 2020 – September 30, 2020)  $0.0001  $0.0001 
 Fourth Quarter (October 1, 2020 – December 31, 2020)  $0.0002  $0.0001 

 

(b) Holders

 Fiscal Year 2019         
 First Quarter (January 1, 2019 – March 31, 2019)  $0.39  $0.01 
 Second Quarter (April 1, 2019 – June 30, 2019)  $0.09  $0.02 
 Third Quarter (July 1, 2019 - September 30, 2019)  $0.09  $0.01 
 Fourth Quarter (October 1, 2019 – December 31, 2019)  $0.02  $.001 

(a)Holders

 

The number of record holders of our common stock as of April 15, 2019August 5, 2022 was approximately 58.120 This excludes shareholders who hold their stock in street name. The Company estimates that there are over 1,300 stockholders who hold their shares of common stock in street name.

 

24(b)Dividends

(c) Dividends

 

The Company did not declare any cash dividends for the years ended December 31, 2018,2020, and 2017.2019. Our Board of Directors does not intend to distribute any cash dividends in the near future. The declaration, payment and amount of any future dividends will be made at the discretion of the Board of Directors, and will depend upon, among other things, the results of our operations, cash flows and financial condition, operating and capital requirements, and other factors as the Board of Directors considers relevant. There is no assurance that future dividends will be paid, and if dividends are paid, there is no assurance with respect to the amount of any such dividend.

 

(c)Securities authorized for issuance under equity compensation plan s

(d) Securities authorized for issuance under equity compensation plans

None

 

None

Recent Sales of Unregistered Equity Securities

 

On February 23, 2018,During the year ending December 31, 2019, the Company issued 111,11112,576,313 shares of common stock toas part of compensation for services for a consultant. The shares were valued at $7,778, based on the market pricetotal value of the common stock on January 31, 2018, the date the Company agreed to issue the shares.

On February 23, 2018, the Company issued 10,397 shares of common stock to an employee. The shares were valued at $728, based on the market price of the common stock on January 31, 2018, the date the Company agreed to issue the shares.

On February 27, 2018, the Company issued 102,564 shares of common stock that were classified as common stock to be issued as of December 31, 2017.

On February 28, 2018, the Company recorded 133,067 shares of common stock to be issued to a marketing consultant (see Note 13) and recorded $8,117 of stock-based compensation expense (based on the market price of the common stock on that date). The shares were certificated on September 5,2018.

On March 31, 2018, the Company recorded 133,333 shares of common stock to be issued to the same marketing consultant (See Note 13) and recorded $9,067 of stock-based compensation expense (based on the market price of the common stock on that date). The shares were certificated on September 5, 2018.

On April 30, 2018, the Company recorded 166,667 shares of common stock to be issued to a marketing consultant (see Note 13) and recorded $6,883 of stock-based compensation expense (based on the market price of the common stock on that date). The shares were certificated on September 5, 2018.

On May 31, 2018, the Company recorded 380,952 shares of common stock to be issued to the same marketing consultant (See Note 13) and recorded $6,667 of stock-based compensation expense (based on the market price of the common stock on that date). The shares were certificated on September 5, 2018.

On June 4, 2018, Matthew, Mark and Kimberly, each cancelled and returned to treasury 6,340,000 shares of common stock, in exchange for the issuance of 3,170,000 shares of Series A Preferred Stock to each. On August 8, 2018, Matthew, Mark and Kim each converted 3,170,000 shares of Series A Preferred Stock for 6,340,000 shares of common stock. The common stock issued replaced the 19,010,000 shares in the aggregate that the Moore’s cancelled in June 2018.

On August 27, 2018, the Company issued 100,000 shares of restricted common stock to a consultant pursuant to the CPRM Agreement (See Note 13). The shares were valued at $8,430 of stock-based compensation expense (based on the market price of the common stock on that date).

On August 27, 2018, the Company issued 129,534 shares of restricted common stock pursuant to the CSMA (See Note 13). The shares were valued at $12,500 based on the average closing price for the three days prior to the effective date of the CSMA.

25

On August 27, 2018, the Company issued 2,500,000 shares of restricted common stock pursuant to the CA (See Note 13). The shares were valued at $175,000 based on the market price of the common stock, and were recorded as deferred stock compensation on the consolidated balance sheet presented herein, and will be amortized to stock compensation expense over the term of the CA. For the year ended December 31, 2018, the Company amortized $116,167 to stock compensation expense.

On September 5, 2018, the Company recorded 340,352 shares of common stock to be issued pursuant to the APA related to Amos Audiology (See Note 2). The shares were issued on November 27, 2018.

On October 9, 2018, the Company issued 186,289 shares of restricted common stock pursuant to the CSMA (See Note 13). The shares were valued at $12,500 based on the average closing price for the three days prior to the month of service pursuant to* the CSMA.

Effective October 10, 2018, the Company issued 500,000 shares of common stock to MEC Consulting, pursuant to the Crone Law Group engagement (see Note 13). The shares were valued at $36,400,$440,666, based on the market price of the common stock on the date of the engagement.

On October 23, 2018, the Company issued 100,000 shares of restricted common stock to a consultant pursuant to the CPRM Agreement (See Note 13). The shares were valued at $7,000 of stock-based compensation expense (based on the market price of the common stock on that date). This issuance was the final issuance under the CPRM Agreement as it was terminated.

On November 8, 2018, the Company issued 21,468 shares of common stock each to two employees as part of their compensation. The Company agreed to issue $20,000 of stock over a six- month period based on continual employment, to each, based on the average closing price of the Company’s common stock for the 3 days prior to employment, and accordingly recorded stock-based compensation of $3,349, included in Compensation and benefits in the consolidated statement of operations, included herein.

On November 20, 2018, the Company issued 170,687 shares of restricted common stock pursuant to the CSMA (See Note 13). The shares were valued at $12,500 based on the average closing price for the three days prior to the month of service pursuant to* the CSMA.

On November 29, 2018, the Company issued 12,588 shares of common stock to an employee as part of their compensation. The Company agreed to issue $10,000 of stock, over a six- month period based on continual employment, based on the average closing price of the Company’s common stock for the 3 days prior to employment, and accordingly recorded stock-based compensation of $745, included in Compensation and benefits in the consolidated statement of operations, included herein.

On December 8, 2018, the Company issued 21,468 shares of common stock each to two employees as part of their compensation. The Company agreed to issue $20,000 of stock over a six- month period based on continual employment, to each, based on the average closing price of the Company’s common stock for the 3 days prior to employment, and accordingly recorded stock-based compensation of $3,349, included in Compensation and benefits in the consolidated statement of operations, included herein.

On December 12, 2018, the Company issued 34,722 shares of common stock to an employee as part of their compensation. The Company agreed to issue $20,000 of stock, over a six- month period based on continual employment, based on the highest closing price of the Company’s common stock for the 5 days prior to employment, and accordingly recorded stock-based compensation of $1,250, included in Compensation and benefits in the consolidated statement of operations, included herein.

On December 26, 2018, the Company issued 12,588 shares of common stock to an employee as part of their compensation. The Company agreed to issue $10,000 of stock, over a six- month period based on continual employment, based on the average closing price of the Company’s common stock for the 3 days prior to employment, and accordingly recorded stock-based compensation of $745, included in Compensation and benefits in the consolidated statement of operations, included herein.

26

On December 26, 2018, the Company issued 28,090 shares of common stock to an employee as part of their compensation. The Company agreed to issue $10,000 of stock, over a six- month period based on continual employment, based on the average closing price of the Company’s common stock for the 3 days prior to employment, and accordingly recorded stock-based compensation of $1,685, included in Compensation and benefits in the consolidated statement of operations, included herein.

On December 26, 2018, the Company issued 37,879 shares of common stock to an employee as part of their compensation. The Company agreed to issue $20,000 of stock, over a six- month period based on continual employment, based on the highest closing price of the Company’s common stock for the 5 days prior to employment, and accordingly recorded stock-based compensation of $1,250, included in Compensation and benefits in the consolidated statement of operations, included herein.shares.

 

During the year endedending December 31, 2018,2019, the Company issued 53,325,227209,116,478 shares of common stock for partial conversion of $681,412principal in the amount of principal$1,082,858 and $40,954 of accrued interest for a totalin the amount of $722,366.$68,383.

 

AllDuring the year ending December 31, 2019, Company’s management made a contribution of the above financings were entered into with accredited investors only and were not part of any public or general solicitation. The Company believes that all of the above transactions were exempt from the registration requirements of the Securities Act, in accordance with Regulation D or other exemptions for such transactions.$12,048. No shares have been issued.

 

On April 3, 2017,During the year ending December 31, 2020, the Company issued 333,3343,286,303,906 shares of restricted common stock to a consultant. The Company valuedfor partial conversion of principal in the shares at $0.30 per share (the market priceamount of $415,964 and accrued interest in the common stock on the dateamount of the agreement) and will amortize the cost over the one-year life of the agreement, accordingly, the Company recorded stock compensation expense of $75,000 for the year ended December 31, 2017.

On April 7, 2017, the Company issued 300,000 shares of restricted common stock to a consultant. The Company valued the shares at $0.30 per share (the market price of the common stock on the date of the agreement) and recorded stock compensation expense of $90,000 for the year ended December 31, 2017.$44,965.

 

 

ITEM 6. SELECTED FINANCIAL DATA

 

Not applicable to a smaller reporting company.

17

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following is management’s discussion and analysis of certain significant factors that have affected our financial position and operating results during the periods included in the accompanying consolidated financial statements, as well as information relating to the plans of our current management. This report includes forward-looking statements. Generally, the words “believes,” “anticipates,” “may,” “will,” “should,” “expect,” “intend,” “estimate,” “continue,” and similar expressions or the negative thereof or comparable terminology are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including the matters set forth in this report or other reports or documents we file with the Securities and Exchange Commission from time to time, which could cause actual results or outcomes to differ materially from those projected. Some of our risks and uncertainties are included in the Risk Factors section of this Report, as well as, other reports that we may file from time to time. Undue reliance should not be placed on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to update these forward-looking statements.

27

The independent auditors’ reports on our financial statements for the years ended December 31, 20182020 and 20172019 includes a “going concern” explanatory paragraph that describes substantial doubt about our ability to continue as a going concern. Management’s plans in regard to the factors prompting the explanatory paragraph are discussed below and also in Note 4 to the consolidated financial statements filed herein.

 

While our financial statements are presented on the basis that we are a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business over a reasonable length of time, our auditors have raised a substantial doubt about our ability to continue as a going concern.

 

Results of Operations

For the year ended December 31, 20182020 compared to the year ended December 31, 20172019

 

Revenues

 

Revenues for the year ended December 31, 20182020 were $324,876$166,111 compared to $470,626$847,109 for the year ended December 31, 2017.2019. The revenue decrease was primarily the resultdue to closing of the cancellations of the third-party Consulting and Marketing Agreements in January 2017, as well as reduced revenues from direct print and mail services.many retail locations due to COVID-19 (Note 14). For the year ended December 31, 2018,2020, a related customer accounted for 25.2%0% of our revenues compared to 18.3%5% for the year ended December 31, 2017.2019. During the year ended December 31, 2017, three other customers2020, one customer accounted for 27.6%, 16.4% and 14.8% respectively. Beginning in the second quarter28% of 2018, the Company began to market and sell hearing aid products online on a direct to consumer basis and beginning in the third quarter of 2018 began selling hearing aids on Walmart.com website. A breakdown of sales is as follows:total revenue.

 

  Year ended December 31,
  

2018

 

2017

Online sales $113,635  $—   
Retail clinic sales  95,626   —   
Consulting fees  —     160,000 
Direct print, mail services and product  33,596   224,177 
Sub total  242,857   384,177 
         
Related party- direct print and mail services  22,019   36,449 
Related party - Marketing and consulting fee  60,000   50,000 
Sub total  82,019   86,449 
Total revenues $324,876  $470.626 

Online sales

 

Beginning in the second quarter of 2018, the Company began to market a line of PSAP hearables and wearablesPSAPs and during the third quarter of 2018, expanded their line of products to include FDA registered hearing aid devices. The Company has introduced the products through new marketing campaigns, to bring awareness to the products, and anticipateswhich resulted in increase in sales of these products to increase during 2019 and thereafter.in 2019.

 

Retail clinic sales

 

Retail clinic sales were $95,626significantly decreased in 2020 as a resultnumber of the acquisition of the Amos Audiology acquisition on September 10, 2018 ($63,401 sales) and the opening of the Company’s first retail clinic in November 2018 ($32,225 in sales). Retail clinic sales will continuelocations were closed due to grow asCOVID-19. As a result, the Company has opened three additional retail clinicsexperienced a negative impact to date in 2019, and anticipates to open as many as 15-20 more by December 31, 2019.

28

Consultingits operating results.

 

For the year ended December 31, 2017, the Company recorded $100,000 of income related to the Store Expansion Agreement, $30,000 of income from the cancellation of the Marketing and Store Expansion Agreements and $30,000 of consulting income from other clients.

Direct print and mail service

During the year ended December 31, 2018, the Company developed marketing materials, including printing and mailing services, for direct marketing campaigns and recorded revenues of $33,596, compared to $224,177 for the year ended December 31, 2017. The Company is currently concentrating on building its’ DTC sales model, which provides a greater gross profit than the direct print and mail service products.

Related Party

On December 24, 2016, Moore Holdings, LLC. (“Moore Holdings”) acquired two retail stores from the buyer of the MFHC stores. On March 1, 2017, the Company entered into a twelve- month Marketing Agreement with each of the stores to provide telemarketing and design and marketing services for $2,500 per month per store, resulting in $60,000 of revenues for the year ended December 31, 2018, compared to $50,000 for the year ended December 31, 2017. For the year ended December 31, 2018, the Company also provided direct print and mailing services for the two retail sales and recognized revenue of $22,019, for the services, compared to $36,499 for the year ended December 31, 2017.

Cost of sales

The Company records the costs of designing, producing, printing and mailing advertisements for our client’s direct mail marketing campaigns in cost of sales in the month of the mailing as well as the licensing of telemarketing software and records cost of sales on products sold online or it its retail locations, when shipped and delivered to the customer, respectively. Cost of sales for the year ended December 31, 20182020 was $181,688$68,768 compared to $293,221$496,736 for the year ended December 31, 2017. Related party cost of sales was $24,779 for the year ended December 31, 2018, compared to $36,303 for the year ended December 31, 2017.2019.

 

Operating Expenses

Operating expenses were $2,851,801,$1,326,587, respectively, for the year ended December 31, 2018,2020, compared to $1,403,897$4,095,200 for the year ended December 31, 2017.2019. The increasedecrease in expenses in the current periods was as follows:

 

  Year ended December 31,
Description 2020 2019
Compensation and benefits $661,840  $1,575,395 
Advertising and promotion  19,762   485,406 
Professional fees  114,476   763,157 
Rent, including related party  322,879   424,613 
Investor relations  14,796   193,696 
Depreciation and Amortization expense  123,646   150,024 
Other general and administrative  69,188   502,908 
  $1,326,587  $4,095,200 

  Year ended December 31,
Description 2018 2017
Compensation and benefits $771,154  $645,723 
Stock compensation  1,087,850   173,974 
Professional fees  335,966   217,193 
Commissions, stockholder  —     60,000 
Advertising and promotion  173,580   —   
Investor relations  125,415   43,845 
Rent, related party  144,000   72,000 
Rent, other  42,700   39,377 
General and other administrative  171,136   151,785 
Total $2,851,801  $1,403,897 

 

Compensation and benefits increaseddecreased in the current period as the Company acquired Amos Audiologydue to overall decrease in September 2018 as well as opened a Company owned retail clinic in November 2018, both of which required staffing as well as additional office support staff.operations due to COVID-19.

 

 2918 

 

Stock based compensationProfessional fees, for the year ended December 31, 2018, is comprised of:

On February 23, 2018, the Company issued 111,111 shares of common stock2020 were $114,476 compared to a marketing consultant. The shares were valued at $7,778, based on the market price of the common stock on January 31, 2018, the date the Company agreed to issue the shares.

On February 23, 2018, the Company issued 10,397 shares of common stock to an employee. The shares were valued at $728, based on the market price of the common stock on January 31, 2018, the date the Company agreed to issue the shares.

On February 28, 2018, the Company recorded 133,067 shares of common stock to be issued to a marketing consultant (see Note 12) and recorded $8,117 of stock-based compensation expense (based on the market price of the common stock on that date).

On March 31, 2018, the Company recorded 133,333 shares of common stock to be issued to the same marketing consultant and recorded $9,067 of stock-based compensation expense (based on the market price of the common stock on that date).

The amortization of deferred stock compensation of $25,000 is included in the year ended December 31, 2018.

On April 30, 2018, the Company recorded 166,667 shares of common stock to be issued to the same marketing consultant and recorded $6,883 of stock-based compensation expense (based on the market price of the common stock on that date).

On May 31, 2018, the Company recorded 380,952 shares of common stock to be issued to the same marketing consultant and recorded $6,667 of stock-based compensation expense (based on the market price of the common stock on that date).

On June 4, 2018, the Company issued 300,000 shares of its Series B Preferred Stock each to Matthew, Mark and Kimberly, in consideration of $45,000 of accrued expenses, the Company’s failure to timely pay current and past salaries, and the willingness to accrue unpaid payroll and non-reimbursement of business expenses without penalty or action for all amounts. The Company determined that fair value of the Series B Preferred Stock issued to the Company’s CEO was $817,600, and accordingly $772,600 is included in stock compensation expense$763,157 for the year ended December 31, 2018. The fair value was determined as set forth in the Statement of Financial Accounting Standard ASC 820-10-35-37, Fair Value in Financial Instruments.

On August 27, 2018, the Company issued 100,000 shares of restricted common stock to a consultant pursuant to the CPRM Agreement (See Note 13). The shares were valued at $8,430 of stock-based compensation expense (based on the market price of the common stock on that date).
On August 27, 2018, the Company issued 129,534 shares of restricted common stock pursuant to the CSMA (See Note 13). The shares were valued at $12,500 based on the average closing price for the three days prior to the effective date of the CSMA.
On August 27, 2018, the Company issued 2,500,000 shares of restricted common stock pursuant to the CA (See Note 13). The shares were valued at $175,000 based on the market price of the common stock, and were recorded as deferred stock compensation on the condensed consolidated balance sheet presented herein, and will be amortized to stock compensation expense over the term of the CA. For the year ended December 31, 2018, the Company amortized $116,667 to stock compensation expense.
On September 7, 2018, the Company recorded 129,534 shares of restricted common stock to be issued pursuant to the CSMA (See Note 13). The shares were valued at $12,500 based on the average closing price for the three days prior to the month of service. The shares were certificated on October 9, 2018.
30

On October 9, 2018, the Company issued 186,289 shares of restricted common stock pursuant to the CSMA (See Note 13). The shares were valued at $12,500 based on the average closing price for the three days prior to the month of service pursuant to the CSMA.
Effective October 10, 2018, the Company issued 500,000 shares of common stock to MEC Consulting, pursuant to the Crone Law Group engagement (see Note 13). The shares were valued at $36,400, based on the market price of the common stock on the date of the engagement.
On October 23, 2018, the Company issued 100,000 shares of restricted common stock to a consultant pursuant to the CPRM Agreement (See Note 13). The shares were valued at $7,000 of stock-based compensation expense (based on the market price of the common stock on that date). This issuance was the final issuance under the CPRM Agreement as it was terminated.
On November 8, 2018, the Company issued 21,468 shares of common stock each to two employees as part of their compensation. The Company agreed to issue $20,000 of stock over a six- month period based on continual employment, to each, based on the average closing price of the Company’s common stock for the 3 days prior to employment, and accordingly recorded stock-based compensation of $3,349, included in Compensation and benefits in the consolidated statement of operations, included herein.
On November 20, 2018, the Company issued 170,687 shares of restricted common stock pursuant to the CSMA (See Note 13). The shares were valued at $12,500 based on the average closing price for the three days prior to the month of service pursuant to the CSMA.

2019. Professional fees, consisted of:

 

On November 29, 2018, the Company issued 12,588 shares of common stock to an employee as part of their compensation. The Company agreed to issue $10,000 of stock, over a six- month period based on continual employment, based on the average closing price of the Company’s common stock for the 3 days prior to employment, and accordingly recorded stock-based compensation of $745, included in Compensation and benefits in the consolidated statement of operations, included herein.
On December 8, 2018, the Company issued 21,468 shares of common stock each to two employees as part of their compensation. The Company agreed to issue $20,000 of stock over a six- month period based on continual employment, to each, based on the average closing price of the Company’s common stock for the 3 days prior to employment, and accordingly recorded stock-based compensation of $3,349, included in Compensation and benefits in the consolidated statement of operations, included herein.
On December 12, 2018, the Company issued 34,722 shares of common stock to an employee as part of their compensation. The Company agreed to issue $20,000 of stock, over a six- month period based on continual employment, based on the highest closing price of the Company’s common stock for the 5 days prior to employment, and accordingly recorded stock-based compensation of $1,250, included in Compensation and benefits in the consolidated statement of operations, included herein.

On December 26, 2018, the Company issued 12,588 shares of common stock to an employee as part of their compensation. The Company agreed to issue $10,000 of stock, over a six- month period based on continual employment, based on the average closing price of the Company’s common stock for the 3 days prior to employment, and accordingly recorded stock-based compensation of $745, included in Compensation and benefits in the consolidated statement of operations, included herein.

On December 26, 2018, the Company issued 28,090 shares of common stock to an employee as part of their compensation. The Company agreed to issue $10,000 of stock, over a six- month period based on continual employment, based on the average closing price of the Company’s common stock for the 3 days prior to employment, and accordingly recorded stock-based compensation of $1,685, included in Compensation and benefits in the consolidated statement of operations, included herein.
31

On December 26, 2018, the Company issued 37,879 shares of common stock to an employee as part of their compensation. The Company agreed to issue $20,000 of stock, over a six- month period based on continual employment, based on the highest closing price of the Company’s common stock for the 5 days prior to employment, and accordingly recorded stock-based compensation of $1,250, included in Compensation and benefits in the consolidated statement of operations, included herein.

  Year ended December 31,
Description 2020 2019
Accounting and auditing fees $45,383  $100,747 
Legal fees  3,228   10,362 
Consulting  65,865   652,048 
Total $114,476  $763,157 

 

Stock based compensation expense for 2017 was as a result of on April 3, 2017, the Company issued 333,334 shares of restricted common stock to a thirdRent, including related party, pursuant to a one-year consulting agreement. The Company valued the shares at $0.30 per share (the market price of the common stock on the date of the agreement). The Company amortized the $100,000 cost over the term of the agreement, and accordingly has included $75,000 in stock-based compensation decreased for the year ended December 31, 2017. Additionally, on April 7, 2017, the Company issued 300,000 shares of restricted common stock to a third party, pursuant to a consulting agreement. The Company valued the shares at $0.30 per share (the market price of the common stock on the date of the agreement), and recorded an expense of $90,000 for the year ended December 31, 2017.  On December 31, 2017, pursuant to an agreement for marketing services, the Company recorded an expense of $8,974 for 102,564 shares of common stock to be issued (certificated on February 28, 2018). The Company valued the shares at $0.0875 (the market price of the common stock on December 31, 2017).

Professional fees, excluding stock-based compensation for the year ended December 31, 2018 were $335,966 compared to and $217,193 for the year ended December 31, 2017. Professional fees, excluding stock-based compensation, consisted of: 

  Year ended December 31,
Description 2018 2017
Legal fees $126,106  $68,580 
Business consulting  102,974   30,000 
Accounting and auditing fees  89,000   87,303 
Information technology  17,886   31,320 
Total $335,966  $217,193 

Commissions, stockholder, are the result of the Company recording commission due on all amounts recognized as revenue in the period related to the Consulting Agreement and Store Expansion Agreement.

Rent, related party, increased for the year ended December 31, 2018,2020, compared to the year ended December 31, 20172019 as a result of the Company on June 14, 2017, entered intotermination of a five-year lease with LLC1 for approximately 6,944 square feet and a monthly rentnumber of $12,000.retail locations.

 

General and administrative costs were $171,136$69,188 for the year ended December 31, 2018,2020, compared to $151,785$502,908 for the year ended December 31, 2017, and were comprised of:

  

For the year ended

December 31,

Description 2018 2017
Travel $21,472  $25,283 
Transfer agent and filing fees  17,256   9,293 
Bad debt expense, net of collections  10,383   63,799 
Office and payroll expenses  82,995   39,584 
Other general and other administrative  39,030   13,826 
Total $171,136  $151,785 

2019. Office and payroll expenses include telephone, office supplies, payroll processing costs and computer and internet costs. Investor relations costs include web hosting on our website, investor presentations and meetings as well as press releases and consultants.

32

Other income (expense), net

Other expense, net was $1,876,505$3,724,448 for the year ended December 31, 2018,2020, compared to $686,840$4,179,513 for the year ended December 31, 2017. Included in other expense, net, for the year ended December 31, 2018 was $1,297,223 as a result of the Helix settlement, whereby the Company recognized $847,223 previously classified as deferred revenues and $450,000 of cash received from the settlement and there was a gain on debt extinguishment of $530,468 for the year ended December 31, 2018.2019. Derivative expenses of $2,436,951$2,289,869 and $1,269,305 of interest expense,$3,602,512, including amortization of debt discounts as of December 31, 2020 and 2019, respectively, decreased due to less new convertible notes during 2020. Interest expense of $489,123 and $386,303 for the years ended December 31, 2020 and 2019, respectively, increased significantly as a result of the convertible notes.due to new loans. The 20172020 period included a loss of $775,000 recorded on the Consulting Agreement, due to the uncertainty of future services being provided, based on the Complaint (see Note 13) and interest and derivative expenses of $77,287 and $265,674, respectively. The expenses for the year were partially offset byintangibles as the Company recognizingdetermined that it was unable to substantiate the actual fair value of the technology that was acquired so has chosen to impair the full amount. Company recorded a gain $160,000loss on the cancellationlease termination of Store Expansion Agreement. The Company received $400,000$201,283 and $146,337 during the yearyears ended December 31, 20172020 and also paid $240,0002019 due to canceling a stockholder for services provided related to the income received pursuant to the Cancellation Agreement.number of leases (Note 11).

 

Net loss

Net loss for the year ended December 31,201831,2020 was $4,585,117$4,953,692 compared to $1,913,332$7,924,339 for the year ended December 31, 2017.2019. The increasedecrease in the loss was mainly due to the increasesdecrease in operating expenses and other expenses as above.operations due to COVID-19.

Capital Resources and Liquidity

Liquidity is the ability of an enterprise to generate adequate amounts of cash to meet its needs to pay ongoing obligations. As of December 31, 2018,2020, we had cash of $87,826, an increase$3,349, a decrease of $3,106,$1,110, from $84,720$4,459 as of December 31, 2017.2019. As of December 31, 2018,2020, we had current liabilities of $3,686,665$10,418,996 (including derivative liabilities of $1,807,404)$4,046,401) compared to current assets of $597,707$23,449 which resulted in working capital deficit of $3,088,9579.10,395,547. The current liabilities are comprised of accounts payable, accrued expenses, notes payable, convertible notes payable and derivative liabilities.

 

Our ability to operate over the next twelve12 months, is contingent upon continuing to realize sales revenue sufficient to fund our ongoing expenses. If we are unable to sustain our ongoing operations through sales revenue, we intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund our working capital, or other cash requirements. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all. Our ability to operate beyond December 2019,31, 2021, is contingent upon continuing to realize sales revenue sufficient to fund our ongoing expenses. If we are unable to sustain our ongoing operations through sales revenue, we intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund our working capital, or other cash requirements. Since December 31, 2018,2020, we have received $813,475,$8,300,686, from the issuance of $996,670$6,550,957 of convertible notes, $650,000 from sale of common stock and approximately $145,000$1,099,729 from the sales of hearing aid products. We do not have any formal commitments or arrangements for the sales of stock or the advancement or loan of funds at this time. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all.

 

Operating Activities

 

Cash used in operating activities was $1,165,526$523,534 for the year ended December 31, 20182020 compared to $776,283$2,925,937 for the year ended December 31, 2017.2019. For the year ended December 31, 2018,2020, the cash used in operations was a result of the net loss of $4,585,117, the recognition of $847,223 of deferred revenue, gains$4,953,692, loss recognized on debt extinguishmentROU asset of $530,468 $204,416, and increases in assets of $300,884,$134,730, offset by increases in liabilities of $454,006$995,017 and the non- cash expense items of depreciation and amortization of $1,115,396,$1,172,111 derivative expenseloss of $2,436,949$1,066,904, loss on intangibles impairment of $775,000 and stock- based compensationgain on equity investment of $1,087,850.$30,646.

 

The Company used $776,283$2,925,941 cash in operating activities for the year ended December 31, 2017.2019. For the year ended December 31, 2017,2019, the cash used in operations was a result of the net loss of $1,913,332,$7,924,339, offset beby the changes in the current assets of $599,240 and changes in liabilities of $631,705,$77,502, respectively, as wellloss recognized on ROU asset of $167,938, and the non- cash expensesexpense items of $265,674depreciation and amortization of $2,850,033, derivative loss of $647,633, stock based compensation of $440,667 and loss on equity investment of $15,083.

Investing Activities

Cash used in investing activities was $7,272 for the initial expenseyear ended December 31, 2020, and fair valuewas comprised of purchase of equipment in the amount of $7,272. Cash used in investing activities was $59,175 for the year ended December 31, 2019. Such investing activities were comprised of purchase of equipment in the amount of $49,614 and $9,561 change in derivatives, $173,974 of stock- based compensation and $63,434 of amortization of debt discounts.equity investment.

 

 3319 

 

Investing Activities

Cash used in investing activities was $196,744 for the year ended December 31, 2018, and was comprised of $183,200 for payments for the acquisition of technology from Zounds as well as the purchase of office furniture and equipment and the payment of security deposits for the retail clinic leases. Cash used in investing activities was $203,413 for the year ended December 31, 2017. Such investing activities was materially comprised of the purchase of a 49% interest in a building. The Company also received $17,938 as payments on a note receivable from an officer and paid $3,000 to acquire the web address innd.com.

Financing Activities

For the year ended December 31, 2018,2020, the Company has received $1,664,450proceeds, net of repayments made, of $269,611 from the issuance of $1,961,133 of convertible notes, and cash proceeds of $77,600$262,445 from the issuance of notes of $101,593, and related party notes payable issued of in the aggregate of $36,800.a Paycheck Protection Program loan. For the year ended December 31, 2018,2020, the Company made principal paymentshad changes in bank overdraft in the amount of $253,663 on convertible notes, $79,499 on notes payable and $6,000 paid on related party notes payable.$2,360. For the year ended December 31, 2017,2019, the Company received $65,000 in exchange for a note payable issued to a related party and $345,000proceeds, net of repayments, of $2,854,250 from the issuance of convertible notes, proceeds, net of $397,000. Therepayments, of $32,820 from notes payable and a related party contribution in the amount of $12,048. For the year ended December 31, 2020, the Company made principal paymentshad changes in bank overdraft in the amount of $18,200 on one of the convertible notes issued.$2,631.

 

OFF BALANCE SHEET ARRANGEMENTS

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition or results of operations.

 

Critical Accounting Policies

 

Basis of presentation

The accompanying consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America ("US GAAP"). The consolidated financial statements of the Company include the consolidated accounts of InnerScope and its’ wholly owned subsidiaries ILLC and Intela-Hear, a California limited liability company.subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

 

Emerging Growth Companies

The Company qualifies as an “emerging growth company” under the 2012 JOBS Act. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. As an emerging growth company, the Company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has elected to take advantage of the benefits of this extended transition period.

 

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Significant estimates relied upon in preparing these financial statements include collectability of accounts receivable, accounts receivable from a related party and notes receivable from an officer, inventory allowances for slow moving or obsolete inventory and the allocation of our CEO’s compensation to the Company. Actual results could differ from those estimates.

 

34

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.

 

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held.

Revenue Recognition

The Company has adopted ASU 2014-09, as amended effective January 1, 2018, and determined that there was no significant impact on its revenue recognition. The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle. The Company recognizes revenue under ASC 606 Revenue from Contracts with Customers. The Company’s revenue recognition policy standards include the following elements:

I.Identify the contract with a customer
II.Identify the performance obligations in the contract
III.Determine the transaction price
IV.Allocate the transaction price to the performance obligations in the contract
V.Recognize revenue when (or as) the entity satisfies a performance obligation.

20

The Company’s contracts with customers are generally on a purchase order basis and represent obligations that are satisfied at a point in time as defined in the new guidance. Accordingly, revenue for each sale is recognized when each sale is complete, which is when the customer receives the goods and any costs incurred before this point in time, are recorded as assets to be expensed during the period the related revenue is recognized. The Company accepts prepayments on hearing aids and records the amount received as customer deposits on its’ balance sheet. When the Company delivers the hearing aid to the customer, revenue is recognized as well as the corresponding cost of sales. All goods are delivered to the customer using public carriers. Company bears any loss during transit. As of December 31, 2018,2020, the Company had received $56,698$10,925 of customer deposits, that will be recognized after December 31, 2018,2021, when the hearing aids are delivered to the customer. For the year ended December 31, 2017, the Company received and recognized $100,000 of revenue related to the Store Expansion agreement, and $30,000 of income from the cancellation of the Marketing and Store Expansion Agreements.For the year ended December 31, 2018, the Company recognized $847,223 as other income (amount was previously in deferred revenues) as well as $450,000 pursuant to a settlement agreement.

 

Deferred Revenue

Deferred Revenue

 

The Company records deferred revenues from the Consulting Agreement when cash has been received, but the related services have not been provided. Deferred revenue will be recognized when the services are provided, and the terms of the agreements have been fulfilled. On May 26, 2017, the Company and the Moores were named in an action filed that included a demand that all monies paid pursuant to the Consulting Agreement be returned. The Company believes the claim is frivolous and without merit, as well as not providing sufficient cause for the Agreement to be terminated (See Note 12). The Company has not recognized any revenue in 2017 from the Consulting Agreement as a result of this litigation. As of December 31, 2017, the Company has deferred revenue of $847,223 related to the Consulting Agreement.

 

Advertising and Marketing Expenses

The Company expenses advertising and marketing costs as incurred. For the years ended December 31, 2018,2020 and 2019, advertising and marketing expenses were $173,580. The Company did not incur any advertising$19,762 and marketing expenses for the year ended December 31, 2017.$485,407, respectively.

 

Investment in Undivided Interest in Real Estate

The Company accounts for its’ investment in undivided interest in real estate using the equity method, as the Company is severally liable only for the indebtedness incurred with its interest in the property. The Company includes its allocated portion of net income or loss in Other income (expense) in its Statement of Operations, with the offset to the equity investment account on the balance sheet. For the yearyears ended December 31, 2018,2020 and 2019, the Company recognized a gain of $2.060.$30,646 and $15,083, respectively. As of December 31, 2018,2020 and 2019, the carrying value the carrying value of our investment in undivided interest in real estate was $1,226,963.$1,227,733 and $1,210,526, respectively.

 

35

Fair Value of Financial Instruments

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance onfair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

 

The following are the hierarchical levels of inputs to measure fair value:

 

Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.
Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
Level 3 - Unobservable inputs reflecting the Company's assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

 

The carrying amounts of the Company's financialfinancial assets and liabilities, such as cash, prepaid expenses, accounts receivable, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments.

 

The following table represents the Company’s financial instruments that are measured at fair value on a recurring basis as of December 31, 2018,2020, and 2017,2019, for each fair value hierarchy level:

 

  December 31, 2019
  Level 1 Level 2 Level 3 Total
Derivative liabilities $—    $—    $3,515,055  $3,515,055 
  $—    $—    $3,515,055  $3,515,055 
                 
   December 31, 2020
   Level 1   Level 2   Level 3   Total 
Derivative liabilities $—    $—    $4,046,401  $4,046,401 
  $—    $—    $4,046,401  $4,046,401 

December 31, 2018 Derivative
Liability
 Total
Level I $—    $—   
Level II $—    $—   
Level III $1,807,404  $1,807,404 
21

 

December 31, 2017 Derivative
Liability
 Total
Level I $—    $—   
Level II $—    $—   
Level III $540,965  $540,965 

IncomeTaxes

Income Taxes

The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes. Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.

 

ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. Interest and penalties are classified as a component of interest and other expenses. To date, the Company has not been assessed, nor paid, any interest or penalties.

 

36

Uncertain tax positions are measured and recorded by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.

 

Earnings (loss) PerShare

The Company reports earnings (loss) per share in accordance with ASC 260, "Earnings per Share." Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of December 31, 2018,2020, and 2017,2019, the Company’s outstanding convertible debt is convertible into approximately 120,715,2944,650,854,286 and 10,043,445155,226,039, respectively, shares of common stock, respectively, subject to adjustment based on changes in the Company’s stock price. This amount is not included in the computation of dilutive loss per share because their impact is antidilutive.

 

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not required for smaller reporting companies.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

See Index to Financial Statements and Financial Statement Schedules appearing on pages F-1 to F-12 of this annual report on Form 10-K.10-K.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

 

None.

ITEM 9A. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

A review and evaluation was performed by the Company’s management, including the Company’s Chief Executive Officer (the “CEO”) and Chief Financial Officer (the “CFO”), as of the end of the period covered by this annual report on Form 10-K, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of the end of the period covered by this annual report. Based on that review and evaluation, the CEO and CFO have concluded that as of December 31, 2018,2020, disclosure controls and procedures were not effective at ensuring that the material information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported as required in the application of SEC rules and forms.

 

22

Management’s Report on Internal Controls over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Internal control over financial reporting is a set of processes designed by, or under the supervision of, a company’s principal executive and principal financial officers, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures that:

 

37

Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and disposition of our assets;
Provide reasonable assurance our transactions are recorded as necessary to permit preparation of our financial statements in accordance with GAAP, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. It should be noted that any system of internal control, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Our CEO and CFO have evaluated the effectiveness of our internal control over financial reporting as described in Exchange Act Rules 13a-15(e) and 15d-15(e) as of the end of the period covered by this report based upon criteria established in “Internal Control-Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission(2013 (2013 framework).As a result of this evaluation, we concluded that our internal control over financial reporting was not effective as of December 31, 2018,2020, as described below.

 

We assessed the effectiveness of the Company’s internal control over financial reporting as of evaluation date and identified the following material weaknesses:

 

Insufficient Resources:We have an inadequate number of personnel with requisite expertise in the key functional areas of finance and accounting.

Inadequate Segregation of Duties: We have an inadequate number of personnel to properly implement control procedures.

Lack of Audit Committee:We do not have a functioning audit committee, resulting in lack of independent oversight in the establishment and monitoring of required internal controls and procedures.

 

We are committed to improving the internal controls and will (1) consider to use third party specialists to address shortfalls in staffing and to assist us with accounting and finance responsibilities, (2) increase the frequency of independent reconciliations of significant accounts which will mitigate the lack of segregation of duties until there are sufficient personnel and (3) may consider appointing additional outside directors and audit committee members in the future.

 

We have discussed the material weakness noted above with our independent registered public accounting firm. Due to the nature of these material weaknesses, there is a more than remote likelihood that misstatements which could be material to the annual or interim financial statements could occur that would not be prevented or detected.

 

This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our independent registered public accounting firm pursuant to the rules of the SEC that permit us to provide only management’s report in this annual report.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in the Company’s internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

38

ITEM 9B. OTHER INFORMATION

 

None.

 

23

PARTIII

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

Identification of directors and executive officers.

 

The names and ages of our directors and executive officers are set forth below. Also included is their principal occupation(s). Our By-Laws provide for three directors. All directors are elected annually by the stockholders to serve until the next annual meeting of the stockholders and until their successors are duly elected and qualified.

 

NameAgeAgePositionPositionDirector Since
Mark Moore5957ChairmanChairmanJune 18, 2012
Kim Moore6563Treasurer and DirectorJune 18, 2012
Matthew Moore3533CEO and DirectorJune 18, 2012

 

Mark Moore, Chairman

 

Mr. Moore has 3037 years in hearing aid dispensing, practice management, private label brand management and marketing, Mr. Moore brings a wealth of experience and perspective to our field. Mr. Moore’s expertise in not only running a successful multi-office retail dispensing practice, but also developing time-tested proven new marketing and advertising strategies over the past 25 years has made him one of the most sought aftersought-after experts in the hearing aid industry. He has personally helped over ten thousand10,000 people hear better with hearing amplification.

 

Mr. Moore previously was a columnist for Advanced for Audiologists as well as Senior Publications throughout Northern California. Mark hasMr. Moorehas also developed patented and patent-pending products in the areas of Nutritional Supplements for hearing related issues, Aural Rehabilitation programs, and Low-Level Laser Therapy for Tinnitus and Sensorineural hearing loss.

 

Mr. Moore is a graduate of San Diego Golf Academy with a business degree. He and his wife, Kim, who is also a licensed dispenser, live in Granite Bay, CA.

 

Kim Moore, Treasurer and Director

 

Mrs. Moore has over 4050 years of experience in the Hearing Aid Industry. She literally grew up in the industry helping her father, Marvin Posey, develop and maintain his hearing aid practice, Posey’s Hearing Aid Center, in Central Valley, California.

 

Mrs. Moore started working for her father at age eight, when she would help stuff direct mail pieces for an upcoming marketing campaign. She learned from her father that no potential customer walks through the door unless you advertise and market properly to the people that want to hear better. Mrs. Moore became a Hearing Instrument Specialist, just as her father did so she can help people hear better. Kim lives in Granite Bay, CA with her husband, Mark Moore.

 

39

Matthew Moore, CEO, Secretary and Director

 

For the last five years Matthew Moore has directed marketing and advertisingwas Chief Marketing Officer as well as day to dayran the day-to-day operations for Moore Family Hearing Company.Company Inc., a chain of hearing aid retail clinics. Matthew specializes in developing print and demographically tailored mail campaigns, as well as monitoring and consulting on Key Business Performance Indicators for all businesses, especially for Audiological Practices. Matthew has the ability and track record of consulting with businesses as well as in his own business streamline efficacies from Top to Bottom and extract better performance from every level of an organization. Matthew is also third generation in the hearing device industry and has literally grown up around the hearing aid industry and entrepreneurship.

 

Matthew Moore’s expertise is in the senior demographics and customized market analysis for elderly related products including hearing aids across the United States. He lives in Roseville, CA. with his wife and two Children.

 

Family Relationships

 

Mark Moore and Kim Moore are married to one another. Matthew Moore is the son of Mark and Kim Moore.

 

Involvement in Certain Legal Proceedings

 

No director, executive officer, significant employee or control person of the Company has been involved in any legal proceeding listed in Item 401(f) of Regulation S-K in the past 10 years.

 

24

Corporate Governance

 

Our Board has not established any committees, including an audit committee, a compensation committee or a nominating committee, or any committee performing a similar function. The functions of those committees are being undertaken by our Board. Because we do not have any independent directors, our Board believes that the establishment of committees of our Board would not provide any benefits to our Company and could be considered more form than substance.

 

We do not have a policy regarding the consideration of any director candidates that may be recommended by our stockholders, including the minimum qualifications for director candidates, nor have our officers and directors established a process for identifying and evaluating director nominees. We have not adopted a policy regarding the handling of any potential recommendation of director candidates by our stockholders, including the procedures to be followed. Our officers and directors have not considered or adopted any of these policies as we have never received a recommendation from any stockholder for any candidate to serve on our Board of Directors.

 

Given our relative size and lack of directors’ and officers’ insurance coverage, we do not anticipate that any of our stockholders will make such a recommendation in the near future. While there have been no nominations of additional directors proposed, in the event such a proposal is made, all current members of our Board will participate in the consideration of director nominees.

 

As with most small, early stageearly-stage companies until such time as our Company further develops our business, achieves a revenue base and has sufficient working capital to purchase directors’ and officers’ insurance, we do not have any immediate prospects to attract independent directors. When we are able to expand our Board to include one or more independent directors, we intend to establish an audit committee of our Board of Directors. It is our intention that one or more of these independent directors will also qualify as an audit committee financial expert. Our securities are not quoted on an exchange that has requirements that a majority of our Board members be independent, and we are not currently otherwise subject to any law, rule or regulation requiring that all or any portion of our Board of Directors include “independent” directors, nor are we required to establish or maintain an audit committee or other committee of our Board.

 

40

Conflicts of Interests

In September 2016, the officers and directors of the Company formed a California Limited Liability Company (“LLC1”), for the purpose of acquiring commercial real estate and other business activities.On December 24, 2016, LLC1 acquired two retail stores from the buyer of the MFHC stores. On March 1, 2017, the Company entered into a twelve-month Marketing Agreement with each of the stores to provide telemarketing and design and marketing services for $2,500 per month per store, resulting in $60,000 and $50,000 of revenues for the year ended December 31, 2018, and 2017, respectively. Additionally, for the years ended December 31, 2018, and 2017, the Company invoiced LLC1 $22,019 and $36,499, respectively, for the Company’s production, printing and mailing services. As of December 31, 2018, and 2017, LLC1 owes the Company $ 203,325 and $73,996, respectively. On May 9, 2017, the Company and LLC1 purchased certain real property from an unaffiliated party. On June 14, 2017, the Company entered into a five-year lease with LLC1 for approximately 6,944 square feet and a monthly rent of $12,000. For the year ended December 31, 2018, and 2017, the Company expensed $144,000 and $64,499, respectively, related to this lease.

In November 2016, the Company’s Chairman formed a California Limited Liability Company (“LLC2”), for the purpose of providing consulting services to the Company.The Company entered into an agreement with LLC2, and paid LLC2 $375,000 during the year ended December 31, 2016, for services performed and to be performed. Of the $375,000 amount paid, $241,667 was recognized as consulting fees- stockholder for the year ended December 31, 2016, and the remaining $133,334 was recorded as deferred commissions- stockholder as of December 31, 2016. During the year ended December 31, 2017, the Company paid LLC2 an additional $771,000 ($96,000 of which reduced previous amounts owed) and expensed $808,334 ($60,000 as commissions for services performed and $748,334 as other expense) due to uncertainty of future services being provided, based on the Complaint filed on May 26, 2017. As of December 31, 2017, the deferred commissions-stockholder is $-0-.

 

On May 9, 2017, the Company and LLC1 purchased certain real property from an unaffiliated party. The Company and LLC1 have agreed that the Company purchased and owns 49% of the building and LLC1 purchased and owns 51% of the building. The contracted purchase price for the building was $2,420,000 and the total amount paid at closing was $2,501,783 including, fees, insurance, interest and real estate taxes. The Company paid for their building interest by delivering cash at closing of $209,971 and being a co-borrower on a note in the amount of $2,057,000, of whichOn June 14, 2017, the Company has agreedentered into a five-year lease with LLC1 to pay $1,007,930.

LLC1 accounted for approximately 25%6,944 square feet and 18%a monthly rent of our sales for$12,000. For the yearsyear ended December 31, 2018,2020, and 2017, respectively.Our CEO, Mr. Matthew Moore, and members of our board of directors, control LLC1, which could create a conflict of interest. Mr. Moore is the Director of Marketing of MFHC, our Chairman is the Chief Executive Officer of MFHC and our treasurer and director is also the Chief Financial Officer and director of MFHC. On August 5, 2016, MFHC and2019, the Company agreedexpensed $144,000 and $144,000, respectively, related to cancel the Marketing Agreement as a result of the sale by MFHC of substantially all of their assets, including the hearing aid dispensaries to which we were providing services.this lease.

 

Code of Ethics

We adopted a Code of Ethics for Senior Financial Management to promote honest and ethical conduct and to deter wrongdoing. This Code applies to our Chief Executive Officer and Chief Financial Officer and other employees performing similar functions. The obligations of the Code of Ethics supplement, but do not replace, any other code of conduct or ethics policy applicable to our employees generally.

 

41

Under the Code of Ethics, all members of the senior financial management shall:

 

Act honestly and ethically in the performance of their duties at our company,
Avoid actual or apparent conflicts of interest between personal and professional relationships,
Provide full, fair, accurate, timely and understandable disclosure in reports and documents that we file with, or submits to, the SEC and in other public communications by our company,
Comply with rules and regulations of federal, state and local governments and other private and public regulatory agencies that effect the conduct of our business and our financial reporting,
Act in good faith, responsibly, with due care, competence and diligence, without misrepresenting material facts or allowing the member’s independent judgment to be subordinated
Respect the confidentiality of information in the course of work, except when authorized or legally obtained to disclosure such information,
Share knowledge and maintain skills relevant to carrying out the member’s duties within our company,
Proactively promote ethical behavior as a responsible partner among peers and colleagues in the work environment and community,
Achieve responsible use of and control over all assets and resources of our company entrusted to the member, and
Promptly bring to the attention of the Chief Executive Officer any information concerning (a) significant deficiencies in the design or operating of internal controls which could adversely affect to record, process, summarize and report financial data or (b) any fraud, whether or not material, that involves management or other employees who have a significant role in our financial reporting or internal controls.

 

25

Director Independence

 

None of the members of our Board of Directors qualifies as an independent director in accordance with the published listing requirements of the NASDAQ Global Market. The NASDAQ independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director, nor any of his family members has engaged in various types of business dealings with us. In addition, our Board has not made a subjective determination as to each director that no relationships exist which, in the opinion of our Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, though such subjective determination is required by the NASDAQ rules. Had our Board of Directors made these determinations, our Board would have reviewed and discussed information provided by the directors and us with regard to each director’s business and personal activities and relationships as they may relate to us and our management.

 

In performing the functions of the audit committee, our board oversees our accounting and financial reporting process. In this function, our board performs several functions. Our board, among other duties, evaluates and assesses the qualifications of the Company’s independent auditors; determines whether to retain or terminate the existing independent auditors; meets with the independent auditors and financial management of the Company to review the scope of the proposed audit and audit procedures on an annual basis; reviews and approves the retention of independent auditors for any non-audit services; reviews the independence of the independent auditors; reviews with the independent auditors and with the Company’s financial accounting personnel the adequacy and effectiveness of accounting and financial controls and considers recommendations for improvement of such controls; reviews the financial statements to be included in our annual and quarterly reports filed with the Securities and Exchange Commission; and discusses with the Company’s management and the independent auditors the results of the annual audit and the results of our quarterly financial statements.

 

Our board as a whole considers executive officer compensation, and our entire board participates in the consideration of director compensation. Our board as a whole oversees our compensation policies, plans and programs, reviews and approves corporate performance goals and objectives relevant to the compensation of our executive officers, if any, and reviews the compensation and other terms of employment of our Chief Executive Officer and our other executive officers. Our board also administers our equity incentive and stock option plans, if any.

 

42

Each of our directors participates in the consideration of director nominees. In addition to nominees recommended by directors, our board will consider nominees recommended by shareholders if submitted in writing to our secretary. Our board believes that any candidate for director, whether recommended by shareholders or by the board, should be considered on the basis of all factors relevant to our needs and the credentials of the candidate at the time the candidate is proposed. Such factors include relevant business and industry experience and demonstrated character and judgment.

 

Compliance with Section 16(a) of the Securities Exchange Act of 1934

 

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our executive officers and directors, and persons who beneficially own more than 10% of a registered class of our equity securities to file with the SEC initial statements of beneficial ownership, reports of changes in ownership and annual reports concerning their ownership of our common shares and other equity securities, on Forms 3, 4 and 5 respectively. Executive officers, directors and greater than 10% shareholders are required by the SEC regulations to furnish us with copies of all Section 16(a) reports they file. Based solely upon a review of such reports, and on written representations from certain reporting persons, the Company believes that, with respect to the fiscal year ended December 31, 2018,2020 each director, executive officer and 10% stockholder made timely filings of all reports required by Section 16 of the Exchange Act.

 

 

ITEM 11. EXECUTIVE COMPENSATION.

The following tables set forth all of the compensation awarded to, earned by or paid to: (i) each individual serving as our principal executive officer; and (ii) each other individual that served as an executive officer at the conclusion of the fiscal year ended December 31, 20182020 and who received in excess of $100,000.

 

Summary Compensation Table

 

Name and principal positionYear

Salary

$

Bonus

$

Stock Options

$

Option Awards

$

Non-
Equity Incentive Plan Compen-
sation

$

Non-
qualified Deferred Compen-
sation Earnings

$

All Other Compen-
sation (1)

$

Total

$

Matthew Moore,2018225,19300000257,533482,726
CEO, Secretary & Director2017225,000000000225,000
Kim Moore,2018125,10700000257,533382,640
Treasurer & Director2017125,000000000125,000
Mark Moore,2018000000257,533257,533
Chairman201700000000
          

(1) On June 4, 2018, the Company issued 300,000 shares of its Series B Preferred Stock each to Matthew, Mark and Kimberly, in consideration of $45,000 of accrued expenses, the Company’s failure to timely pay current and past salaries, and the willingness to accrue unpaid payroll and non-reimbursement of business expenses without penalty or action for all amounts. The Series B Preferred Stock is not convertible into common stock, nor does the Series B Preferred Stock have any right to dividends and any liquidation preference. The Series B Preferred Stock entitles its holder to a number of votes per share equal to 1,000 votes. The Company determined that fair value of the Series B Preferred Stock issued was $817,600. The fair value was determined as set forth in the Statement of Financial Accounting Standard ASC 820-10-35-37, Fair Value in Financial Instruments.As of December 31, 2018, there were 900,000 shares of Series B Preferred Stock issued and outstanding.

  Non- Non-    
          Equity qualified    
          Incentive Deferred All   
        Plan Compen- Other  
        Stock Option Compen- sation Compen-  
    Salary Bonus Options Awards sation Earnings sation (1) Total
  Name and principal position Year $ $ $ $ $ $ $ $
Matthew Moore,  2020   225,000   0   0   0   0   0   0   225,000 
CEO, Secretary & Director  2019   225,000   0   0   0   0   0   0   225,000 
Kim Moore,  2020   150,000   0   0   0   0   0   0   150,000 
Treasurer & Director  2019   150,000   0   0   0   0   0   0   150,000 
Mark Moore,  2020   0   0   0   0   0   0   0   0 
Chairman  2019   0   0   0   0   0   0   0   0 

 

26

Employment Agreements

 

On November 15, 2016, the Company executed an employment agreement with Matthew Moore for an annual compensation of $225,000 and with Kimberly Moore for $125,000 annual compensation. On January 1,2019, the Company increased compensation of Kimberly Moore to $150,000 per year.

 

43

Outstanding Equity Awards at Fiscal Year-EndYear-End

 

No executive officer received any equity awards or holds exercisable or unexercisable options as of December 31, 2018.2020.

 

Long-Term Incentive Plans

 

There are no arrangements or plans in which the Company would provide pension, retirement or similar benefits for directors or executive officers.

 

Compensation Committee

 

We currently do not have a compensation committee of our Board of Directors. The Board as a whole determines executive compensation.

 

Director Compensation

 

We do not pay fees to our directors for attendance at meetings of the board; however, we may adopt a policy of making such payments in the future. We will reimburse out-of-pocket expenses incurred by directors in attending board and committee meetings.

 

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

 

The following table sets forth information known to the Company with respect to the beneficial ownership (as such term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) of the outstanding common stock of the Company as of April 15, 2019 by: (1) each person known by the Company to beneficially own 5% or more of the Company’s outstanding common stock; (2) each of the named executive officers as defined in Item 402(m)(2); (3) each of the Company’s directors; and (4) all of the Company’s executive officers and directors as a group. The number of shares beneficially owned is determined under rules promulgated by the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Including those shares in the tables does not, however, constitute an admission that the named stockholder is a direct or indirect beneficial owner of those shares. The below table is as of April 15, 2019.June 30, 2022. As of April 15, 2019,June 30, 2022, there were 151,737,3057,323,973,266 shares of common stock issued and outstanding. The Company also has outstanding 900,000 shares of Series B Preferred Stock, which is not convertible but votes on a 1,000 for one basis with the common stock and is considered a “control block” of shares.

 

Name and Address of Beneficial Owner (1)

 Common Stock Beneficially Owned 

Percent

of Class (2)

 

 Preferred Stock Beneficially

Owned

 Percent of Class (3) 

Common Stock Beneficially

Owned

 Percent of Class (2) 

Preferred Stock Beneficially

Owned

 Percent of Class (3)
Mark Moore (4)  19,020,000   12.53%  300,000   33.33%  19,020,000   0.2%  300,000   33.33%
Kimberly Moore (5)  19,020,000   12.53%  300,000   33.33%  19,020,000   0.2%  300,000   33.33%
Matthew Moore (6)  19,020,000   12.53%  300,000   33.33%  19,020,000   0.2%  300,000   33.33%
Officers and Directors as a group, 3 persons (7)  57,060,000   37.6%  900,000   100.0%  57,060,000   0.6%  900,000   100.0%

 

(1)

(1) Beneficial Ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities.

(2)Percentages are based on a total of 151,737,3057,323,973,266 shares of common stock outstanding as of April 15, 2019.

June 30, 2022.

(3)Percentages are based on a total of 900,000 shares of common stock outstanding as of April 15, 2019.

June 30, 2022.

(4)Excludes 19,020,000 shares owned by Kimberly Moore, the spouse of Mark Moore.

(5)Excludes 19,020,000 shares owned by Mark Moore, the spouse of Kimberly Moore.

(6)Excludes 450,000 shares owned by Margaret May Moore, the spouse of Matthew Moore.

(7)Includes Matthew Moore shares, Kimberly Moore shares and Mark Moore shares.

 

 4427 

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

 

On November 1, 2013, the Company acquired Intela-Hear, in exchange for 27,000,000 shares of the Company’s common stock. This resulted in Intela-Hear becoming a wholly-owned subsidiary of the Company. The shares were issued equally to Mark Moore and Kim Moore, who owned all of the outstanding equity of Intela-Hear. Because of the common ownership, all accounts were recorded at Intela-Hear’s historical cost basis. The Company also issued 1,530,000 shares of common stock to its’ CEO for services rendered. The shares were recorded as compensation expense at $40,800 ($0.0267 per share), based upon the Company’s internal valuation on a discounted cash flow basis.

The Company loaned the CEO $20,500 during the year ended December 31, 2013. During the year ended December 31, 2017, the Company received payments in full of all principal and interest due. As of December 31, 2017,2020, we had $662,178of the balance owed the Company is $-0-. The Company recorded interest incomeamount payable to related parties as compared to $266,419 as of $228 for the year ended December 31, 2017.

2019. The Company loaned the CEO $20,500 during the year ended December 31, 2013. The notebalance primarily represents advance payable to shareholders and interest were paid in full during the year ended December 31, 2017. The Company recorded interest income of $228 for the year ended December 31, 2017.

During the year ended December 31, 2018, and 2017, our CEO (stockholder) paid expensesmanagement of the Company and accounts payable on behalf of the Company (see Note 5). As of December 31, 2018, and 2017, the Company owed the CEO $57,526 and $138,637, respectively, which is included in Advances payable, stockholders on the consolidated balance sheets included herein.Company.

During the year ended December 31, 2018, and 2017, our Chairman (stockholder) paid expenses of the Company and accounts payable on behalf of the Company (see Note 5). As of December 31, 2018, and 2017, the Company owed the Chairman $0 and $38,201, respectively, which is included in Advances payable, stockholders on the consolidated balance sheets included herein.

Pursuant to a Marketing Agreement (cancelled August 5, 2016), the Company provided marketing programs to promote and sell hearing aid instruments and related devices to Moore Family Hearing Company (“MFHC”). MFHC owned and operated retail hearing aid stores. Based on common control of MFHC and the Company, all transactions with MFHC are classified as related party transactions. On August 8, 2016, in consideration of $128,000 (the “Cancellation Fee”), MFHC and the Company agreed to cancel the Marketing Agreement as a result of the sale by MFHC of substantially all of their assets (see Note 6). On August 11, MFHC paid $229,622 to the Company (inclusive of the balance owed as of June 30, 2016, the Cancellation Fee and other related party activity).

Pursuant to the Marketing Agreement, beginning in January 2014, the monthly fee was increased from $2,500 to $3,200 per retail location. For January through June 2015, there were 18 MFHC retail stores and one store was added July 1, 2015. From January 1, 2016 thru August 5, 2016, there were 20 stores resulting in revenue of $458,667 and $720,000 for the year ended December 31, 2016. Also, during the year ended December 31, 2016, the Company invoiced MFHC $330,353 for the production, printing and mailing of direct mail advertising materials. Lastly, the Company recognized $128,000 from the Cancellation Fee of the Marketing Agreement as related party income for the year ended December 31, 2016. The Company has offset the accounts receivable owed from MFHC for expenses of the Company that have been paid by MFHC. As a result of these payments in addition to MFHC’s payments to the Company during the years ended December 31, 2017, and 2016, the balance due to MFHC as of December 31, 2018, and 2017, was $22,548.

On April 1, 2013, the Company entered into a five-year sublease agreement with MFHC to sublease approximately 729 square feet of office space for $1,500 per month. The monthly rent reduced the amounts owed to the Company from MFHC for the marketing services provided to MFHC. For the year ended December 31, 2017, the Company expensed $1,500 related to this lease.

On February 1, 2016, the Company entered into a one- year sublease agreement with MFHC to sublease approximately 2,119 square feet of office space for $4,026 per month. The monthly rent reduced the amounts owed to the Company from MFHC for the marketing services provided to MFHC. Effective April 30, 2016, MFHC released the Company from the sublease. For the year ended December 31, 2017, the Company expensed $12,078 related to this lease.

45

Prior to August 1, 2016, the Company’s CEO was being compensated from MFHC, as he also held a position with MFHC. During that time the Company estimated the portion of the CEO’s salary that should be allocated to the Company, and subsequent to August 1, 2016, the Company agreed to compensation of $225,000 per year. Effective August 1, 2016, the Company agreed to compensate our Chief Financial Officerand $125,000 per annum.year for the Company’s CEO and CFO, respectively. On November 15, 2016, the Company entered into an employment agreementagreements with ourits CEO and CFO, which includes antheir annual base salarysalaries of $225,000 and $125,000, respectively. TheOn January 1, 2019, the Company has expensed $225,193 and $225,000agreed to increase compensation to $ $150,000 per year for the CEO, for the years ended December 31, 2018, and 2017, respectively, and the Company recognized $125,107 and $124,519 of expense for the CFO for the year ended December 31, 2018, and 2017, respectively.Company’s CFO.

In September 2016, the officers and directors of the Company formed a California Limited Liability Company (“LLC1”), for the purpose of acquiring commercial real estate and other business activities.On December 24, 2016, LLC1 acquired two retail stores from the buyer of the MFHC stores. On March 1,June 14, 2017, the Company entered into a twelve-month Marketing Agreementfive-year lease with eachLLC1 for approximately 6,944 square feet and a monthly rent of the stores to provide telemarketing and design and marketing services for $2,500 per month per store, resulting in $60,000 and $50,000 of revenues for the years ended December 31, 2018, and 2017, respectively. Additionally, for the years ended December 31, 2018, and 2017, the Company invoiced LLC1 $22,019 and $36,499, respectively, for the Company’s production, printing and mailing services. As of December 31, 2018, and 2017, LLC1 owes the Company $203,325 and $73,996, respectively.$12,000 (Note 11).

 

On May 9, 2017, the Company and LLC1 purchased certain real property from an unaffiliated party. The Company and LLC1 have agreed that the Company purchased and owns 49% of the building and LLC1 purchased and owns 51% of the building. The contracted purchase price for the building was $2,420,000 and the total amount paid at closing was $2,501,783 including, fees, insurance, interest and real estate taxes. The Company paid for their building interest by delivering cash at closing of $209,971 and being a co-borrower on a note in the amount of $2,057,000, of which the Company has agreed with LLC1 to pay $1,007,930. On June 14, 2017, the company entered into a five-year lease with LLC1 for approximately 6,944 square feet and a monthly rent of $12,000. For the years ended December 31, 2018, and 2017, the Company expensed $144,000 and $64,499, respectively, related to this lease and is included in Rent, related party, on the consolidated statement of operations, included herein.

In November 2016, our Chairman formed a California limited liability Company (“LLC”), for the purpose of providing consulting services to the Company.The Company entered into an agreement with the LLC and paid the LLC, $375,000 during the year ended December 31, 2016 for services performed and to be performed. Of the $375,00 amount paid, $241,667 was recognized as consulting fees- stockholder for the year ended December 31, 2016, and the remaining $133,334 was recorded as deferred commissions- stockholder as of December 31, 2016. Additionally, the Company has accrued and recorded $96,000 in other expense- stockholder and $96,000 was recorded as commission payable, stockholder. During the year ended December 31, 2017, the Company paid the LLC an additional $771,000 ($96,000 of which reduced previous amounts owed) and expensed $808,334 ($60,000 as commissions for services performed and $748,334 as other expense) due to uncertainty of future services being provided, based on the Complaint filed on May 26, 2017. As of December 31, 2017, the deferred commissions-stockholder is $-0-.$1,007,930 (see Note 9).

 

 

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

The following table shows the fees that were billed for the audit and other services provided by D. Brooks and Associates CPA’s P.A.Paris Kreit & Chiu CPA for the years ended December 31, 20182020 and 2017.2019.

 

 2018 2017  2020   2019 
Audit Fees $28,606  $28,606  $—    $—   
Audit-Related Fees  —     —     —     —   
Tax Fees  —     —     —     —   
All Other Fees  —     —     —     —   
Total $28,606  $28,606  $—    $—   

 

46

Audit Fees — This category includes the audit of our annual financial statements, review of financial statements included in our Quarterly Reports on Form 10-Q and services that are normally provided by the independent registered public accounting firm in connection with engagements for those fiscal years. This category also includes advice on audit and accounting matters that arose during, or as a result of, the audit or the review of interim financial statements.

 

Audit-Related Fees — This category consists of assurance and related services by the independent registered public accounting firm that are reasonably related to the performance of the audit or review of our financial statements and are not reported above under “Audit Fees.” The services for the fees disclosed under this category include consultation regarding our correspondence with the SEC and other accounting consulting.

 

Tax Fees — This category consists of professional services rendered by our independent registered public accounting firm for tax compliance and tax advice.

 

All Other Fees— This category consists of fees for other miscellaneous items.

 

Our board of directors has adopted a procedure for pre-approval of all fees charged by our independent registered public accounting firm. Under the procedure, the board approves the engagement letter with respect to audit, tax and review services. Other fees are subject to pre-approval by the board. All audit and permissible non-audit services provided by the auditors with respect to 20162020 and 20152019 were pre-approved by the board of directors.

 

PARTIV

 

ITEM 15. EXHIBITS AND REPORTS.

 

(a)1.(a)1. Financial Statements

The consolidated financial statements and Report of Independent Registered Public Accounting Firm is included on pages F-1 through F-13

2.Financial Statement Schedules

All schedules for which provisions made in the applicable accounting regulations of the Securities and Exchange Commission (the “Commission”) are either not required under the related instructions, are not applicable (and therefore have been omitted), or the required disclosures are contained in the financial statements included herein.

 28 

3.The consolidated financial statements and Report of Independent Registered Public Accounting Firm is included on pages F-1 through F-13
2.Financial Statement Schedules
All schedules for which provisions made in the applicable accounting regulations of the Securities and Exchange Commission (the “Commission”) are either not required under the related instructions, are not applicable (and therefore have been omitted), or the required disclosures are contained in the financial statements included herein.
3.Exhibits (including those incorporated by reference).

 

 

Exhibit

Number

 

Description of Exhibit

3.1* Articles of Incorporation
3.2* Bylaws of InnerScope Advertising Agency, Inc.
3.3* Amended and Restated Articles of Incorporation
3.4* Amended and Restated Articles of Incorporation dated August 25,2017
4.3* Private Placement Offering Memorandum
10.2* InnerScope, Inc. Marketing Agreement between the Company and Moore Family Hearing Company, Inc.
10.3* 

Acquisition Agreement and Plan of Share Exchange dated June 20, 2012, between the Company and InnerScope Advertising Agency, LLC

47

10.4* 

Acquisition Agreement and Plan of Share Exchange dated November 1, 2013, between the Company and Intela-Hear,LLC

10.5* Promissory Note dated April 1, 2013, between the Company and Matthew Moore
10.6* Promissory Note dated June 25, 2013, between the Company and Matthew Moore
10.7* June 2012 Business Consulting Agreement
10.8+* GN ReSound Sales Agreement
10.9+* Store Expansion Consulting Agreement
10.10+* Consulting Agreement
10.11#* Employment Agreement with Matthew Moore, CEO
10.12#* Employment Agreement with Kimberly Moore, CFO
10.13* Financial Consulting Agreement between the Company and Venture Equity, LLC
10.14* Consulting and Representation Agreement between the Company and CorporateAds.com
10.15* 

Business Loan Agreement, dated May 5, 2017, between InnerScope Advertising Agency, Inc. and Moore Holdings, LLC and First Community Bank.

10.16* 

Commercial Security Agreement, dated May 5, 2017, between InnerScope Advertising Agency, Inc. and Moore Holdings, LLC and First Community Bank.

10.17* U.S. Small Business Administration Note.
10.18* 

Deed of Trust, dated May 5, 2017, among InnerScope Advertising Agency, Inc. and Moore Holdings, LLC. and First Community Bank and Placer Title Company.

10.19* 

Securities Purchase Agreement dated October 5, 2017 by and between InnerScope Hearing Technologies, Inc. and Power Up Lending Group, LTD.

10.20* 

Convertible Promissory Note dated October 5, 2017, by and between InnerScope Hearing Technologies, Inc. and Power Up Lending Group, LTD.

10.21* 

Securities Purchase Agreement dated November 10, 2017, by and between InnerScope Hearing Technologies, Inc. and Carebourn Capital, L.P.

10.22* 

Convertible Promissory Note dated November 10, 2017, by and between InnerScope Hearing Technologies, Inc. and Carebourn Capital, L.P.

10.23* 

Securities Purchase Agreement dated February 8, 2018 by and between InnerScope Hearing Technologies, Inc. and Power Up Lending Group, LTD.

10.24* 

Convertible Promissory Note dated February 8, 2018, by and between InnerScope Hearing Technologies, Inc. and Power Up Lending

Group, LTD.

10.25* 

Securities Purchase Agreement dated April 8, 2019, by and between InnerScope Hearing Technologies, Inc. and Carebourn Capital,L.P.

10.26* 

Convertible Promissory Note dated April 8, 2018, by and between InnerScope Hearing Technologies, Inc. and Carebourn Capital,L.P.

10.27* 

Securities Purchase Agreement dated May 11, 2018, by and between InnerScope Hearing Technologies, Inc. and One44 CapitalLLC

10.28* 

Convertible Promissory Note dated May 11, 2018, by and between InnerScope Hearing Technologies, Inc. and One44 CapitalLLC

10.29* 

Convertible Back- End Promissory Note dated May 11, 2018, by and between InnerScope Hearing Technologies, Inc. and One44 Capital LLC

10.30* Mutual Settlement Agreement and Release with Helix Hearing Care (California), Inc.
10.31* Manufacturing Design and Marketing Agreement.
10.32* 

Securities Purchase Agreement between InnerScope Hearing Technologies, Inc. and Eagle Equities, LLC, dated November 2, 2018.

10.33* 

Form of 8% Convertible Redeemable Notes issued by Company to Eagle Equities, LLC, dated November 2, 2018.

 4829 

 

10.34* $255,500 Principal Amount 8% Collateralized Secured Promissory Note issued by Eagle Equities, LLC.
10.35* 

First Amendment to Manufacturing Design and Marketing Agreement (the “Zounds Agreement”) between InnerScope Hearing Technologies, Inc. and Zounds Hearing, Inc., a Delaware corporation (“Zounds”), dated November 2, 2018

10.36* Joint Development Agreement between InnerScope Hearing Technologies, Inc. and Erchonia Corporation.
10.37* 

Exclusive Distributor Agreement between InnerScope Hearing Technologies, Inc. and Erchonia Corporation.

31.1** Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer
31.2** Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer
32.1** Section 1350 Certification of Chief Executive Officer and Chief Financial Officer
101.INS** XBRL Instance
101.SCH** XBRL Taxonomy Extension Schema
101.CAL** XBRL Taxonomy Extension Calculation Linkbase
101.DEF** XBRL Taxonomy Extension Definition Linkbase
101.LAB** XBRL Taxonomy Extension Labels Linkbase
101.PRE** XBRL Taxonomy Extension Presentation Linkbase

* Previously filed.

+ Confidential Treatment has been requested for certain portions thereof pursuant to Confidential Treatment Request under Rule 406 promulgated under the Securities Act. Such provisions and attachments have been filed with the Securities and Exchange Commission.

** Filed Herewith

# Denotes management contract or compensatory plan or arrangement.

*Previously filed.
+Confidential Treatment has been requested for certain portions thereof pursuant to Confidential Treatment Request under Rule 406 promulgated under the Securities Act. Such provisions and attachments have been filed with the Securities and Exchange Commission.
**Filed Herewith
#Denotes management contract or compensatory plan or arrangement.

 4930 

 

SignaturesSIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

InnerScope Hearing Technologies, Inc.


InnerScope Hearing Technologies,
Inc.

 

By:/s/ Matthew Moore
Matthew Moore
Chief Executive Officer
Date:April 16, 2019


By:/s/ Matthew Moore                    

Matthew Moore

Chief Executive Officer

Date: September 13, 2022

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature Title Date

/s/ Mark Moore

 

Chairman

 September 13, 2022

Mark Moore

/s/ Mark Matthew Moore

 ChairmanApril 16, 2019
Mark Moore
/s/ Matthew Moore

Chief Executive Officer, CEOand

 April 16, 2019September 13, 2022

Matthew Moore

Director (principal executive officer)

/s/ Kimberly Moore

 

Director (Principal Executive Officer)

Chief Financial Officer and Director

 April 16, 2019September 13, 2022
Kimberly Moore (chief accounting officer)Chief Accounting Officer) 

 

 5031 

 

 

INNERSCOPE ADVERTISING AGENCY, HEARING TECHNOLOGIES, INC.

FOR THE YEARS ENDED DECEMBER 31, 20182020 AND 20172019

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

Report of Independent Registered Public Accounting FirmF-2F-2
Consolidated Balance Sheets as of December 31, 20182020 and 20172019F-3F-3
Consolidated Statements of Operations for the years ended December 31, 20182020 and 20172019F-4F-4
Consolidated Statement of Changes in Stockholders’ Deficit for the years ended December 31, 20182020 and 20172019F-5F-5
Consolidated Statements of Cash Flows for the years ended December 31, 20182020 and 20172019F-6F-6
Notes to Consolidated Financial StatementsF-7 – F-31F-27

 

 F-1 

 

Paris, Kreit & Chiu CPA LLP

 200 Park Ave, Suite 1700

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMNew York, NY 10166

(949) 326-CPAS (2727)

 

Report of Independent Registered Public Accounting Firm

 

To the

Board of Directors and
Stockholders of

InnerScope Hearing Technologies, Inc.

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of InnerScope Hearing Technologies, Inc. (the Company) as of December 31, 20182020 and 2017,2019, and the related consolidated statements of operations, stockholders’ deficit, and cash flows for each of the years in the two-year periodthen ended, December 31, 2018, and the related notes to the consolidated financial statements (collectively referred to as the consolidated financial statements).statements. In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the CompanyInnerScope Hearing Technologies, Inc. as of December 31, 20182020 and 2017,2019, and the results of its operations and its cash flows for each of the years in the two year periodthen ended December 31, 2018, in conformity with accounting principles generally accepted in the United States of America.

Going Concern

The accompanying consolidated financial statements have been prepared assuming that the entity will continue as a going concern. As discussed in Note 3 to the consolidated financial statements, the entity has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 3. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’sentity’s management. Our responsibility is to express an opinion on the Company’s consolidatedthese financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB)("PCAOB") and are required to be independent with respect to the CompanyInnerScope Hearing Technologies, Inc. in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The CompanyInnerScope Hearing Technologies, Inc. is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’sentity’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the consolidated financial statements, the Company has incurred a net loss of $4,585,117 for the year ended December 31, 2018.  Additionally, the Company has a working capital deficit of $3,088,957 and an accumulated deficit of $6,372,129 as of December 31, 2018. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plan regarding these matters is also described in Note 3 to the consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

D. Brooks and Associates CPA’s, P.A.Paris Kreit & Chiu CPA LLP

Paris, Kreit & Chiu CPA LLP

We have served as the Company’sInnerScope Hearing Technologies, Inc.'s auditor since 2015.

Palm Beach Gardens, Florida

April 16, 20192021.

 

 New York, NY

September 12, 2022

 F-2 

 

INNERSCOPE HEARING TECHNOLOGIES, INC.
CONSOLIDATED BALANCE SHEETS
   
  December 31,
  2018 2017
     
ASSETS        
         
Current Assets:        
Cash $87,826  $84,720 
Accounts receivable, allowance for doubtful accounts $18,383 and $63,799 respectively  6,112   12,950 
Accounts receivable from related party  203,325   73,996 
Employee advances  40,942   —   
Prepaid assets  167,992   101,110 
Inventory  91,510   5,959 
Total current assets  597,707   278,735 
         
Security deposits $11,056  $—   
Domain name 3,000  3,000 
Intangible assets, net of accumulated amortization of $2,168 (2018)  1,010,840   —   
Property and equipment, net of accumulated depreciation of $4,705 (2018) and $1,068 (2017)  43,450   1,583 
Investment in undivided interest in real estate  1,226,963   1,224,903 
Total assets $2,893,014  $1,508,221 
         
LIABILITIES AND STOCKHOLDERS' DEFICIT        
         
Current Liabilities:        
Accounts payable and accrued expenses $1,233,653  $161,919 
Accounts payable to related party  22,548   22,548 
Notes payable - stockholder  95,800   65,000 
Advances payable, stockholders  57,526   176,838 
Current portion of convertible notes payable, net of discounts  151,166   74,140 
Current portion of notes payable, net of deferred loan fees  29,270   —   
Current portion of note payable - undivided interest in real estate  19,660   18,518 
Customer deposits  56,698   —   
Officer salaries payable  188,942   47,248 
Income taxes payable  23,998   33,682 
Derivative liabilities  1,807,404   540,965 
Deferred revenue  —     847,223 
Total current liabilities  3,686,665   1,988,081 
         
Long term portion of note payable- undivided interest in real estate  964,847   982,176 
Long term portion of convertible notes payable, net of discounts  —     12,587 
Total liabilities  4,651,512   2,982,844 
         
Commitments and contingencies        
         
Stockholders' Deficit:        
Preferred stock, $0.0001 par value; 25,000,000 shares authorized;        
Series A preferred stock, par value $0.0001, 9,510,000 shares authorized and -0- issued and outstanding $—    $—   
Series B preferred stock, par value $0.0001, 900,000 shares authorized and issued and outstanding (2018)  90   —   
Common stock, $0.0001 par value; 490,000,000 shares authorized; 120,425,344 and 61,539,334 shares issued and outstanding December 31, 2018, and 2017, respectively  12,042   6,153 
Common stock to be issued, $0.0001 par value, 6,373,848, and 102,564 shares December 31, 2018, and 2017, respectively  637   10 
Additional paid-in capital  4,836,557   331,227 
Deferred stock compensation  (235,694)  (25,000)
Accumulated deficit  (6,372,129)  (1,787,012)
         
Total stockholders' deficit  (1,758,498)  (1,474,623)
         
  $2,893,014  $1,508,221 
         
         
See notes to consolidated financial statements.

INNERSCOPE HEARING TECHNOLOGIES, INC.

CONSOLIDATED BALANCE SHEETS

     
  As of December 31,
  2020 2019
ASSETS    
Current Assets:        
Cash $3,349  $4,459 
Accounts receivable, allowance for doubtful accounts  12,429   51,160 
Accounts receivable from related party          
Employee advances  3,000   3,750 
Prepaid assets       73,249 
Inventory  4,671   18,781 
Total current assets  23,449   151,399 
         
Security deposits  4,863   12,752 
Domain name  3,000   3,000 
Intangible assets, net of accumulated amortization       879,336 
Property and equipment, net of accumulated depreciation  60,203   72,241 
Operating leases right-of-use assets, net  364,062   846,132 
Investment in undivided interest in real estate  1,227,733   1,210,526 
Total assets $1,683,310  $3,175,386 
         
LIABILITIES AND STOCKHOLDERS' DEFICIT        
Current Liabilities:        
Bank overdraft $271  $2,631 
Accounts payable and accrued expenses  1,841,300   1,316,185 
Accounts payable to related party  662,178   266,419 
Notes payable - stockholder  95,800   95,800 
Current portion of convertible notes payable, net of discounts  3,255,598   2,390,481 
Note payable, other and related party  118,786   106,942 
Customer deposits  10,925   21,505 
Current portion of note payable- undivided interest in real estate  22,150   20,708 
Derivative liabilities  4,046,401   3,515,055 
Operating lease liabilities, current portion  365,587   299,794 
Total current liabilities  10,418,996   8,035,520 
         
Long term portion of note payable- undivided interest in real estate  938,003   952,884 
PPP loan  262,445      
Operating lease liabilities, Less current portion  416,788   731,496 
Total liabilities $12,036,232   9,719,900 
         
Commitments and contingencies        
Stockholders' Deficit:        
Preferred stock, $0.0001 par value; 25,000,000 shares authorized;        
Series A preferred stock, par value $0.0001, -0- (2020) and -0- (2019)          
Series B preferred stock, par value $0.0001, 900,000 (2020) and 900,000 (2019) shares authorized, and 900,000 (2020) and 900,000 (2019) shares issued and outstanding  90   90 
Common stock, $0.0001 par value; 14,975,000,000 (2020) and 14,975,000,000 (2019) shares authorized and 3,628,422,042 (2020) and 342,118,136 (2019) shares issued and outstanding  362,845   34,212 
Common stock to be issued, $0.0001 par value, 2,412,671 (2020) and 2,412,671 (2019) shares  241   241 
Additional paid-in capital  8,534,062   7,717,411 
Accumulated deficit  (19,250,160)  (14,296,468)
Total stockholders' deficit  (10,352,922)  (6,544,514)
Total Liabilities and Stockholders' Equity $1,683,310  $3,175,386 

 

See notes to consolidated financial statements.

 F-3 

 

INNERSCOPE HEARING TECHNOLOGIES, INC.

INNERSCOPE HEARING TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
   
   Year Ended December 31,
   2018   2017 
         
Revenues:        
Revenues, other $242,857  $384,177 
Revenues, related party  82,019   86,449 
Total revenues  324,876   470,626 
         
Cost of sales        
Cost of sales, other  156,909   256,918 
Cost of sales, related  24,779   36,303 
Total cost of sales  181,688   293,221 
         
Gross profit  143,188   177,405 
         
Operating Expenses:        
Compensation and benefits (including stock- based fees of $785,702 (2018))  1,543,754   645,723 
Advertising and promotion  173,580   —   
Professional fees (including stock- based fees of $302,148 (2018) and $173,794 (2017))  651,216   391,177 
Consulting fees, stockholder  —     60,000 
Rent (including related party of $144,000 (2018) and $111,377 (2017))  186,700   111,377 
Investor relations  125,415   43,845 
Bad debt expense, net of recoveries  10,383   63,799 
Other general and administrative  160,753   87,974 
Total operating expenses  2,851,801   1,403,897 
         
Loss from operations  (2,708,613)  (1,226,492)
         
Other Income (Expense):        
Other income  —     5,533 
Derivative expense  (2,436,951)  (265,674)
Gain (loss) on investment in undivided interest in real estate  2,060   (1,378)
Write off of deferred commissions  —     (508,334)
Gain on contract cancellations and settlements  1,297,223   160,000 
Gain on debt extinguishment  530,468   —   
Interest income, including $228 (2017) from officer  —     300 
Interest expense and finance charges  (1,269,305)  (77,287)
Total other income (expense), net  (1,876,505)  (686,840)
         
Net loss $(4,585,117) $(1,913,332)
         
Basic and diluted loss per share $(0.06) $(0.03)
         
Weighted average number of common shares outstanding        
Basic and diluted  78,891,884   61,320,706 

CONSOLIDATED STATEMENTS OF OPERATIONS

     
  Year Ended December 31st,
  2020 2019
Revenues:        
Revenues, other $166,111  $802,109 
Revenues, related party       45,000 
Total revenues  166,111   847,109 
         
Cost of sales        
Cost of sales, other  68,768   496,736 
Total cost of sales  68,768   496,736 
         
Gross profit  97,343   350,374 
         
Operating Expenses:        
Compensation and benefits  661,840   1,575,395 
Advertising and promotion  19,762   485,407 
Professional fees  114,476   763,157 
Rent, including related party  322,879   424,613 
Investor relations  14,796   193,696 
Depreciation and Amortization expense  123,646   150,024 
Other general and administrative  69,188   502,908 
Total operating expenses  1,326,587   4,095,200 
         
Loss from operations  (1,229,244)  (3,744,826)
         
Other Income (Expense):        
Other income        
Derivative income (loss)  (1,066,904)  (647,633)
Gain on equity investment  30,646   15,083 
Amortization of debt discount  (1,222,965)  (2,954,879)
Loss on debt extinguishment       (52,702)
Loss on lease termination  (201,283)  (146,337)
Other income (expenses)  181   (6,742)
Loss on intangibles  (775,000)     
Interest expense and finance charges  (489,123)  (386,303)
Total other income (expense), net  (3,724,448)  (4,179,513)
         
Loss before income tax  (4,953,692)  (7,924,339)
         
Income tax provision          
         
Net Loss $(4,953,692) $(7,924,339)
         
Basic and diluted income (loss) per share  (0.00)  (0.02)
         
Weighted average number of common shares outstanding        
Basic and diluted  2,769,472,382   486,708,071 

See notes to consolidated financial statements.

See notes to consolidated financial statements.

 F-4 

 

INNERSCOPE HEARING TECHNOLOGIES, INC.

INNERSCOPE HEARING TECHNOLOGIES , INC.
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)
YEARS ENDED DECEMBER 31, 2018 and 2017
                    
      Common stock to Deferred Series B Additional Retained  Total Stockholders’
  Common stock be issued stock Preferred stock Paid-in Earnings Equity
  Shares Amount Shares Amount Compensation Shares Amount Capital (Deficit) (Deficit)
                     
Balances December 31, 2016  60,906,000  $6,090   —    $—    $—     —    $—    $104,110  $126,320  $236,520 
                                         
Common stock issued for services  633,334   63   —     —     (100,000)  —     —     189,937   —     90,000 
                                         
Reclassification of derivative liabilities upon payment of convertible debt  —     —     —     —     —     —     —     28,215   —     28,215 
                                         
Stock based compensation  —     —     102,564   10   75,000   —     —     8,965   —     83,975 
                                         
Net loss  —     —     —     —     —     —     —     —     (1,913,332)  (1,913,332)
                                         
Balances December 31, 2017  61,539,334   6,153   102,564   10   (25,000)  0   0   331,227   (1,787,012)  (1,474,623)
                                         
Stock based compensation  5,117,867   512   3,535,284   354   (150,694)  —     —     465,079   —     315,250 
                                         
Stock issued from common stock to be issued  102,564   10   (102,564)  (10)  —     —     —     —     —     —   
                                         
Issuance of Series B preferred stock  —     —     —     —     —     900,000   90   817,510   —     817,600 
                                         
Common stock issued or to be issued for convertible notes  53,325,227   5,333   1,838,564   184   —     —     —     819,306   —     824,822 
                                         
Common stock issued for asset purchase  340,352   34   —     —     —     —     —     22,940   —     22,974 
                                         
Common stock to be issued for joint development project  —     —     1,000,000   100   (60,000)  —     —     59,900   —     —   
                                         
Reclassification of derivative liabilities upon payment of convertible debt  —     —     —     —     —     —     —     2,320,595   —     2,320,595 
                                         
Net loss  —     —     —     —     —     —     —     —     (4,585,117)  (4,585,117)
                                         
Balances December 31, 2018  120,425,344   12,042   6,373,848  $637  $(235,694)  900,000  $90  $4,836,556  $(6,372,129) $(1,758,498)

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT

YEARS ENDED DECEMBER 31, 2020 and 2019

                   
  Series B Preferred stock Common stock Deferred stock Common stock to be issued Additional Paid-in Retained Total Stockholders'
  Shares Amount Shares Amount Compensation Shares Amount Capital deficit Deficit
Balances December 31, 2018  900,000  $90   120,425,344  $12,042  $(235,694)  6,376,848  $637  $4,836,556  $(6,372,129) $(1,758,498)
                                         
Amortization of deferred stock compensation  —          —          235,694   —                    235,694 
                                         
Issuance of stock for services  —          12,576,313   1,258        (3,961,177)  (396)  439,804        440,666 
                                         
Related party contribution  —          —               —          12,048        12,048 
                                         
Debt conversion and retirement of derivative liabilities  —          209,116,478   20,912        —          2,429,003        2,449,915 
                                         
Net loss for the period ended December 31, 2019  —          —               —               (7,924,339)  (7,924,339)
                                         
Balances December 31, 2019  900,000  $90   342,118,135  $34,212  $     2,415,671  $241  $7,717,411  $(14,296,468) $(6,544,514)
                                         
Debt conversion and retirement of derivative liabilities  —          3,286,303,906   328,633        —          816,651        1,145,284 
                                         
Net loss for the period ended  December 31, 2020  —          —               —               (4,953,692)  (4,953,692)
                                         
Balances December 31, 2020  900,000  $90   3,628,422,041  $362,845  $     2,415,671  $241  $8,534,062  $(19,250,160) $(10,352,922)

See notes to consolidated financial statements.

 

See notes to consolidated financial statements.

 F-5 

 

INNERSCOPE HEARING TECHNOLOGIES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

     
  Year Ended December 31,
  2020 2019
Cash flows from operating activities:        
Net loss $4,953,692  $7,924,339 
Adjustments to reconcile net loss to net cash used in operations:       
Depreciation and amortization  123,646   150,024 
Gain/Loss on settlement of debt       44,852 
Loss on lease termination  (11,020)  5,426 
Loss on ROU asset  204,416   167,938 
Discount amortization  1,172,111   2,850,033 
Derivative loss (gain)  1,066,904   647,633 
Stock-based compensation       440,667 
Gain/Loss on equity investment  (30,646)  15,083 
Loss on intangibles  775,000     
Changes in operating assets and liabilities:        
Accounts receivable  38,732   (45,048)
Inventory  14,110   72,729 
Pre-paids and other current asset  73,999   369,930 
Related party receivable       203,325 
Security deposit  7,889   (1,696)
Accounts payable  570,077   (130,405)
Customer deposits  (10,580)  (35,193)
Related party advances  395,759   231,310
Changes in lease liability  39,761   11,790 
Net cash used in operating activities  (523,534)  (2,925,941)
         
Cash flows from investing activities:        
Changes in intangibles          
Purchase/Sale of office and computer equipment  (7,272)  (49,614)
Equity investment       (9,561)
Net cash used in investing activities  (7,272)  (59,175)
         
Cash flows from financing activities:        
Proceeds from related party contribution       12,048 
Payments/Proceeds from convertible notes payable  269,611   2,854,250 
Proceeds/payments from notes payable       32,820 
Bank overdraft  (2,360)  2,631 
Proceeds from pay check protection program loan  262,445      
Net cash provided by financing activities  529,696   2,901,749 
         
Net decrease in cash and cash equivalents  (1,110)  (83,367)
         
Cash and cash equivalents, beginning of year $4,459  $87,826 
         
Cash and cash equivalents, end of year $3,349  $4,459 
         
Supplemental disclosure of cash flow information:        
Cash paid for interest          
Cash paid for income taxes          
         
Schedule of non-cash Investing or Financing Activity:        
Reclassification of derivative liabilities upon principal repayments of convertible notes  684,355   1,322,092 
Conversion of notes payable and accrued interest in common stock  460,929   1,127,823 
Operating lease right-of-use assets and liabilities       1,038,580 

See notes to consolidated financial statements.

INNERSCOPE HEARING TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
         
   2018   2017 
         
Cash flows from operating activities:        
Net loss $(4,585,117) $(1,913,332)
Adjustments to reconcile net loss to net cash used in operations:        
Loss on fair value of derivatives  2,436,949   265,674 
Amortization of debt discounts  1,109,590   63,434 
Depreciation and amortization  5,806   884 
Stock compensation expense  1,087,850   173,974 
Non cash interest expense  6,025     
(Gain) loss on investment in undivided interest in real estate  (2,060)  1,378 
Gain on debt extinguishment  (530,468)  —   
Gain on collection of bad debts  —     —   
Recognition of deferred revenues per settlement  (847,223)  —   
Changes in operating assets and liabilities:        
Decrease (increase) in:        
Interest receivable, related party  —     146 
Accounts receivable  6,838   (12,950)
Employee advances  (40,942)    
Inventory  (85,551)  (3,638)
Deferred commissions, stockholder  —     133,334 
Prepaid assets  (51,900)  (94,887)
Accounts receivable, related party  (129,329)  (73,996)
Increase (decrease) in:        
Accounts payable and accrued expenses  265,298   114,179 
Income taxes payable  (9,684)  —   
Commissions payable, stockholder  —     (96,000)
Officer salaries payable  141,694   40,517 
Deferred revenue  —     625,000 
Customer deposits  56,698   —   
Net cash used in operating activities  (1,165,526)  (776,283)
         
Cash flows from investing activities:        
Payment of security deposit  (6,440)  —   
Purchase of domain name  —     (3,000)
Purchase of office and computer equipment  (7,104)  —   
Repayments from shareholder loans receivable  —     17,938 
Investment in undvided interest in real estate  —     (218,351)
Purchase of technology  (183,200)  —   
Net cash used in investing activities  (196,744)  (203,413)
         
Cash flows from financing activities:        
Proceeds from issuance of note payable  77,600   —   
Advances (repayments) to stockholder  (74,312)  186,338 
Proceeds from advances, stockholder  36,800   65,000 
Proceeds from issuances of convertible notes payable  1,664,450   345,000 
Repayments of note payable  (79,499)  (7,236)
Repayments of advances, shareholder  (6,000)  —   
Repayments of principal of convertible note payable  (253,663)  (18,200)
Net cash provided by financing activities  1,365,376   570,902 
         
Net increase (decrease) in cash and cash equivalents  3,106   (408,794)
         
Cash and cash equivalents, Beginning of period  84,720   493,514 
         
Cash and cash equivalents, End of period $87,826  $84,720 
         
Supplemental disclosure of cash flow information:        
Cash paid for interest $102,203  $4,521 
Cash paid for income taxes $—    $—   
         
Schedule of non-cash Investing or Financing Activity:        
Reclassification of derivative liabilities upon principal repayments of convertible notes $2,320,595  $—   
Intangible assets in accounts payable $816,800   —   
Issuance of note payable for investment in undivided interest in real estate $—    $1,007,930 
Conversion of notes payable and accrued interest in common stock $824,823   —   
Series B Preferred Stock issued for payment of related party liabilities $45,000  $—   
         
Acquisition of Assets        
Issuance of common stock as consideration for assets purchased $22,974  $—   
Assumed liabilities  33,049  —   
Property and equipment  (38,400) —   
Other Assets  (4,616) —   
Customer base  (300)  —   
Non- compete  (12,707)  —   
  $—    $—   
         
         
See notes to consolidated financial statements.

 F-6 

 

NOTE 1 - ORGANIZATION

Business

InnerScope Hearing Technologies, Inc. (“Company”, “InnerScope”) is a Nevada Corporation incorporated on June 15, 2012, with its principal place of business in Roseville, California. The Company was originally named InnerScope Advertising Agency, Inc. and was formed to provide advertising and marketing services to retail establishments in the hearing device industry. On August 25, 2017, the Company changed its name to InnerScope Hearing Technologies, Inc.to better reflect the Company’s current direction as a hearing health technology driven company with a scalable business model, encompassing; business to business (B2B)that manufactures, develops, distributes, and sells numerous innovative hearing health-related products, hearing treatments, and hearing solutions direct to consumer (DTC) sales and marketing and business to consumer (and B2C) solutions. The Company is a manufacturer and a DTC distributor/retailer of FDA (Food and Drug Administration) registered hearing aids, personal sound amplifier products (“PSAP’s”), hearing related treatment therapies,doctor-formulated dietary hearing supplements and proprietary CDB oil for treating tinnitus.The Company also owns and operates audiological and retail hearing device clinics and plans to continue to open and acquire additional clinics. As of the date of this filing, the Company operates five retail hearing device clinics in California.

On August 5, 2016, the Company along with Mark Moore (“Mark”, the Company’s Chairman of the Board), Matthew Moore (“Matthew”, the Company’s Chief Executive Officer) and Kim Moore (“Kim”, the Company’s Chief Financial Officer) entered into a Store Expansion Consulting Agreement (the “Expansion Agreement”) with a third party (the “Client”). Mark, Matthew and Kim are herein referred to collectively as the “Moores”. Pursuant to the Expansion Agreement, the Company and the Moores were responsible for all physical plant and marketing details for the Client’s new store openings during the initial term of six-months. The Expansion Agreement was cancelled on January 6, 2017. The Client decided to do their own marketing in-house and eliminate the out-sourced contract and decided to open only one location and delay the opening of any other new stores.  For the year ended December 31 2017, the Company recognized $100,000 of income for the one new store, opened in January 2017, and $160,000 in other income, net, for payments received for the Expansion Agreement pursuant to the cancellation. The Client also paid an additional $30,000 for the cancellation of the Store Expansion Agreement and a marketing agreement.scalable business model.

Also, on August 5, 2016, the Company and the Moores entered into a Consulting Agreement (the “Consulting Agreement”) with the same Client as the store Expansion Agreement. Under the Consulting Agreement, including the Non-Compete provision covering a ten-mile radius of any retail store, the Company and the Moores were to provide unlimited licensing of the Intela-Hear brand name, exclusive access to the Aware Aural Rehab Program within 10 miles of retail stores, exclusive territory of all services within 10 miles of retail stores and up to 40 hours per month of various consulting services. The Consulting Agreement continues until January 31, 2019, unless terminated for cause, as defined in the Consulting Agreement. On May 26, 2017, the Company and the Moores were named in an action filed by the Client, that included a demand that all monies paid pursuant to the Consulting Agreement be returned. On August 13, 2018, the Client, InnerScope and the Moores executed a Settlement Agreement (See Note 13).

NOTE 2 – Asset Purchase Acquisition of Kathy L Amos Audiology 

Effective September 10, 2018, the Company acquired all of the assets and assumed certain liabilities of Kathy L Amos Audiology (“Amos Audiology”) in exchange for 340,352 shares of common stock (the “Acquisition”). Amos Audiologyprovides retail hearing aid sales and audiological services in the East Bay area of San Francisco.

Based on the fair value of the common stock issued of $22,974 and the assumed liabilities of $33,049, the total purchase consideration was $56,023.

F-7

The following table summarizes the purchase price allocation of the fair value of assets acquired and liabilities assumed in the acquisition:

  Purchase Price Allocation
 Fair value of consideration for Acquisition $22,974 
 Liabilities assumed  33,049 
  Total purchase consideration $56,023 
Tangible assets acquired $43,016 
Intangible assets  13,007 
  $56,023 

The total purchase price of $56,023 has been allocated to the tangible and intangible assets acquired and liabilities assumed based on estimated fair values as of the completion of the Acquisition. The fair value of Amos Audiology’s identifiable intangible assets was estimated primarily using the income approach which requires an estimate or forecast of all the expected future cash flows, either through the use of the relief-from-royalty method or the multi-period excess earnings method. The Company determined the identifiable intangible assets, consisting of a customer base and non-compete had fair values of $300 and $12,707, respectively.

 

NOTE 32 – SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES

 

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America ("US GAAP"). The consolidated financial statements of the Companyinclude the consolidated accounts of InnerScope and its’ wholly owned subsidiaries ILLC and Intela-Hear.subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

 

Emerging Growth Companies

The Company qualifies as an “emerging growth company” under the 2012 JOBS Act. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. As an emerging growth company, the Company can delay the adoption of certainaccounting standards until those standards would otherwise apply to private companies. The Company has elected to take advantage of the benefits of this extended transition period.

 

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include the fair value of the derivative liabilities.

 

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. The Company held no cash equivalents as of December 31, 20182020 and 2017.2019. Cash balances may, at certain times, exceed federally insured limits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail. No losses have been recognized as a result of these excess amounts.

 

F-8

Accounts receivable

The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience. As of December 31, 2018,2020 and 2019, management’s evaluation required the establishment of an allowance for uncollectible receivables of $18,383. As of December 31, 2017, management’s evaluation did not require an allowance.$27,991 and $27,615, respectively.

Sales Concentration and Credit Risk

 

Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the years ended December 31, 20182020 and 2017,2019, and accounts receivable balances as of December 31, 2018,2020 and 2017:2019:

         
  December 31,    
  2018 2017 

Accounts Receivable

as of

 

Accounts Receivable

as of

  % % December 31, 2018 December 31, 2017
Customer A  —     16.4% $—    $63,799 
Customer B  —     14.8% $—    $4,000 
Customer C, related  25.2%  18.3% $145,505  $81,193 
Customer D  —     27.6% $—     —   

  December 31, Accounts Receivable as of Accounts Receivable as of
  2020 2019 December 31, 2020 December 31, 2019
   %   %         
Customer A  28%  5%  0%  41%

Inventory

 

Inventory

Inventory is valued at the lower of cost or net realizable value. Cost is determined using the first in first out (FIFO) method. Provision for potentially obsolete or slow-moving inventory is made based on management analysis or inventory levels and future sales forecasts. As of December 31, 2018,2020, and 2017,2019, management’s analysis did not require any provisions to be recognized.

F-7

Intangible Assets

 

Intangible Assets

Costs for intangible assets are accounted for through the capitalization of those costs incurred in connection with developing or obtaining such assets. Capitalized costs are included in intangible assets in the consolidated balance sheets. On October 3, 2018, the Company entered into a Manufacturing Design and Marketing Agreement (the “Agreement”) with Zounds Hearing, Inc., a Delaware corporation (“Zounds”), whereby, Zounds as the Subcontractor will provide design, technology, manufacturing and supply chain services to the Company (see Note 13) for a period of ten years .years. The Company will pay Zounds One Million ($1,000,000) for the right to use proprietary technology (the “Technology Access Fee”). As of December 31, 2018, the Company has capitalized the $1,000,000 Technology Access Fee as an intangible asset on the consolidated balance sheets. The Technology Access Fee will be amortized over the term of the Agreement. The Company also acquired intangible assets from an asset purchase agreement (see Note 2)4).

During the year ended December 31, 2017,2020, the Company purchaseddetermined that they do not expect to realize any benefit in the domain namewww.innd.com from a third party for $3,000.foreseeable future, therefore, have recorded an impairment of $775,000.

Property and Equipment

 

Property and Equipment

Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful liveslives of the assets. The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The estimated useful lives of property and equipment are as follows:

 

F-9

Computer equipment

3 years
Machinery and equipment5 years
Furniture and fixtures5 years
Leasehold improvements3-5 years

The Company's propertyproperty and equipment consisted of the following at December 31, 2018,2020, and 2017:2019:

  December 31,
2018
 December 31,
2017
Computer equipment $2,651  $2,651 
Machinery and equipment  31,122   —   
Furniture and fixtures  2,160   —   
Leasehold improvements  12,222   —   
Accumulated depreciation  (4,705)  (1,068)
Balance $43,450  $1,583 

  

December 31,

2020

 

December 31,

2019

Computer and equipment $4,272  $4,272 
Leasehold improvements  12,222   12,222 
Machinery and equipment  45,411   38,139 
Furniture and equipment  39,152   39,152 
   101,057   93,785 
Accumulated depreciation  (40,854)  (21,544)
Property and equipment, net $60,203  $72,241 

Depreciation expense of $3,638$19,310 and $884$25,453 was recorded for the years ended December 31, 20182020 and 2017, 2019, respectively.

Investment in Undivided Interest in Real Estate

The Company accounts for its’ investment in undivided interest in real estate using the equity method, as the Company is severally liable only for the indebtedness incurred with its interest in the property. The Company includes its allocated portion of net income or loss in Other income (expense) in its Statement of Operations, with the offset to the equity investment account on the balance sheet. For the years ended December 31, 20182020 and 2017,2019, the Company recognized a gaingains of $2,060$30,646 and loss of $1,378,$15,083, respectively. As of December 31, 2018,2020, and 2017,2019, the carrying value of the Company’s investment in undivided interest in real estate was $1,226,963$1,227,733 and $1,224,903,$1,210,526, respectively (see Note 10)9).

 

Fair Value of Financial Instruments

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

 

The following are the hierarchical levels of inputs to measure fair value:

 

Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.
Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
Level 3 - Unobservable inputs reflecting the Company's assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

 

F-8

The carrying amounts of the Company's financial assetsassets and liabilities, such as cash, prepaid expenses, accounts receivable, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments.

F-10

The following table represents the Company’s financial instruments that are measured at fair value on a recurring basis as of December 31, 2018,2020, and 2017,2019, for each fair value hierarchy level:

         
  December 31, 2019
  Level 1 Level 2 Level 3 Total
Derivative liabilities $    $    $3,515,055  $3,515,055 
  $    $    $3,515,055  $3,515,055 
                 
   December 31, 2020
   Level 1   Level 2   Level 3   Total 
Derivative liabilities $    $    $4,046,401  $4,046,401 
  $    $    $4,046,401  $4,046,401 

 

December 31, 2018  Derivative Liabilities   Total 
Level I $—    $—   
Level II $—    $—   
Level III $1,807,404  $1,807,404 
         
December 31, 2017        
Level I $—    $—   
Level II $—    $—   
Level III $540,965  $540,965 

 

Embedded Conversion Features

 

The Company evaluates embedded conversion features within convertible debt under ASC 815 "Derivatives and Hedging" to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 "Debt with Conversion and Other Options" for consideration of any beneficial conversion feature.

 

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of it financial instruments, including stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income.

 

For option-based simple derivative financial instruments, the Company uses the Monte Carlo simulations to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessedre- assessed at the end of each reporting period.

 

Debt Issue Costs and Debt Discount

 

The Company may record debt issue costs and/or debt discounts in connection with raising funds through the issuance of debt. These costs may be paid in the form of cash, or equity (such as warrants). These costs are amortized to interest expense through the maturity of the debt. If a conversion of the underlying debt occurs prior to maturity a proportionate share of the unamortized amounts is immediately expensed. Any unamortized debt issue costs and debt discount are presented net of the related debt on the consolidated balance sheets.

 

Original Issue Discount

 

For certain convertible debt issued, the Company may provide the debt holder with an original issue discount. The original issue discount would be recorded to debt discount, reducing the face amount of the note and is amortized to interest expense through the maturity of the debt. If a conversion of the underlying debt occurs prior to maturity a proportionate share of the unamortized amounts is immediately expensed. Any unamortized original issue discounts are presented net of the related debt on the consolidated balance sheets.

 

F-11

Revenue Recognition

Effective January 1, 2018, the Company adopted ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and all the related amendments. The Company elected to adopt this guidance using the modified retrospective method. The adoption of this guidance did not have a material effect on the Company’s financial position, results of operations or cash flows.

 

The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.

F-9

 

The Company’s contracts with customers are generally on a purchase order basis and represent obligations that are satisfied at a point in time, as defined in the new guidance, generally upon delivery or has services are provided. Accordingly, revenue for each sale is recognized when the Company has completed its performance obligations, Any costs incurred before this point in time, are recorded as assets to be expensed during the period the related revenue is recognized. The Company accepts prepayments on hearing aids and records the amount received as customer deposits on its’ balance sheet. When the Company delivers the hearing aid to the customer, revenue is recognized as well as the corresponding cost of sales.

 

As of December 31, 2018,2020 and 2019, the Company had received $56,698$21,505 and $10,925 of customer deposits, thatwhere revenue will be recognized as revenue after December 31, 2018, when the hearing aids are delivered to the customercustomer.

 

Income Taxes

The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes. Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.

 

ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. Interest and penalties are classified as a component of interest and other expenses. To date, the Company has not been assessed, nor paid, any interest or penalties.

 

Uncertain tax positions are measured and recorded by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.

Advertising and Marketing Expenses

The Company expenses advertising and marketing costs as incurred. For the years ended December 31, 2018,2020 and 2019, advertising and marketing expenses were $173,580. The Company did not incur any advertising$19,762 and marketing expenses for the year ended December 31, 2017.$485,407, respectively.

 

Earnings (Loss) Per Share

The Company reports earnings (loss) per share in accordance with ASC 260, "Earnings per Share." Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of December 31, 2018,2020, and 2017,2019, the Company’s outstanding convertible debt is convertible into approximately 120,715,2944,650,854,286 and 10,043,445155,226,039 shares of common stock, respectively. This amount is not included in the computation of dilutive loss per share because their impact is antidilutive.

 

Recent Accounting Pronouncements

In August 2018, the FASB issued ASU 2018-13, “Changes to Disclosure Requirements for Fair Value Measurements”, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 (for “emerging growth company” beginning after December 15, 2020). The Company will be evaluating the impact this standard will have on the Company’s consolidated financial statements.

The FASB recently issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, which requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for public entities for fiscal years beginning after December 15, 2021, with early adoption permitted (for “emerging growth company” beginning after December 15, 2023). The Company will be evaluating the impact this standard will have on the Company’s consolidated financial statements.

 F-12F-10 

 

Recent Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (“FASB”)FASB issued Accounting Standards Update (“ASU”)ASU No. 2016-02, “LeasesLeases (Topic 842). Under this guidance, an entity is requiredIn July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to recognizeTopic 842, Leases (ASU 2018-10), which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU No. 2018-11, Leases (Topic 842)—Targeted Improvements (ASU 2018-11), which addressed implementation issues related to the new lease standard. These and certain other lease-related ASUs have generally been codified in ASC 842. ASC 842 supersedes the lease accounting requirements in ASC Topic 840, Leases (ASC 840). ASC 842 establishes a right-of-use assetsmodel that requires a lessee to record a right-of-use asset and a lease liabilitiesliability on itsthe balance sheet and disclose key information about leasing arrangements. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessorsall leases. Under ASC 842, leases are required to disclose qualitative and quantitative information about leasing arrangements to enable a userclassified as either finance or operating, with classification affecting the pattern of expense recognition in the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. This guidance isincome statement. ASU 2016-02 was effective for annual reporting periods beginning after December 15, 2018 includingand interim periods within that reporting period and requires a modified retrospective adoption, with early adoption permitted.(for “emerging growth company” from January 1, 2020). The Company is currently evaluatingadopted ASC 842 on January 1, 2019 using the impact the adoption of this standard will have on our consolidated financial statements.effective date transition method.

 

WithThe Company elected the exception of the new standard discussed above, there have been no other recent accounting pronouncements or changes in accounting pronouncements during the year ended December 31, 2018, as comparedpractical expedient to the recent accounting pronouncements described in the Company’s Annual Reportnot record short-term leases on Form 10-K for the fiscal year ended December 31, 2017, as filed on April 17, 2018, that are of significance or potential significance to the Company.its consolidated balance sheet.

NOTE 43 – GOING CONCERN AND MANAGEMENT’S PLANS

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern.concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company experienced a net loss of $4,585,117$4,953,692 for the year ended December 31, 2018.2020. At December 31, 2018,2020, the Company had a working capital deficit of $3,088,957,$10,395,547, and an accumulated deficit of $6,372,129.$19,250,160. These factors raise substantial doubt about the Company’s ability to continue as a going concern and to operate in the normal course of business. The Company’s ability to continue as a going concern is dependent upon obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due and / or generating profitable operations in the future. Management believes that actions presently being taken to further implement our business plan will generate additional revenues and eventually positive cash flow and provide opportunity for the Company to continue as a going concern. While we believe in the viability of our strategy to generate additional revenues and our ability to raise additional funds, there can be no assurances to that effect. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

 

Management’s Plans

The Company continues to implement an industry encompassing revenue strategy, including the current revenue model to other major sectors of the global hearing industry. On September 10, 2018, the Company acquired all of the assets and assumed certain liabilities of Amos Audiology (see Note 2). This transaction is part of management’s plans to expand the Company’s retail clinic business by opening multiple clinics in the next 12 months. During the year ended December 31, 2018, the Company opened 2 retail clinics, and during the three months ended March 31, 2019, the Company opened an additional 3 retail clinics.

NOTE 54 – INTANGIBLE ASSETS, NET (OTHER THAN GOODWILL)

 

The Company’s intangible assets consist of a customer list and non-compete acquired from Kathy L Amos Audiology (see Note 2)in 2018 and a Technology Access Fee required to be paid by the Company in connection with a manufacturing design and marketing agreement executed with a supplier (see Note 13)11). During the year ended December 31, 2020, the Company determined that it was unable to substantiate the actual fair value of the technology that was acquired so has chosen to impair the full amount. These intangible assets are amortized over their estimated useful lives as indicated below. The estimated useful lives of property and equipment are as follows:

Customer List2 years
Non-compete2 years
Technology Access Fee10 years

The Company's intangibles consisted of the following is a summary of activity related to intangible assets for the year endedat December 31, 2018:2020, and 2019:

  Customer List Non-compete Technology Access Fee  
Useful Lives 2 Years 2 Years 10 Years Total
Carrying Value at December 31, 2017 $—    $—    $—    $—   
Additions  300   12,708   1,000,000   1,013,008 
Amortization  (50)  (2,118)  (0)  (2,168)
Carrying Value at December 31, 2018 $250  $10,590  $1,000,000  $1,010,840 

  

December 31,

2020

 

December 31,

2019

Customer List $300  $300 
Non-Compete  12,708   12,708 
Technology Access Fee       1,000,000 
Intellectual Property  3,000   3,000 
Intangibles  16,008   1,016,008 
Accumulated amortization  (13,008)  (133,672)
Intangibles, net $3,000  $882,336 

The Company recognized $2,168$104,336 and $124,571 of amortization expense during the yearyears ended December 31, 2018.2020 and 2019.

 

 

 F-13F-11 

 

Future expected amortization of intangible assets is as follows:

 Fiscal Year Ending December 31,  
 2019  $106,504 
 2020   104,336 
 2021   100,000 
 2022   100,000 
 2023   100,000 
 Thereafter   500,000 
    $1,101,840 

NOTE 6 – ADVANCES PAYABLE, STOCKHOLDERS

Chief Executive Officer

A summary of the activity for the years ended December 31, 2018, and 2017, representing amounts paid by the Company’s CEO (stockholder) on behalf of the Company and amounts reimbursed is as follows.

  December 31, 2018 December 31,
2017
Beginning Balance $138,637  $-0- 
Amounts paid on Company’s behalf  589,524   149,370 
Reimbursements  (625,635)  (10,733)
Cancelled in exchange for Series B preferred stock  (45,000)  —   
Ending Balance $57,526  $138,637 

The ending balances as of December 31, 2018, and 2017, are included in Advances payable, stockholders on the consolidated balance sheets included herein. These advances have no specific repayment terms.

Director

A summary of the activity for the years ended December 31, 2018, and 2017, representing amounts paid by the Company’s Chairman (stockholder) on behalf of the Company and amounts reimbursed is as follows.

  December 31, 2018 December 31,
2017
Beginning Balance $38,201  $-0- 
Amounts paid on Company’s behalf  24,299   39,201 
Reimbursements  (62,500)  (1,000)
Ending Balance $-0-  $38,201 

The ending balances as of December 31, 2017, is included in Advances payable, stockholders on the consolidated balance sheets included herein. These advances have no specific repayment terms.

NOTE 75 – NOTE PAYABLE, STOCKHOLDER

 

A summary of the activity for the years ended December 31, 2018,2020, and 2017,2019, of amounts the Company’s CEO (stockholder) loaned the Company and amounts repaid is as follows:

 

F-14

 December 31,
2018
 December 31,
2017
 

December 31,

2020

 

December 31,

2019

Beginning Balance $65,000  $-0-  $95,800  $95,800 
Amounts loaned to the Company  36,800   65,000 
Repaid  (6,000)  -0- 
Amounts loaned/repaid          
Ending Balance $95,800  $65,000  $95,800  $95,800 

 

The ending balance amount is due on demand, carries interest at 8% per annum and is included NotesAccounts payable stockholderand accrued expenses on the consolidated balance sheets included herein.

 

NOTE 86 – NOTE PAYABLE

 

On February 27, 2018, the Company entered into a Business Loan Agreement (the “February BLA”) for $43,358 with a third- party, whereby the Company received $32,600 on March 1, 2018, with a 33% interest rate and maturing on March 1, 2019. The February BLA requires the Company to make the first six monthly paymentsIn October of principal and interest of $4,102 per month, and then $3,124 for months seven through twelve. The Company paid the note in full on August 28, 2018.

On July 30, 2018, the Company entered into a Business Loan Agreement (the “July BLA”) for $11,020 with a third- party, whereby the Company received $9,500 on July 30, 2018, with a 16% interest rate and maturing on February 16, 2019. The July BLA requires the Company to make the first two monthly payments of principal and interest of $2,106 per month, and then $1,702 for months three through six. The Company paid the note in full on August 28, 2018.

On October 8, 2018, the Company entered into a Business Loan Agreement (the “October BLA”) for $47,215 with a third- party, whereby the Company received $35,500

$35,500 on October 10, 2018. The October BLA requires the Company to make the first six monthly payments of principal and interest of $4,467 per month, and then $3,402 for months seven through twelve.t12. The note carries a 33% interest rate and matures on October 28, 2019. The Company paid the note in full during the year ending December 31, 2019.

In July of 2019, the Company entered into a Loan Agreement for $60,000 with a third- party. The loan requires the Company to make weekly payments of $1,538. As of December 31, 2018, there was2020, and 2019, the note balance is $50,581 and $50,581.

In November of 2019, the Company entered into a balance of $38,280 on the October BLA,Loan Agreement for $87,000 with a carrying valuethird- party, whereby the Company received $58,000. The loan requires the Company to make weekly payments of $29,270,principal and interest of $790. As of December 31, 2020, and 2019, the note balance is $56,945 and $37,938, net of unamortized discounts of $9,011.$0 and $21,380 respectively.

In December of 2019, the Company entered into a Loan Agreement for $21,750 with a third- party. The loan requires the Company to make weekly payments of principal and interest of $255. As of December 31, 2020, and 2019, the note balance is $11,258 and $18,423.

 

NOTE 97 – RELATED PARTY TRANSACTIONS

 

The Company loaned the CEO $20,500 during the year endedAs of December 31, 2013. The note and interest were paid in full during2020, we had $662,178 of the year endedamount payable to related parties as compared to $266,419 as of December 31, 2017.2019. The Company recorded interest incomebalance primarily represents advance payable to shareholders and management of $228 for the year ended December 31, 2017.

During the year ended December 31, 2018, and 2017, our CEO (stockholder) paid expenses and accounts payableCompany on behalf of the Company (see Note 5). As of December 31, 2018, and 2017, the Company owed the CEO $57,526 and $138,637, respectively, which is included in Advances payable, stockholders on the consolidated balance sheets included herein.Company.

During the year ended December 31, 2018, and 2017, our Chairman (stockholder) paid expenses of the Company and accounts payable on behalf of the Company (see Note 5). As of December 31, 2018, and 2017, the Company owed the Chairman $0 and $38,201, respectively, which is included in Advances payable, stockholders on the consolidated balance sheets included herein.

On August 8, 2016, in consideration of $128,000 (the “Cancellation Fee”), MFHC and the Company agreed to cancel the Marketing Agreement as a result of the sale by MFHC of substantially all of their assets. On August 11, 2016, MFHC paid $229,622 to the Company (inclusive of the balance owed as of June 30, 2016, the Cancellation Fee and other related party activity).

Pursuant to a Marketing Agreement (cancelled August 5, 2016), the Company provided marketing programs to promote and sell hearing aid instruments and related devices to Moore Family Hearing Company (“MFHC”). MFHC owned and operated retail hearing aid stores. Based on common control of MFHC and the Company, all transactions with MFHC are classified as related party transactions. For the year ended December 31, 2016 (through August 5, 2016), there were 20 stores resulting in revenue of $458,667. The Company has offset the accounts receivable owed from MFHC for these services with expenses of the Company that have been paid by MFHC. As a result of these payments, in addition to MFHC’s payments to the Company through December 31, 2016, the balance due to MFHC as of December 31, 2018, and 2017, was $22,548, which is included in Accounts payable, related party, on the consolidated balance sheets included herein.

F-15

Effective August 1, 2016, the Company agreed to compensation of $225,000 and $125,000 per year for the Company’s CEO and CFO, respectively. On November 15, 2016, the Company entered into employment agreements with its CEO and CFO, which includes their annual base salaries of $225,000 and $125,000, respectively.On January 1, 2019, the Company agreed to increase compensation to $ $150,000 per year for the Company’s CFO. For the years ended December 31, 2018,2020, and 2017,2019, the Company recorded expenses to its officers in the following amounts:

 

  Year ended December 31,
 Description 2018 2017
 CEO  $225,193  $224,691 
 CFO   125,107   124,828 
 Total  $350,300  $349,519 
  Year ended Year ended
 Description December 31, 2020 December 31, 2019
 CEO  $225,000  $225,000 
 CFO   150,000   150,000 
 Total  $375,000  $375,000 

 

As of December 31, 2018, the Company owes the CEO and CFO $49,142 and $139,800, respectively, and as of December 31, 2017, the Company owed the CEO and CFO $4,327 and $40,385, respectively for accrued and unpaid wages. These amounts are included in Officer salaries payable on the balance sheets included herein.

In September 2016, the officers and directors of the Company formed a California Limited Liability Company (“LLC1”), for the purpose of acquiring commercial real estate and other business activities.On December 24, 2016, LLC1 acquired two retail stores from the buyer of the MFHC stores. On March 1, 2017, the Company entered into a twelve-month Marketing Agreement with each of the stores to provide telemarketing and design and marketing services for $2,500 per month per store, resulting in $60,000 and $50,000, respectively, for the years ended December 31, 2018, and 2017. Additionally, for the year ended December 31, 2018, the Company invoiced LLC1 $20,226 for the Company’s production, printing and mailing services and $1,793 for sale of products. As of December 31, 2018, and December 31, 2017, LLC1 owes the Company $203,325 and $73,996, respectively, for the consulting fees and mailing services as well expenses of LLC1 paid by the Company.

As of December 31, 2018, the Company is owed On June 14, 2017, the Company entered into a five-year lease with LLC1 for approximately 6,944 square feet and a monthly rent of $12,000. For the years ended December 31, 2018, and 2017, the Company expensed $144,000 and $111,377, respectively, related to this lease and is included in Rent, related party, on the consolidated statement of operations, included herein. As of December 31, 2018, the Company owed LLC1 $30,500 for unpaid rent.

In November 2016, the Company’s Chairman formed a California Limited Liability Company (“LLC2”), for the purpose of providing consulting services to the Company.The Company entered into an agreement with LLC2, and paid LLC2 $375,000 during the year ended December 31, 2016, for services performed and to be performed. Of the $375,000 amount paid, $241,667 was recognized as consulting fees- stockholder for the year ended December 31, 2016, and the remaining $133,334 was recorded as deferred commissions- stockholder as of December 31, 2016. For the year ended December 31, 2017, the Company paid LLC2 an additional $771,000 ($96,000 of which reduced previous amounts owed) and expensed $808,334 ($60,000 as commissions for services performed and $748,334 as other expense)$12,000 (Note 11). As of December 31, 2018, and 2017, the deferred commissions-stockholder is $-0-.

 

On May 9, 2017, the Company and LLC1 purchased certain real property from an unaffiliated party. The Company and LLC1 have agreed that the Company purchased and owns 49% of the building and LLC1 purchased and owns 51% of the building. The contracted purchase price for the building was $2,420,000 and the total amount paid at closing was $2,501,783 including, fees, insurance, interest and real estate taxes. The Company paid for their building interest by delivering cash at closing of $209,971 and being a co-borrower on a note in the amount of $2,057,000, of which the Company has agreed with LLC1 to pay $1,007,930 (see Note 9).

F-12

NOTE 10–8– INVESTMENT IN UNDIVIDED INTEREST IN REAL ESTATE

 

On May 9, 2017, the Company and LLC1 purchased certain real property from an unaffiliated party. The Company and LLC1 have agreed that the Company purchased and owns 49% of the building and LLC1 purchased and owns 51% of the building. The contracted purchase price for the building was $2,420,000 and the total amount paid at closing was $2,501,783 including, fees, insurance, interest and real estate taxes. The Company paid for their building interest by delivering cash at closing of $209,971 and being a co-borrower on a note with and initial amount of $2,057,000, of which the Company has agreed with LLC1 to pay $1,007,930$1,007,930 (see Note 10)9).

F-16

The Company accounts for its investment in undivided interest in real estate as an equity method investment and recognizes it’sits proportionate share of profits and losses. For the years ended December 31, 2018,2020, and 2017,2019, a net gain of $2,060$30,646 and loss of $1,378,$15,736, respectively, is included on the Statements of Operations. As of December 31, 2018,2020, the carrying value of the Company’s investment in undivided interest in real estate was $1,226,963.$1,227,733.

 

The consolidated balance sheets as of December 31, 2018,2020, and 20172019 and the statement of operations for the years ended December 31, 2018,2020, and 2017,2019, for the real property is as follows:

 

Current assets: 2018 2017
Cash $2,257  $8,331 
Due from InnerScope  30,500   2,711 
Prepaid expenses and other current assets  72,931   37,471 
Total current assets  105,958   48,512 
 Land and Building, net  2,354,282   2,397,848 
Other Assets, net  53,323   54,426 
Total assets $2,513,563  $2,500,606 
         
Current portion of mortgage payable $40,122  $37,792 
Other current liabilities  48,551   10,560 
Total current liabilities  88,673   48,352 
Mortgage payable, long-term  1,969,076   2,004,440 
Security deposits  13,064   9,268 
Total liabilities  2,070,813   2,062,060 
Total equity  442,750   438,546 
Total liabilities and equity $2,513,563  $2,500,060 
Current assets: 2020 2019
Cash $25,144  $   
Accounts Receivable  125,698   106,163 
Due from InnerScope  138,360   79,934 
Prepaid expenses and other current assets  8,848      
Total current assets  298,050   186,097 
Land and Building, net  2,267,156   2,310,722 
Other Assets, net  43,729   45,943 
Total assets $2,608,935  $2,542,762 
         
Accounts Payable $119,446  $72,475 
Current portion of mortgage payable  22,150   20,708 
Other current liabilities  37,399   16,104 
Total current liabilities  178,995   109,287 
Mortgage payable, long-term  1,937,345   1,966,215 
Security deposits  3,283   13,064 
Total liabilities  2,119,623   2,088,566 
Total equity  489,312   454,196 
Total liabilities and equity $2,608,935  $2,542,762 
         
   2020   2019 
Rental income $243,986  $297,383 
Expenses:        
Property taxes  30,185   29,605 
Depreciation and amortization  45,780   50,940 
Insurance  9,559   18,783 
Repairs and maintenance       6,202 
Utilities and other  45,654   68,156 
Interest expenses  77,692   113,858 
Total expenses  208,870   287,544 
Net income (loss) $35,116  $9,839 

 

  2018 2017
Rental income $285,976  $154,454 
Expenses:        
Property taxes  26,583   16,752 
Depreciation and amortization  43,566   27,229 
Insurance  2,033   6,253 
Repairs and maintenance  30,128   17,829 
Utilities and other  40,066   15,083 
Interest expense  139,416   74,120 
Total expenses  281,772   157,226 
Net income (loss) $4,204  $(2,812)

 

NOTE 11– NOTE9– CONVERTIBLE NOTES PAYABLE - UNDIVIDED INTEREST IN REAL ESTATE

 

On May 9, 2017, the Company and LLC1 purchased certain real property from an unaffiliated party. The Company and LLC1 have agreed that the Company purchased and owns 49% of the building and LLC1 purchased and owns 51% of the building. The contracted purchase price for the building was $2,420,000 and the total amount paid at closing was $2,501,783 including, fees, insurance, interest and real estate taxes. The Company is a co-borrower on a $2,057,000 Small Business Administration Note (the “SBA Note”). The SBA Note carries a 25-year term, with an initial interest rate of 6% per annum, adjustable to the Prime interest rate plus 2% (6.75% as of December 31, 2018),20120, and is secured by a first position Deed of Trust and business assets located at the property. The Company initially recorded a liability of $1,007,930 for its portion of the SBA Note, with the offset being to Investment in undivided interest in real estate on the consolidated balance sheets presented herein. As of December 31, 2018,2020, the Company’s current and long-term portion of the SBA Note is $19,660$0 and $964,847,$960,153, respectively. Future principal payments for the Company’s portion are:

 

 F-17F-13 

 

 Twelve months ending December 31, Amount
 2019  $19,660 
 2020   20,708 
 2021   22,150 
 2022   23,516 
 2023   24,966 
 Thereafter   873,507 
 Total  $984,507 

NOTE 12– CONVERTIBLE NOTES PAYABLE

On October 11, 2017, the Company completed the closing of a private placement financing transaction (the “Transaction”) with a third-party investor, pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) dated October 5, 2017. Pursuant to the Purchase Agreement, the investor purchased a 12% Convertible Promissory Note (the “Note”), dated October 5, 2017, in the principal amount of $48,000. On October 11, 2017, the Company received proceeds of $45,000 which excluded transaction costs, fees, and expenses of $3,000. Principal and interest was due and payable July 15, 2018, and the Note was convertible into shares of the Company’s common stock at any time after one hundred eighty (180) days, at the average of the two lowest closing bid prices during the ten (10) prior trading days from which a notice of conversion is received by the Company multiplied by sixty-five percent (65%), representing a thirty-five percent (35%) discount. The embedded conversion feature included in the note resulted in an initial debt discount of $40,300, and an initial derivative liability of $40,300. For the years ended December 31, 2018, and 2017, amortization of the debt discount of $27,739 and $12,561, respectively, was charged to interest expense. The Company also recorded a discount for debt issuance costs of $3,000 and has amortized $2,065 and $935, respectively, to interest expense for the years ended December 31, 2018, and 2017. During the year ended December 31, 2018, the investor converted $48,000 of principal and $2,880 of accrued interest into 4,330,984 shares of common stock. As of December 31, 2018, and 2017, the note balance is $-0- and $48,000 with a December 31, 2017, carrying value of $18,196, net of unamortized discounts of $29,804, respectively.

On November 10, 2017, the Company issued a convertible promissory note (the “Note”), with a face value of $299,000, maturing on January 12, 2019, and stated interest of 10% to a third-party investor. The note was convertible at any time after ninety (90) days of the funding of the note into a variable number of the Company's common stock, based on a conversion ratio of 65% of the lowest trading price for the 20 days prior to conversion. The note was funded on November 10, 2017, when the Company received proceeds of $250,000, after disbursements for the lender’s transaction costs, fees and expenses. The Note also required daily payments of $700 per day via ACH through January 12, 2019, when all unpaid principal and interest was due. The embedded conversion feature included in the note resulted in an initial debt discount of $250,000, an initial derivative expense of $213,549 and an initial derivative liability of $463,549. For the years ended December 31, 2018, and 2017, amortization of the debt discount of $208,583 and $41,417, respectively, was charged to interest expense. The Company also recorded an original issue discount and debt issue discount of $49,000 and amortized $40,883 and $8,118 to interest expense for the years ended December 31, 2018, and 2017, respectively. During the year ended December 31, 2018, the Company made principal payments of $81,900, and the investor converted $123,250 of principal and $21,843 of interest into 21,887,432 shares of common stock. On August 10, 2018, the investor sold $40,000 of the Note to a third party, and the investor also forgave $35,650 of principal. As of December 31, 2018, and 2017, the note balance is $-0- and $280,800, with a December 31, 2017, carrying value of $31,335, net of unamortized discounts of $249,465, respectively.

On December 12, 2017, the Company completed the closing of a private placement financing transaction (the “Transaction”) when a third-party investor purchased a convertible note (the “Convertible Note”). The Convertible Note carries a 10% annual interest rate and is in the principal amount of $50,000. Principal and interest is due and payable December 12, 2018, and the Note was convertible into shares of the Company’s common stock at any time after one hundred eighty (180) days, at a conversion price (the “Conversion Price”) equal to seventy-five percent (75%) of the average closing price of the Company’s common stock for the ten (10) days immediately preceding the conversion, representing a twenty-five percent (25%) discount. The embedded conversion feature included in the note resulted in an initial debt discount of $13,207, and an initial derivative liability of $13,207. For the years ended December 31, 2018, and 2017, amortization of the debt discount of $12,803 and $404, respectively was charged to interest expense. As of December 31, 2018, and 2017, the note balance is $-0- and $50,000 with a carrying value as of December 31, 2017, of $37,197, net of unamortized discounts of $12,803.

F-18

On February 1, 2018, the Company completed the closing of a private placement financing transaction (the “Transaction”) when a third-party investor purchased a convertible note (the “Convertible Note”). The Convertible Note carries a 10% annual interest rate and is in the principal amount of $35,000. Principal and interest was due and payable February 1, 2019, and the Note was convertible into shares of the Company’s common stock at any time after one hundred eighty (180) days, at a conversion price (the “Conversion Price”) equal to seventy-five percent (75%) of the average closing price of the Company’s common stock for the ten (10) days immediately preceding the conversion, representing a twenty-five percent (25%) discount. The embedded conversion feature included in the note resulted in an initial debt discount of $9,554, and an initial derivative liability of $9,554. For the year ended December 31, 2018, amortization of the debt discount of $9,554 was charged to interest expense. During the year ended December 31, 2018, the investor converted $35,000 of principal and $1,750 of interest into 2,085,106 shares of common stock. As of December 31, 2018, the note balance is $-0-

On February 8, 2018, the Company completed the closing of a private placement financing transaction (the “Transaction”) with a third-party investor, pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) dated February 8, 2018. Pursuant to the Purchase Agreement, the investor purchased a 12% Convertible Promissory Note (the “Note”), dated February 8, 2018, in the principal amount of $58,300. On February 8, 2018, the Company received proceeds of $50,000 which excluded transaction costs, fees, and expenses of $8,300. Principal and interest was due and payable November 8, 2018, and the Note was convertible into shares of the Company’s common stock at any time after one hundred eighty (180) days, at the average of the two lowest closing bid prices during the ten (10) prior trading days from which a notice of conversion is received by the Company multiplied by seventy-five percent (75%), representing a twenty-five percent (25%) discount. The embedded conversion feature included in the note resulted in an initial debt discount of $50,000, an initial derivative liability of $65,525 and an initial derivative expense of $15,525. For the year ended December 31, 2018, amortization of the debt discount of $50,000 was charged to interest expense. The Company also recorded a debt issue discount of $8,300 and has amortized $8,300 to interest expense for the year ended December 31, 2018. During the year ended December 31, 2018, the Company made principal payments of $46,121, and the investor converted $12,179 of principal into 2,925,932 shares of common stock. As of December 31, 2018, the note balance is $-0-.

 Twelve months ending December 31, Amount
 2021  $22,150 
 2022   23,516 
 2023   24,966 
 2024   26,500 
 2025   28,118 
 Thereafter   834,903 
 Total  $960,153 

 

On March 2, 2018, the Company completed the closing of a private placement financing transaction (the “Transaction”) when a third-party investor purchased a convertible note (the “Convertible Note”). The Convertible Note carries a 10% annual interest rate and is in the principal amount of $50,000. Principal and interest was due and payable March 2, 2019, and the Note is convertible into shares of the Company’s common stock at any time after one hundred eighty (180) days, at a conversion price (the “Conversion Price”) equal to seventy-five percent (75%) of the average closing price of the Company’s common stock for the ten (10) days immediately preceding the conversion, representing a twenty-five percent (25%) discount. The embedded conversion feature included in the note resulted in an initial debt discount of $13,399, and an initial derivative liability of $13,399. ForDuring the yearyears ended December 31, 2018,2020 and 2019, amortization of the debt discount of $11,166$- 0- and $13,399 was charged to interest expense. As of December 31, 2018, the note balance is $50,000, with a carrying value of $47,767, net of unamortized discounts of $2,233.

On March 26, 2018, the Company completed the closing of a private placement financing transaction (the “Transaction”) when a third-party investor purchased a convertible note (the “Convertible Note”). The Convertible Note carries a 10% annual interest rate and is in the principal amount of $50,000. Principal and interest was due and payable March 26, 2019, and the Note was convertible into shares of the Company’s common stock at any time after one hundred eighty (180) days, at a conversion price (the “Conversion Price”) equal to seventy-five percent (75%) of the average closing price of the Company’s common stock for the ten (10) days immediately preceding the conversion, representing a twenty-five percent (25%) discount. The embedded conversion feature included in the note resulted in an initial debt discount of $13,420, and an initial derivative liability of $13,420. For the year ended December 31, 2018, amortization of the debt discount of $13,420 was charged to interest expense.expense, respectively. During the year endedending December 31, 2018, the investor2019, convertible note principal plus their accrued interest totaling $52,514 were converted $50,000 of principal and $1,205 of interest into 844,8701,239,161 shares of common stock. As of December 31, 2018, the note balance is $-0-.

 

On March 27, 2018, the Company completed the closing of a private placement financing transaction (the “Transaction”) when a third-party investor purchased a convertible note (the “Convertible Note”). The Convertible Note carries a 10% annual interest rate and is in the principal amount of $25,000. Principal and interest was due and payable March 27, 2019, and the Note is convertible into shares of the Company’s common stock at any time after one hundred eighty (180) days, at a conversion price (the “Conversion Price”) equal toseventy-five percent (75%) of the average closing price of the Company’s common stock for the ten (10) days immediately preceding the conversion, representing a twenty-five percent (25%) discount. The embedded conversion feature included in the note resulted in an initial debt discount of $6,736, and an initial derivative liability of $6,736. For the year ended December 31, 2018, amortization of the debt discount of $5,108 was charged to interest expense. As of December 31, 2018, the note balance is $25,000, with a carrying value of $23,372, net of unamortized discounts of $1,628.

F-19

On April 8, 2018, the Company issued a convertible promissory note (the “Note”), with a face value of $95,450, maturing on July 8, 2019, and stated interest of 10% to a third-party investor. The note was convertible at any time after ninety (90) days of the funding of the note into a variable number of the Company's common stock, based on a conversion ratio of 65% of the lowest trading price for the 20 days prior to conversion. The note was funded on April 11, 2018, when the Company received proceeds of $75,000, after disbursements for the lender’s transaction costs, fees and expenses. The Note also requires daily payments of $375 per day via ACH through July 8, 2019, when all unpaid principal and interest is due. The embedded conversion feature included in the note resulted in an initial debt discount of $75,000, an initial derivative expense of $77,108 and an initial derivative liability of $152,108. For the year ended December 31, 2018, amortization of the debt discount of $75,000 was charged to interest expense. The Company also recorded an original issue discount and debt issue discount of $20,450 and amortized $20,450 to interest expense for the year ended December 31, 2018. During the year endedending December 31, 2018, the Company made2019, convertible note principal payments of $20,625, the investorplus their accrued interest totaling $26,260 were converted $76,700 of principal and $3,962 of interest into 2,354,393716,124 shares of common stock and the investor also forgave $1,875 of principal. As of December 31, 2018, the note balance is $-0-.stock.

 

On May 11, 2018, the Company issued a convertible promissory note (the “Note”), with a face value of $100,000, maturing on May 11, 2019, and stated interest of 10% to a third-party investor. The note is convertible at any time after the funding of the note into a variable number of the Company's common stock, based on a conversion ratio of 62% of the lowest trading price for the 20 days prior to conversion. The note was funded on May 16, 2018, when the Company received proceeds of $75,825, after disbursements to vendors and for the lender’s transaction costs, fees and expenses. The embedded conversion feature included in the note resulted in an initial debt discount of $95,000, an initial derivative expense of $60,635 and an initial derivative liability of $155,635. For the year ended December 31, 2018, amortization of the debt discount of $77,980 was charged to interest expense. The Company also recorded a debt issue discount of $5,000 and amortized $4,105 to interest expense for the year ended December 31, 2018. During the year ended December 31, 2018, the investor converted $50,000 of principal and $1,831 of interest into 5,184,572 shares of common stock. As ofDuring the year ended December 31, 2018,2019, the note balance isinvestor converted $50,000 with a carrying value of $32,085, netprincipal and $3,564 of unamortized discountsinterest into 5,539,273 shares of $17,915.

common stock.

On May 23, 2018, the Company issued a convertible promissory note (the “Note”), with a face value of $60,000, maturing on February 22, 2019, and stated interest of 12% to a third-party investor. The note is convertible at any time after the funding of the note into a variable number of the Company's common stock, based on a conversion ratio of 65% of the lowest trading price for the 20 days prior to conversion. The note was funded on May 30, 2018, when the Company received proceeds of $57,000, after the lender’s transaction costs, fees and expenses. The embedded conversion feature included in the note resulted in an initial debt discount of $57,000, an initial derivative expense of $48,033 and an initial derivative liability of $105,033. For the year ended December 31, 2018, amortization of the debt discount of $45,708 was charged to interest expense. The Company also recorded a debt issue discount of $3,000 and amortized $2,406 to interest expense for the year ended December 31, 2018. During the year ended December 31, 2018,2019, the investor converted $14,750$51,275 of principal and $9,838 of interest into 1,500,0007,909,037 shares of common stock. As of December 31, 2018, the note balance is $51,275, with a carrying value of $39,389, net of unamortized discounts of $11,886.

 

On June 12, 2018, the Company issued a convertible promissory note (the “Note”), with a face value of $88,000, maturing on March 12, 2019, and stated interest of 10% to a third-party investor. The note was convertible at any time after the funding of the note into a variable number of the Company's common stock, based on a conversion ratio of 65% of the lowest trading price for the 25 days prior to conversion. The note was funded on June 14, 2018, when the Company received proceeds of $80,250, after the lender’s transaction costs, fees and expenses. The embedded conversion feature included in the note resulted in an initial debt discount of $80,250, an initial derivative expense of $93,150 and an initial derivative liability of $173,400. For the year ended December 31, 2018, amortization of the debt discount of $80,250 was charged to interest expense. The Company also recorded a debt issue discount of $7,750 and amortized $7,750 to interest expense for the year ended December 31, 2018. During the year ended December 31, 2018, the Company made principal payments of $45,817, and the investor converted $42,183 of principal and $3,134 of interest into 2,618,122 shares of common stock. As of December 31, 2018, the note balance is $-0-.

F-20

On June 26, 2018, the Company issued a convertible promissory note (the “Note”), with a face value of $92,000, maturing on September 26, 2019, and stated interest of 10% to a third-party investor. The note is convertible at any time after ninety (90) days of the funding of the note into a variable number of the Company's common stock, based on a conversion ratio of 65% of the lowest trading price for the 20 days prior to conversion. The Company recorded an initial note balance of $42,000 on June 27, 2018, when the Company received proceeds of $25,000 (the initial funding), after disbursements for the lender’s transaction costs, fees and expenses. The embedded conversion feature included in the note resulted in an initial debt discount of $25,000, an initial derivative expense of $31,685 and an initial derivative liability of $56,685. For the year ended December 31, 2018, amortization of the debt discount of $25,000 was charged to interest expense. The Company also recorded an original issue discount and debt issue discount of $17,000 and amortized $17,000 to interest expense for the year ended December 31, 2018. During the year ended December 31, 2018, the Company made principal payments of $900 and the investor converted $41,100 of principal and $1,354 of interest into 1,239,161 shares of common stock. As of December 31, 2018, the note balance of the initial funding is $-0-.

On June 26, 2018, the Company completed the closing of a private placement financing transaction (the “Transaction”) with a third-party investor, pursuant to a Securities Purchase Agreement (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the investor purchased a 12% Convertible Promissory Note (the “Note”), in the principal amount of $58,300, maturing on April 15, 2019. On June 29, 2018, the Company received proceeds of $50,000 which excluded transaction costs, fees, and expenses of $8,300. The Note was convertible into shares of the Company’s common stock at any time after one hundred eighty (180) days, at the average of the two lowest closing bid prices during the twenty (20) prior trading days from which a notice of conversion is received by the Company multiplied by seventy-five percent (75%), representing a twenty-five percent (25%) discount. The embedded conversion feature included in the note resulted in an initial debt discount of $50,000, an initial derivative liability of $116,550 and an initial derivative expense of $66,550. For the year ended December 31, 2018, amortization of the debt discount of $50,000 was charged to interest expense. The Company also recorded an original issue discount and debt issue discount of $8,300 and amortized $8,300 to interest expense for the year ended December 31, 2018. During the year ended December 31, 2018, the Company paid the principal of $58,300 and interest of $3,840. As of December 31, 2018, the note balance is $-0-.

On August 7, 2018, the Company issued a convertible promissory note (the “Note”), with a face value of $88,250, maturing on November 7, 2019, and stated interest of 10% to a third-party investor. The note was convertible at any time after ninety (90) days of the funding of the note into a variable number of the Company's common stock, based on a conversion ratio of 65% of the lowest trading price for the 20 days prior to conversion. The note was funded on August 7, 2018, when the Company received proceeds of $80,250, after disbursements for the lender’s transaction costs, fees and expenses. The embedded conversion feature included in the note resulted in an initial debt discount of $80,250, an initial derivative expense of $86,207 and an initial derivative liability of $166,457. For the year ended December 31, 2018, amortization of the debt discount of $80,250 was charged to interest expense. The Company also recorded a debt issue discount of $8,000 and amortized $8,000 to interest expense for the year ended December 31, 2018. During the year ended December 31, 2018, the investor converted $88,250 of principal and $1,910 of interest into 2,631,647 shares of common stock. As of December 31, 2018, the note balance is $-0-.

On August 10, 2018, the Company issued a convertible promissory note (the “Note”), with a face value of $110,000, maturing on November 10, 2019, and stated interest of 10% to a third-party investor. The note was convertible at any time after ninety (90) days of the funding of the note into a variable number of the Company's common stock, based on a conversion ratio of 65% of the lowest trading price for the 20 days prior to conversion. The note was funded on August 10, 2018, when the Company received proceeds of $100,000, after disbursements for the lender’s transaction costs, fees and expenses. The embedded conversion feature included in the note resulted in an initial debt discount of $100,000, an initial derivative expense of $113,173 and an initial derivative liability of $213,173. For the year ended December 31, 2018, amortization of the debt discount of $100,000 was charged to interest expense. The Company also recorded a debt issue discount of $10,000 and amortized $10,000 to interest expense for the year ended December 31, 2018. During the year ended December 31, 2018, the investor converted $110,000 of principal and $2,290 of interest into 3,277,595 shares of common stock. As of December 31, 2018, the note balance is $-0-.

On August 10, 2018, an investor purchased a $40,000 portion of a convertible promissory note issued on November 10, 2017. During the year ended December 31, 2018, the investor converted $40,000 of the face value into 3,209,283 shares of common stock. As of December 31, 2018, the outstanding principal amount of the purchased note was $-0-.

F-21

On November 2, 2018, the Company issued a convertible redeemable note with a face value of $280,500 (the “Note”), and a back-end convertible redeemable note for $280,500 (the “Notes”), maturing$280,000 each. The notes mature on November 2, 2019, and a stated interest of 8% to a third-party investor. The notes arenote is convertible at any time after funding of the note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The first note was funded on November 2, 2018, when the Company received proceeds of $255,000,$225,500, after disbursements for the lender’s transaction costs, fees and expenses. The embedded conversion feature included in the first note resulted in an initial debt discount of $250,000,$225,500, an initial derivative expense of $148,544 and an initial derivative liability of $398,544. For the year ended December 31, 2018,2019, amortization of the debt discount of $41,667$225,500 was charged to interest expense. The Company also recorded a debt issue discount of $30,500$55,500 and amortized $5,083$55,500 to interest expense for the year ended December 31, 2018.2019. During the year ending December 31, 2019, an additional penalty of $28,050 was added to the principal of the note due to failure to pay off the note on time. As of December 31, 2018,2020 and 2019, the firstoutstanding note balance is $280,500, with a carrying value$308,550 and $308,550, respectively. The second note was funded in November of $46,750, net of unamortized discounts of $233,750. On December 26, 2018, the investor partially funded $187,000 of the back-end note, when the Company received proceeds of $166,667,$225,000, after disbursements for the lender’slender's transaction costs, fees, and expenses.expenses, resulting in $55,500 debt issue discount. The embedded conversion feature included in the partial funding of the back-end noteNote resulted in an initial debt discount of $166,667, an initial derivative expense of $100,081$93,738 and an initial derivative liability of $266,748. For$93,738. During the yearyears ended December 31, 2018,2020 and 2019, amortization of the debt discount of $2,608$- 0- and $149,238 was charged to interest expense. The Company also recorded a debt issue discount of $20,333 and amortized $318 to interest expense, forrespectively. During the year endedending December 31, 2018.2019, the Company converted a principal of $280,500 accrued interest of $14,261. As of December 31, 2018,2020 and 2019, the back-endoutstanding note balance is $187,000, with a carrying value of $2,926, net of unamortized discounts of $184,074.$-0- and $-0-, respectively.

F-14

 

On December 4, 2018, the Company issued a convertible redeemable note (the “Note”) with a face value of $158,333 maturing on December 4, 2019, and a stated interest of 8% to a third-party investor. The note is convertible at any time after funding of the note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The note was funded on December 4, 2018, when the Company received proceeds of $137,250,$137,500, after disbursements for the lender’s transaction costs, fees and expenses. The embedded conversion feature included in the note resulted in an initial debt discount of $137,500, an initial derivative expense of $87,293 and an initial derivative liability of $224,793. For the year ended December 31, 2018,2019, amortization of the debt discount of $11,458$137,500 was charged to interest expense. The Company also recorded a debt issue discount of $20,833$20,900 and amortized $1,736the full amount to interest expense for the year ended December 31, 2018. As2019. During the year ending December 31, 2019, the note holder converted principal amount of $158,333 and accrued interest in the amount of $9,909, resulting in zero balance as of December 31, 2018, the note balance is $158,333, with a carrying value of $13,194, net of unamortized discounts of $145,139.2019.

 

On December 4, 2018, the Company issued to a third-party investor a convertible redeemable note (the “Note”) with a face value of $230,000 and a back-end convertible redeemable note for $230,000. The notes mature on December 4, 2019, have a stated interest of 8% and each note is convertible at any time following the funding of such note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The note was funded on December 4, 2018, when the Company received proceeds of $210,000,$218,000, after disbursements for the lender’s transaction costs, fees and expenses.expenses, resulting in debt issue discount of $12,000. The embedded conversion feature included in the note resulted in an initial debt discount of $210,000,$218,000, an initial derivative expense of $108,922$108,922 and an initial derivative liability of $318,292. For the year ended December 31, 2018,2019, amortization of the debt discount of $17,500$218,000 was charged to interest expense. The Company also recorded a debt issue discount of $20,000 and amortized $1,667 to interest expense forDuring the year endedending December 31, 2018.2019, the Company converted a principal of $225,000 and accrued interest of $14,117. During the year ending December 31, 2020, the Company converted remaining principal of $5,000 and accrued interest of $1,471. As of December 31, 2018,2020 and 2019, theoutstanding note balance is $230,000, with$-0- and $5,000 respectively. The second note was funded in December of 2018, when the Company received proceeds of $188,575, after disbursements for the lender's transaction costs, fees, and expenses, resulting in $41,425 debt issue discount. The embedded conversion feature included in the Note resulted in an initial debt discount of $116,600 and an initial derivative liability of $116,600. During the years ended December 31, 2020 and 2019, amortization of the debt discount of $- 0- and $137,500 was charged to interest expense, respectively. During the year ending December 31, 2019, the Company converted a carrying valueprincipal of $19,167, net$115,000 accrued interest of unamortized discounts$17,388. During the year ending December 31, 2020, the Company converted a principal of $210,833.$115,000 accrued interest of $14,060. As of December 31, 2020 and 2019, the outstanding note balance is $-0- and $115,000, respectively.

 

On December 24, 2018, the Company issued to a third-party investor a convertible redeemable note (the “Note”) with a face value of $195,000 and a back-end convertible redeemable note for $195,000. The notes maturenote matures on December 24, 2019, have a stated interest of 8% and each note is convertible at any time following the funding of such note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The note was funded on December 26, 2018, when the Company received proceeds of $177,000,$160,000, after disbursements for the lender’s transaction costs, fees and expenses.expenses, resulting in debt issue discount of $35,000. The embedded conversion feature included in the note resulted in an initial debt discount of $177,000,$160,000, an initial derivative expense of $92,464 and an initial derivative liability of $269,464. For the year ended December 31, 2018,2019, amortization of the debt discount of $2,360$195,000 was charged to interest expense. During the year ending December 31, 2020, the Company converted a principal of $4,150 and accrued interest of $1,521. As of December 31, 2020 and 2019, the outstanding note balance is $190,850 and $195,000 respectively.

On January 22, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $245,000 and two back-end convertible redeemable notes for $122,500 each. The notes mature on January 22, 2020, have a stated interest of 8%. Each Note is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The initial Note was funded on January 22, 2019, when the Company also recorded areceived proceeds of $200,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in $45,000 debt issue discount. The embedded conversion feature included in the Note resulted in an initial debt discount of $18,000$200,000, an initial derivative expense of $134,208, and amortized $240 to interest expense foran initial derivative liability of $334,208. During the year ended December 31, 2018.2020 and 2019, amortization of the debt discount of $14,767 and $230,233 was charged to interest expense, respectively. As of December 31, 2018,2020 and 2019, theoutstanding note balance is $195,000,$245,000 and $245,000, respectively. The second note was funded on January 22, 2019, when the Company received proceeds of $100,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in $22,500 debt issue discount. The embedded conversion feature included in the Note resulted in an initial debt discount of $100,000, an initial derivative expense of $77,884, and an initial derivative liability of $177,884. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $7,384 and $115,116 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $122,500 and $122,500, respectively. The third note was funded in July of 2019, when the Company received proceeds of $96,202, after disbursements for the lender's transaction costs, fees, and expenses, resulting in $22,500 debt issue discount. The embedded conversion feature included in the Note resulted in an initial debt discount of $96,202 and an initial derivative liability of $96,202. During the years ended December 31, 2020 and 2019, amortization of the debt discount of $7,155 and $111,547 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $122,500 and $122,500, respectively

On February 22, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a carryingface value of $2,600, net$116,667. The Note matures on February 22, 2020, has a stated interest of unamortized discounts8%, and is convertible at any time following the funding of $192,400.

such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on February 22, 2019, when the Company received proceeds of $90,000 after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $26,667. The embedded conversion feature included in the Note resulted in an initial debt discount of $90,000, an initial derivative expense of $36,138, and an initial derivative liability of $126,138. During the years ended December 31, 2020 and 2019, amortization of the debt discount of $16,941 and $99,726 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $38,917 and $38,917, respectively.

 F-22F-15 

 

On March 8, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $133,333. The Note matures on March 8, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on March 8, 2019, when the Company received proceeds of $106,200, after disbursements for the lender's transaction costs, fees, and expenses. The embedded conversion feature included in the Note resulted in an initial debt discount of $106,200, debt issues discount of $27,133, an initial derivative expense of $82,538, and an initial derivative liability of $188,738. During the years ended December 31, 2020 and 2019, amortization of the debt discount of $24,772 and $108,561 was charged to interest expense, respectively. During the year ending December 31, 2020, the Company converted a principal of $133,333 and accrued interest of $20,900. As of December 31, 2020 and 2019, the outstanding note balance is $-0- and $133,333, respectively.

On March 20, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $89,085 and a back-end convertible redeemable note for $89,085. The notes mature on March 20, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The initial Note was funded on March 20, 2019, when the Company received proceeds of $75,000 after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $14,085. The embedded conversion feature included in the Note resulted in an initial debt discount of $75,000, an initial derivative expense of $48,913, and an initial derivative liability of $123,913. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $19,472 and $69,613 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $-0- and $133,333, respectively. The second note was funded on March 20, 2019, when the Company received proceeds of $75,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in $14,085 debt issue discount. The embedded conversion feature included in the Note resulted in an initial debt discount of $75,000, an initial derivative expense of $66,439, and an initial derivative liability of $141,439. During the years ended December 31, 2020 and 2019, amortization of the debt discount of $19,472 and $69,613 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $89,085 and $89,085, respectively.

Also, on March 20, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $89,085 and a back-end convertible redeemable note for $89,085. The notes mature on March 20, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The initial Note was funded on March 20, 2019, when the Company received proceeds of $75,000 after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $14,085. The embedded conversion feature included in the Note resulted in an initial debt discount of $75,000, an initial derivative expense of $48,913, and an initial derivative liability of $123,913. During the years ended December 31, 2020 and 2019, amortization of the debt discount of $19,472 and $69,613 was charged to interest expense, respectively. During the year ending December 31, 2020, a penalty of $16,517 was added to the principal balance due to failure to pay off the note on time. During the year ending December 31, 2020, the Company converted a principal of $6,500 and accrued interest of $549. As of December 31, 2020 and 2019, the outstanding note balance is $99,102 and $89,085, respectively. The second note was funded on March 20, 2019, when the Company received proceeds of $75,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in $14,085 debt issue discount. The embedded conversion feature included in the Note resulted in an initial debt discount of $75,000, an initial derivative expense of $66,439, and an initial derivative liability of $141,439. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $19,472 and $69,613 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $89,085 and $89,085, respectively.

On April 12, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $208,000. The Note matures on April 12, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on April 12, 2019, when the Company received proceeds of $175,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $33,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $175,000, an initial derivative expense of $104,450, and an initial derivative liability of $279,450. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $58,536 and $149,464 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $208,000 and $208,000, respectively.

Also, on April 12, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $208,000. The Note matures on April 12, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on April 12, 2019, when the Company received proceeds of $175,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $33,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $175,000, an initial derivative expense of $104,450, and an initial derivative liability of $279,450. During the year ending December 31, 2020, a penalty of $41,600 was added to the principal balance due to failure to pay off the note on time. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $58,536 and $149,464 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $249,600 and $208,000, respectively.

On May 15, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $208,000. The Note matures on May 15, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on May 15, 2019, when the Company received proceeds of $175,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $33,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $175,000, an initial derivative expense of $104,082, and an initial derivative liability of $279,082. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $77,290 and $130,710 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $208,000 and $208,000, respectively.

F-16

Also, on May 15, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $167,352. The Note matures on May 15, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on May 15, 2019, when the Company received proceeds of $140,250, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $27,102. The embedded conversion feature included in the Note resulted in an initial debt discount of $140,250, an initial derivative expense of $85,329, and an initial derivative liability of $225,579. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $62,185 and $105,167 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $167,352 and $167,352, respectively.

On June 13, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $119,000. The Note matures on June 13, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on June 13, 2019, when the Company received proceeds of $100,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $19,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $100,000, an initial derivative expense of $49,779, and an initial derivative liability of $149,779. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $53,648 and $65,352 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $119,000 and $119,000, respectively.

Also, on June 13, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $119,000. The Note matures on June 13, 2020, has a stated interest of 8%, and convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on June 13, 2019, when the Company received proceeds of $100,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $19,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $100,000, an initial derivative expense of $49,779, and an initial derivative liability of $149,779. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $53,648 and $105,167 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $119,000 and $119,000, respectively.

On July 1, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $183,975. The Note matures on July 1, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on July 1, 2019, when the Company received proceeds of $150,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $33,975. The embedded conversion feature included in the Note resulted in an initial debt discount of $150,000, an initial derivative expense of $65,783, and an initial derivative liability of $215,783. During the year ending December 31, 2020, the Company converted a principal of $121,475and accrued interest of $6,376. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $91,988 and $91,988 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $62,500 and $183,975, respectively.

On August 9, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $122,650. The Note matures on August 9, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on August 9, 2019, when the Company received proceeds of $100,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $11,150. The embedded conversion feature included in the Note resulted in an initial debt discount of $100,000, an initial derivative expense of $18,522, and an initial derivative liability of $118,522. . During the year ended December 31, 2020 and 2019, amortization of the debt discount of $79,255 and $43,395 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $122,650 and $122,650, respectively.

On September 12, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $160,000. The Note matures on September 12, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on September 12, 2019, when the Company received proceeds of $130,050, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $29,950. The embedded conversion feature included in the Note resulted in an initial debt discount of $130,050, an initial derivative expense of $25,433, and an initial derivative liability of $155,483. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $111,913 and $48,087 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $160,000 and $160,000, respectively.

F-17

On October 3, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $75,000. The Note matures on October 3, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on October 3, 2019, when the Company received proceeds of $60,645, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $14,355. The embedded conversion feature included in the Note resulted in an initial debt discount of $60.645, an initial derivative expense of $74,404, and an initial derivative liability of $135,049. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $56,762 and $18 238 was charged to interest expense, respectively. During the year ending December 31, 2020, the Company converted a principal of $21,250. As of December 31, 2020 and 2019, the outstanding note balance is $53,750 and $75,000, respectively.

On November 1, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $100,000. The Note matures on November 1, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on November 1, 2019, when the Company received proceeds of $79,650, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $20,350. The embedded conversion feature included in the Note resulted in an initial debt discount of $79,650, an initial derivative expense of $50,171, and an initial derivative liability of $129,821. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $79,781and $20,219 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $100,000 and $100,000, respectively.

On November 1, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $56,000. The Note matures on November 1, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on November 1, 2019, when the Company received proceeds of $50,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $6,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $50,000, an initial derivative expense of $17,328, and an initial derivative liability of $67,328. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $46,820 and $9,180 was charged to interest expense, respectively. During the year ending December 31, 2020, the Company converted a principal of $9,256. As of December 31, 2020 and 2019, the outstanding note balance is $46,744 and $100,000, respectively.

On December 24, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $33,000. The Note matures on November 1, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on December 24, 2019, when the Company received proceeds of $30,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $3,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $30,000, an initial derivative expense of $9,670, and an initial derivative liability of $39,670. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $32,369 and $631 was charged to interest expense, respectively. of December 31, 2020 and 2019, the outstanding note balance is $33,000 and $33,000, respectively.

On January 23, 2020, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $22,000. The Note matures on January 23, 2021, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on January 23, 2020, when the Company received proceeds of $20,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $2,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $20,000, an initial derivative expense of $15,101, and an initial derivative liability of $35,101. During the year ended December 31, 2020, amortization of the debt discount of $20,617 was charged to interest expense, respectively. As of December 31, 2020, the outstanding note balance is $22,000.

On January 30, 2020, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $60,000. The Note matures on January 30, 2021, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on January 30, 2020, when the Company received proceeds of $50,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $10,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $50,000, an initial derivative expense of $73,171, and an initial derivative liability of $123,171. During the year ended December 31, 2020, amortization of the debt discount of $55,082 was charged to interest expense, respectively. As of December 31, 2020, the outstanding note balance is $60,000.

On January 30, 2020, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $60,000. The Note matures on January 30, 2021, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on January 30, 2020, when the Company received proceeds of $50,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $10,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $50,000, an initial derivative expense of $73,171, and an initial derivative liability of $123,171. During the year ended December 31, 2020, amortization of the debt discount of $55,082 was charged to interest expense, respectively. As of December 31, 2020, the outstanding note balance is $60,000.

F-18

On March 12, 2020, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $100,000. The Note matures on March 12, 2021, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on March 12, 2020, when the Company received proceeds of $79,650, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $20,350. The embedded conversion feature included in the Note resulted in an initial debt discount of $79,650, an initial derivative expense of $51,707, and an initial derivative liability of $131,357. During the year ended December 31, 2020, amortization of the debt discount of $111,905 was charged to interest expense, respectively. As of December 31, 2020, the outstanding note balance is $100,000.

A summary of the convertible note balances as of December 31, 2018,2020, and 2017,2019, is as follows:

  December 31, 2020 December 31, 2019
Principal balance $3,286,270  $3,402,117 
Unamortized discounts  (30,672)  (1,011,636)
Ending balance, net $3,255,598  $2,390,481 

  December 31, 2018 December 31, 2017
Principal balance $1,277,108  $378,800 
Unamortized discounts  (1,125,942)  (292,073)
Ending balance, net $151,166  $86,727 

A summary ofAll convertible notes are due within 12 months and classified as a short-term liability on the balance sheet classification of the short-term and long-term portions of convertible note balances as of December 31, 2017, is as follows:sheet.

  Current portion Long-term portion Total
Principal balance $266,000  $112,800  $378,800 
Unamortized discount  (191,860)  (100,213)  (292,073)
Ending balance, net $74,140  $12,587  $86,727 

The following is a roll-forward of the Company’s convertible notes and related discounts for the years ended December 31, 2018, and 2017:

  Principal Balance Debt Discounts Total
Balances January 1, 2017 $—    $—    $—   
New issuances  397,000   (355,507)  41,493 
Cash payments  (18,200)  —     (18,200)
Amortization  —     63,434   63,434 
Balance at December 31, 2017  378,800  $(292,073) $86,727 
New issuances  1,961,133   (1,943,459)  17,674 
Liquidated damages added to note  6,025   —     6,025 
Conversions  (781,412)  —     (781,412)
Cash payments  (253,633)  —     (253,663 
Debt forgiveness  (33,775)  —     (33,775)
Amortization  —     1,109,590   1,109,590 
Balance at December 31, 2018 $1,277,108  $(1,125,942) $151,166 

  

NOTE 1310 – DERIVATIVE LIABILITESLIABILITIES

The Company determined that the conversion features of the convertible notes represented embedded derivatives since the Notes are convertible into a variable number of shares upon conversion. Accordingly, the notes are not considered to be conventional debt under EITF 00-19 and the embedded conversion feature is bifurcated from the debt host and accounted for as a derivative liability. Accordingly, the fair value of these derivative instruments is recorded as liabilities on the consolidated balance sheet with the corresponding amount recorded as a discount to each Note, with any excess of the fair value of the derivative component over the face amount of the note recorded as an expense on the issue date. Such discounts are amortized from the date of issuance to the maturity dates of the Notes. The change in the fair value of the derivative liabilities are recorded in other income or expenses in the condensed consolidated statements of operations at the end of each period, with the offset to the derivative liabilities on the balance sheet. See Note 12.

 

The Company valued the derivative liabilities at issuance, December 31, 2018,2020, and December 31, 2017,2019, at $1,807,404$412,801 and $540,965,$4,745,194, respectively. The Company used the Monte Carlo simulation valuationmultinomial lattice valuation model with the following assumptions for new notes issued during the nine monthsyear ended December 31, 2018,2020, risk-free interest rates from 1.82% to 2.71%rate of 0.05% and volatility of 303%150% to 432%250%, and as of December 31, 2018,2019, risk-free interest rates from 2.56% to 2.62%rate of 0.05% and volatility of 355%200% to 391%300%.

 

F-23

A summary of the activity related to derivative liabilities forduring the yearsyear ended December 31, 2018,2020, and 2017,2019, is as follows:

 December 31, 2018 December 31, 2017 December 31, 2020 December 31, 2019
Beginning Balance $540,965  $—    $3,515,055  $1,807,404 
Initial derivative liability  2,821,437   517,046   412,801   4,745,194 
Fair value change  1,262,290   52,125   1,198,529   (942,398)
Reclassification for principal payments and conversions  (2,817,288)  (28,216)  (1,079,984)  (2,095,145)
Ending Balance $1,807,404  $540,965  $4,046,401  $3,515,055 

Derivative liability expense of $2,436,951$1,016,050 for the year ended December 31, 2018,2020, consisted of the initial derivative expense of $1,174,661$213,151 and the above loss on changes in fair value of $802,900. Derivative liability expense of $540,678 for the year ended December 31, 2019, consisted of the initial derivative expense of $1,734,337 and the above gain on change in fair value of $1,262,290.$1,736,559.

 

NOTE 14–11– COMMITMENTS AND CONTINGENCIES

 

Lease Agreements

Lease Agreements

On June 14, 2017, the company entered into a five-year lease with LLC1 for approximately 6,944 square feet and a monthly rent of $12,000.$12,000 with a related party (Note 7). Upon adoption of ASC 842, the Company recognized $434,504 of right-to-use assets as operating leases and operating lease obligations.

 

On September 10, 2018, pursuant to the Amos Audiology acquisition, the Company assumed a lease dated December 1, 2017 and expiring April 30, 2023, in Walnut Creek, California. Lease payments in the first year of the lease are $3, 988 per month and increase by 3% on December 1 each new lease year. As of December 31, 2018, the Company was in arrears of $25,182 (including late fees) in lease payments and has agreed with the landlord to pay the arrears in seven monthly payments of $3,597 in addition to the monthly lease payments for January 2019 through July 2019. Settlement fees were fully paid during the year ending December 31, 2019.

 

F-19

On October 15, 2018, the Company entered into a lease to operate a retail hearing aid clinic in Roseville, California expiring December 31, 2023. Initial lease payments of $3,102 beginbegan on January 1, 2019, and increase by 3% on January 1 each new lease year. Upon adoption of ASC 842, the Company recognized $160,623 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in November of 2020, therefore, a ROU asset loss was recognized in the amount of $106,419 during year ending December 31, 2020. No changes to operating lease liability have been made until the settlement has been reached.

On November 18, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Walnut Creek, expiring in October of 2022. Initial lease payments of $3,930 began on December 1, 2019, and increase by 3% on December 1 each new lease year. Upon adoption of ASC 842, the Company recognized $129,281 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in April of 2021.

 

On December 1, 2018, the Company entered into a lease to operate a retail hearing aid clinic in Sacramento, California expiring March 31, 2024. Initial lease payments of $3,002 beginbegan on April 1, 2019, and increase by 3.33% on April 1, 2020 and 2021, and by 3% on April 1, 2022. Upon adoption of ASC 842, the Company recognized $149,507 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in November of 2020, therefore, a ROU asset loss was recognized in the amount of $102,312 during year ending December 31, 2020. No changes to operating lease liability have been made until the settlement has been reached. Subsequent to year ending December 31, 2020, the Company reached the settlement where the Company agreed to make either one time payment of $44,000 or make fourteen monthly payments of $3,220.

 

On February 1, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Elk Grove, California expiring January 31, 2024. Initial lease payments of $2,307 beginbegan on February 1, 2019, and increase by an average of 2.6% on February 1, each new lease year. Upon adoption of ASC 842, the Company recognized $116,153 of right-to-use assets as operating leases and operating lease obligations. The Company terminated the lease in March of 2021 where the Company agreed to pay $23,911 in order to settle the lease.

On May 31, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Greenhaven, California expiring June 30, 2022. Initial lease payments of $1,450 began on July 1, 2019, and increase by 5% on July 1, each new lease year. Upon adoption of ASC 842, the Company recognized $48,512 of right-to-use assets as operating leases and operating lease obligations. The Company terminated the lease in November of 2020, therefore, a ROU asset loss was recognized in the amount of $27,041, during year ending December 31, 2020. No changes to operating lease liability have been made until the settlement has been reached. Subsequent to year ending December 31, 2021, the Company made a final payout of $6,000, upon which the lease was settled.

On April 15, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Pleasanton, California expiring April of 2024. Initial lease payments of $3,551 began on May 1, 2019, and increase by 3% on May 1 each new lease year. Upon adoption of ASC 842, the Company recognized $185,068 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in December of 2019, therefore, a ROU asset loss was recognized in the amount of $153,589 during year ending December 31, 2019. No changes to operating lease liability have been made until the settlement has been reached.

 

On February 1, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Fremont, California expiring February 28, 2021. Initial lease payments of $2,019 beginbegan on March 1, 2019, and increases by 3% on March 1, 2020. The Company terminated the lease in 2019 and agreed to make a payment of $4,038 in order to settle the lease.

 

On June 1, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Hayward, California expiring June of 2021. Initial lease payments of $1,816 began on June 1, 2019, and increase by 3% on June 1 each new lease year. Upon adoption of ASC 842, the Company recognized $34,486 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in December of 2019, therefore, a ROU asset loss was recognized in the amount of $14,348 during year ending December 31, 2019. No changes to operating lease liability have been made until the settlement has been reached.

The operating lease expense for the year ending December 31, 2020 and 2019 was $322,879 and $424,613, respectively. These leases will expire between 2021 and 2023. The weighted average discount rate used for these leases were 8% (average borrowing rate of the Company). Future principal payments for the Company’s portion are:

 

 For the twelve months ending December 31, Amount
 2019  $326,089 
 2020   320,805 
 2021   304,064 
 2022   232,774 
 2023   127,261 
 Thereafter   12,423 
 Total  $1,323,816 

The Company is using the straight line method for expensing monthly rent based on the total monthly payments due under each lease divided by the number of months of each lease, and accordingly, rent expense for the year ended December 31, 2018, was $186,700 ($144,000 related) and $111,377 ($109,500 related) for the year ended December 31, 2017.

 For the twelve months ending December 31, Amount
 2021  $360,815 
 2022   156,548 
 2023   89,208 
 2024      
 Thereafter      
 Total  $606,571 

 

 F-24F-20 

 

Consulting Agreements

On August 5, 2016, the Company along with Mark Moore (“Mark”, the Company’s chairman), Matthew Moore (“Matthew”, the Company’s Chief Executive Officer) and Kim Moore (“Kim”, the Company’s Chief Financial Officer) entered into a Store Expansion Consulting Agreement (the “Expansion Agreement”) Mark, Matthew and Kim are herein referred to collectively as the Moores. Pursuant to the Expansion Agreement, the Company and the Moores were responsible for all physical plant and marketing details for new store openings during the initial term of six-months. The Expansion Agreement was cancelled on January 6, 2017. The Company’s client has decidedto do their own marketing in-house and eliminate this out-sourced contract and has decided to delay the opening of any new stores. For the year ending December 31, 2017, the Company has received and recognized $400,000 in other income for payments received for the cancellation of the Expansion Agreement.

Also, on August 5, 2016, the Company and the Moores entered into a Consulting Agreement (the “Consulting Agreement”) with the same party as the store Expansion Agreement. Under the Consulting Agreement, including the Non-Compete provision covering a ten- mile radius of any retail store, the Company and the Moores were to provide unlimited licensing of the Intela-Hear brand name, exclusive access to the Aware Aural Rehab Program within 10 miles of retail stores, exclusive territory of all services within 10 miles of retail stores and 40 hours per month of various consulting services. The Consulting Agreement was to continue until January 31, 2019, unless terminated for cause, as defined in the Consulting Agreement. On May 2, 2017, the Company received a demand letter threatening litigation unless all monies paid pursuant to the Consulting Agreement are returned. On May 26, 2017, a complaint (the “Complaint”) was filed against the Company and the Moores, which includes a request for rescission of the Consulting Agreement. The Company filed a countersuit against this third party for breach of contract so that it may recover the amounts owed under the Consulting Agreement, however, effective January 1, 2017, the Company had not recognized revenue from the Consulting Agreement, and accordingly, $847,223 was classified as deferred revenue on the December 31, 2017, consolidated balance sheets presented herein. On August 13, 2018, Helix, the Company and the Moores signed a Settlement Agreement, whereby, the Company received $450,000 andall parties dismissed all claims against the other party with prejudice. Accordingly, the Company recognized Other income of $1,297,223 for the year ended December 31, 2018, comprised of the deferred revenues for amounts previously received and the $450,000 settlement amount.

Effective December 1, 2017, the Company entered into a one-year Marketing Services Agreement (the “MSA”). Pursuant to the terms of the MSA, the Company will receive consulting and advisory services regarding the implementation of marketing programs, including the design and creation of commercial websites and commercialization of products through social media or other marketing methods. The Company will pay consideration for the services of $5,000 cash and $5,000 of common stock each month. The Company will issue the number of shares of common stock equal to a twenty-five percent (25%) discount to the lowest closing price of the common stock for the five (5) last trading days of the common stock for that month. The parties agreed to terminate the services and contract effective June 30, 2018. For the year ended December 31, 2018, the Company recorded $30,000 of consulting expense and recorded $38,512 of stock-based compensation expense (pursuant to the terms of the MSA) from the issuance of 925,130 shares of common stock. On February 27, 2018, the Company issued 102,564 shares of common stock that were previously recorded as common stock to be issued.as of December 31, 2017.

On August 9, 2018, the Company entered into a monthly Consulting Services Master Agreement (the “CSMA”). The CSMA requires a two- month minimum and a 30- day termination notice. Pursuant to the CSMA, the Company is to compensate the consultant $12,500 per month by the issuance of restricted shares of common stock, based on the average closing trading prices for the three days prior to each monthly payment.

On August 10, 2018, the Company entered into a one- year Consulting, Public Relations and Marketing Agreement (the “CPRM Agreement”), which can be cancelled by either party with a 30- day notice to the other party. Pursuant to the terms of the CPTM Agreement the Company is to issue 100,000 shares of restricted common stock each month. The parties agreed to terminate the CPRM Agreement on October 23, 2018.

On August 15, 2018, the Company entered into a six-month Consulting Agreement (the “CA”). Pursuant to the CA, the Company agreed to issue 2,500,000 shares of restricted common stock to the consultant.

F-25

On October 3, 2018, the Company entered into a Manufacturing Design and Marketing Agreement (the “Agreement”) with Zounds, whereby, Zounds will provide design, technology, manufacturing and supply chain services to the Company, to enable the Company to manufacture comparable hearing aids and related components and accessories to be sold under the Company’s exclusive brand names (the “Manufacturer’s Products”) through the Company’s various marketing and distribution channels. The Company will pay Zounds One Million ($1,000,000) (the “Technology Access Fee”). The Technology Access Fee, as amended will be paid in eight (8) installments of $75,000 each, in four- week intervals until $600,000 is paid and $400,000 is to be paid as Product Surcharges based on $200 per unit manufactured for up to the first 2,000 units. Once $400,000 of Product Surcharges are paid said per unit surcharge will be discontinued. As of December 31, 2018, the Company has paid $183,200 towards the Technology Access Fee and as of December 31, 2018, $816,800 is included in accounts payable and accrued expenses.

On October 10, 2018, the Company executed an engagement letter with The Crone Law Group (“Crone”). Crone will provide certain SEC filing services for a fee of $2,500 per month. Additionally, the Company has agreed to issue Crone 500,000 shares of common stock. The Company valued the shares at $36,400, based on the market price of the common stock on the date of the agreement, and is included in professional fees, as stock- based compensation for During the year ended December 31, 2108.2020, the Company determined that it was unable to substantiate the actual fair value of the technology that was acquired so has chosen to impair the full amount (Note 4).

 

On October 31, 2018, the Company entered into a three-year Joint Development Agreement (the “JD Agreement”) and an Exclusive Distribution Agreement (the “ED Agreement”) with Erchonia Corporation (“Erchonia”). As part of the JD Agreement, the Company and Erchonia will conduct FDA clinical research and trials for the purposes of obtaining 510k FDA Clearances for devices, technologies, methods and techniques used in the treatment of hearing relating conditions and disorders such as Tinnitus, Sensorineural hearing Loss, dizziness and other disorders. The agreements give the Company the exclusive worldwide rights for all designs and any newly developed Erchonia 3LT lasers and related technologies and gives the Company the rights to license and distribute such products worldwide. Pursuant to the JD Agreement, the Company has agreed to issue 1,000,000 shares of common stock. The Company valued the common stock to be issued at $60,000, based on the market price of the common stock on the date of the JD Agreement, to be amortized over the three-year term.. As of December 31, 2018, there remains $60,000 of deferred stock compensation on the consolidated balance sheet, to be amortized over the three-year contract term.NOTE 12– INCOME TAXES

 

On December 7, 2018, the Company entered into a one- year consulting agreement (the “Media Consulting Agreement”) with a third- party consultant (the “Consultant”). The Consultant will provide communication and broadcast services, as well as strategic planning services. Pursuant to the Media Consulting Agreement, the Company has agreed to issue the Consultant 3,125,000 shares of restricted common stock. On December 7, 2018, the Company recorded 3,125,000 shares of common stock to be issued. The company valued the common stock to be issued at $125,000 based on the market price of the common stock on the date of the Media Consulting Agreement, to be amortized over the term of the agreement. The Company amortized $7,639 for the year ended December 31, 2018, and is included in Professional fees on the consolidated Statement of operations. As of December 31, 2018, there remains $117,361 of deferred stock compensation on the consolidated balance sheet, to be amortized in 2019.

Legal Matters

On May 26, 2017, Helix Hearing Care (California), Inc. a California corporation (“Helix”), filed a complaint (the “Complaint”) against the InnerScope and the Moores, in the Circuit Court of the 11th Judicial Circuit in and for Miami-Dade County, Florida, that includes a rescission of the Consulting Agreement and a demand that all monies paid pursuant to the Consulting Agreement be returned, on the basis that an injunction against certain Officers and Directors renders the Consulting Agreement impossible to perform. The Company had previously received $1,250,000 under the Consulting Agreement. InnerScope was not named as an enjoined party in such previous litigation, and the services contemplated under the Consulting Agreement are not within the scope of the injunction, thus InnerScope believes the accusation by the third party is frivolous and without merit, as well as not providing sufficient cause for the Agreement to be terminated. InnerScope and the Moores filed their Answer and Affirmative Defenses to the Complaint on June 27, 2017.  On the same date, InnerScope, the Moores, and MFHC filed a counterclaim. On February 27, 2018, the Counterclaim was amended to include four claims for breach of contract, one claim for anticipatory breach of contract, one claim for negligent misrepresentation, and one claim for account stated. On August 13, 2018, Helix, the Company and the Moores signed a Settlement Agreement, whereby, the Company received $450,000,all parties dismissed all claims against the other party with prejudice and Matthew, Mark and Kimberly have been released from their covenant not to compete agreement signed in August 2016 with Helix.

F-26

NOTE 15 – INCOME TAXES

TheCompany has deferred tax assets and liabilities as shown in the following: 

  2018 2017
Deferred Tax Assets:        
   Stock based compensation $369,560  $102,400 
Net operating losses  555,279   575,408 
Deferred Tax Liabilities        
 Derivative liabilities  (257,716)  (101,000)
Net deferred tax assets  667,123   576,808 
Valuation Allowance  (667,123)  (576,808)
  $—    $—   

A valuation allowance has been recognized to offset the deferred tax assets because realization of such assets is uncertain. 

The income tax provision differs from the amount of income tax determined by applying the U.S. federal and state income statutory tax rates to pretax income (loss) from continuing operations as follows: 

  2018 2017
Statutory federal income tax rate  -21.00%  -34.00%
State taxes, net of federal income tax  -8.84%  -8.84%
Effect of change in valuation allowance  1.97%  28.48%
Non deductible expenses and other  27.87%  14.36%
   0.00%  0.00%

As of December 31, 2018, the Company has approximately $2,016,000 net operating loss carryforwards to reduce future taxable income.The NOL deduction for a tax year is equal to the lesser of (1) the aggregate of the NOL carryovers to such year, plus the NOL carry-backs to such year, or (2) 80% of taxable income (determined without regard to the deduction). Generally, NOLs can no longer be carried back but are allowed to be carried forward indefinitely. The special extended carryback provisions are generally repealed, except for certain farming and insurance company losses. The amendments incorporating the 80% limitation apply to losses arising in tax years beginning after Dec. 31, 2017.It is more likely than not that the deferred tax assets cannot be utilized in the future because there will not be significant future earnings from the entity which generated the net operating loss. Therefore, the Company recorded a full valuation allowance on its deferred tax assets.

As of December 31, 2018, and 2017, the Company has no material unrecognized tax benefits which would favorably affect the effective income tax rate in future periods, and does not believe that there will be any significant increases or decreases of unrecognized tax benefits within the next twelve months. No interest or penalties relating to income tax matters have been imposed on the Company during the years ended December 31, 2018 and 2017, and no provision for interest and penalties is deemed necessary as of December 31, 2018, and 2017.

The U.S. Tax Cuts and Jobs Act (Tax Act) was(the “Act”) enacted on December 22, 2017 and introduces significant changes to U.S. income tax law. Effective in 2018, the Tax Act reduces the U.S. statutoryUS federal corporate tax rate from 35% to 21% and requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and creates new taxes on certain foreign-sourced earnings and certain related-party payments, which are referred to as the global intangible low-taxed income tax and the base erosion tax, respectively. The Tax Act requires the Company to pay U.S. income taxes on accumulated foreign subsidiary earnings not previously subject to U.S. income tax at a ratesourced earnings. As of 15.5% to the extent of foreign cash and certain other net current assets and 8% on the remaining earnings. Due to the timing of the enactment and the complexity involved in applying the provisions of the Tax Act,December 31, 2020, the Company has not recorded any adjustments according to Tax Act. Ascompleted the Company collects and prepares necessary data, and interprets the Tax Act and any additional guidance issued by the U.S. Treasury Department, the IRS, and other standard-setting bodies, the Company may make adjustments to the provisional amounts. The accounting for the tax effects of enactment of the Tax ActAct; however, as described below, it has made a reasonable estimate of the effects on existing deferred tax balances. These amounts are provisional and subject to change.

The provision for income taxes is calculated at US corporate tax rate of approximately 21% (2019: 21%) as follows:

  2020 2019
Expected income tax recovery from net loss $1,040,275  $1,663,974 
Tax effect of expenses not deductible for income tax:        
Annual effect of book/tax difference  (523,142)  (890,866)
Change in valuation allowance  (517,133)  (773,108)
           

Deferred tax assets

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be completedrealized. Deferred tax assets and liabilities are adjusted for the effects of changes in 2019. tax laws and rates on the date of enactment.

Net deferred tax assets consist of the following components as of December 31:

  2020 2019
Tax effect of NOL carryover $2,594,396  $2,077,264 
Less valuation allowance  (2,594,396)  (2,077,264)
           

At December 31, 2020, the Company performed a comprehensive analysis of its tax estimates and revised comparative figures accordingly, which had no net impact on deferred tax recorded. The Company had net operating loss carry forwards of approximately $2,594,396 (2019: $2,077,264) that may be offset against future taxable income from the year by 2040. No tax benefit has been reported in the December 31, 2020 and 2019 consolidated financial statements since the potential tax benefit is offset by a valuation allowance of the same amount. The Company is taxed in the United States at the Federal level. All tax years since inception are open to examination because no tax returns have been filed.

 F-27F-21 

 

NOTE 1613 – STOCKHOLDERS’ EQUITY

 

Preferred Stock

Preferred Stock

The Company has 25,000,000 authorized shares of $0.0001 preferred stock.

Series A Preferred Stock

On June 4, 2018, the Company filed in the State of Nevada a Certificate of Designation of a series of preferred stock, the Series A Preferred Stock. 9,510,000 shares were designated as Series A Preferred Stock. The Series A Preferred Stock has mandatory conversion rights, whereby each share of Series A Preferred Stock will convert two (2) shares of common stock upon the Company filing Amended and Restated Articles of Incorporation with the Secretary of State of Nevada, increasing the authorized shares of common stock. The Series A Preferred Stock has voting rights on an is if converted basis. The Series A Preferred Stock does not have any right to dividends. On June 4, 2018 the Company issued 3,170,000 shares of Series A Preferred Stock each to Matthew, Mark and Kimberly, in exchange for each of them cancelling and returning to treasury 6,340,000 shares of common stock.The issuances were made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, and Rule 506(b) promulgated thereunder, as the 1shareholdersshareholders are accredited investors, there was no general solicitation, and the transaction did not involve a public offering.On August 8, 2018, Matthew, Mark and Kim each converted 3,170,000 shares of Series A Preferred Stock for 6,340,000 shares of common stock each. The common stock issued replaced the 19,020,000 shares in the aggregate that the Moore’s cancelled in June 2018.As of December 31, 2018,2020 and 2019, there were no shares of Series A Preferred Stock issued and outstanding.

 

Series B Preferred Stock

On June 4, 2018, the Company also filed in the State of Nevada a Certificate of Designat1ionDesignation of a series of preferred stock, the Series B Preferred Stock. 900,000 shares were designated as Series B Preferred Stock. The Series B Preferred Stock is not convertible into common stock, nor does the Series B Preferred Stock have any right to dividends and any liquidation preference. The Series B Preferred Stock entitles its holder to a number of votes per share equal to 1,000 votes. On June 4, 2018, the Company issued 300,000 shares of its Series B Preferred Stock each to Matthew, Mark and Kimberly, in consideration of $45,000 of accrued expenses, the Company’s failure to timely pay current and past salaries, and the willingness to accrue unpaid payroll and non-reimbursement of business expenses without penalty or action for all amounts.The issuances were made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, and Rule 506(b) promulgated thereunder, as the shareholders are accredited investors, there was no general solicitation, and the transaction did not involve a public offering. The Company determined that fair value of the Series B Preferred Stock issued to the Company’s CEO was $817,600. The fair value was determined as set forth in the Statement of Financial Accounting Standard ASC 820-10-35-37, Fair Value in Financial Instruments.As of December 31, 2018,2020 and 2019, there were 900,000 shares of Series B Preferred Stock issued and outstanding.

 

Common Stock

Common Stock

The Company has 490,000,000 authorized shares of $0.0001 common stock. On January 30, 2020, the Company increased a number of authorized common shares to 14,975,000,000. As of December 31, 2018,2020, and December 31, 2017,2019, there are 120,425,3443,628,422,041 and 61,539,334,342,118,135, respectively, shares of common stock outstanding.

 

During the year endedending December 31, 2018,2019, the Company issued 925,13112,576,313 shares of common stock toas part of compensation for services for a marketing consultant (see Note 14) and recorded $38,512total value of stock-based compensation,$440,666, based on the market price of the common stock on the date the Company agreed to issue the shares.

 

On February 23, 2018,During the year ending December 31, 2019, the Company issued 10,397209,116,478 shares of common stock to an employee. The shares were valued at $728, based on the market pricefor partial conversion of the common stock on January 31, 2018, the date the Company agreed to issue the shares.

On February 27, 2018, the Company issued 102,564 shares of common stock that were classified as common stock to be issued as of December 31, 2017.

F-28

On June 4, 2018, Matthew, Markprincipal and Kimberly, each cancelled and returned to treasury 6,340,000 shares of common stock, in exchange for the issuance of 3,170,000 shares of Series A Preferred Stock to each. On August 8, 2018, Matthew, Mark and Kim each converted 3,170,000 shares of Series A Preferred Stock for 6,340,000 shares of common stock. The common stock issued replaced the 19,020,000 shares in the aggregate that the Moore’s cancelled in June 2018.accrued interest.

 

During the year endedending December 31, 2018, the Company issued 200,0002019, Company’s management made a contribution of $12,048. No shares of restricted common stock to a consultant pursuant to the CPRM Agreement (See Note 14). The shares were valued at $15,430 of stock-based compensation expense (based on the market price of the common stock on that date of issuance). This agreement was terminated in October 2018.

During the year ended December 31, 2018, the Company issued 770,601 shares of restricted common stock pursuant to the CSMA (See Note 14). The shares were valued at $50,000 based on the average closing price for the three days prior to the month of service, pursuant to the CSMA.

On August 27, 2018, the Company issued 2,500,000 shares of restricted common stock pursuant to the CA (See Note 14). The shares were valued at $175,000 based on the market price of the common stock, and were recorded as deferred stock compensation on the consolidated balance sheet presented herein, and will be amortized to stock compensation expense over the term of the CA. For the year ended December 31, 2018, the Company amortized $116,167 to stock compensation expense.

On September 5, 2018, the Company recorded 340,352 shares of common stock to be issued pursuant to the APA related to Amos Audiology (See Note 2). The shares were issued on November 27, 2018.

Effective October 10, 2018, the Company issued 500,000 shares of common stock to MEC Consulting, pursuant to the Crone Law Group engagement (see Note 14). The shares were valued at $36,400, based on the market price of the common stock on the date of the engagement.have been issued.

 

During the year endedending December 31, 2018,,2020, the Company issued 42,937 shares of common stock each to two employees as part of their compensation. The Company agreed to issue $20,000 of stock over a six- month period starting November 2018 based on continual employment, to each, based on the average closing price of the Company’s common stock for the 3 days prior to employment, and accordingly recorded stock-based compensation of $6,697, included in Compensation and benefits in the consolidated statement of operations, included herein.

During the year ended December 31, 2018, the Company issued 25,176 shares of common stock to an employee as part of their compensation. The Company agreed to issue $10,000 of stock, over a six- month period starting November 2018 based on continual employment, based on the average closing price of the Company’s common stock for the 3 days prior to employment, and accordingly recorded stock-based compensation of $1,490, included in Compensation and benefits in the consolidated statement of operations, included herein.

On December 12, 2018, the Company issued 34,722 shares of common stock to an employee as part of their compensation. The Company agreed to issue $20,000 of stock, over a six- month period based on continual employment, based on the highest closing price of the Company’s common stock for the 5 days prior to employment, and accordingly recorded stock-based compensation of $1,250, included in Compensation and benefits in the consolidated statement of operations, included herein.

On December 26, 2018, the Company issued 12,588 shares of common stock to an employee as part of their compensation. The Company agreed to issue $10,000 of stock, over a six- month period based on continual employment, based on the average closing price of the Company’s common stock for the 3 days prior to employment, and accordingly recorded stock-based compensation of $745, included in Compensation and benefits in the consolidated statement of operations, included herein.

On December 26, 2018, the Company issued 28,090 shares of common stock to an employee as part of their compensation. The Company agreed to issue $10,000 of stock, over a six- month period based on continual employment, based on the average closing price of the Company’s common stock for the 3 days prior to employment, and accordingly recorded stock-based compensation of $1,685, included in Compensation and benefits in the consolidated statement of operations, included herein.

F-29

On December 26, 2018, the Company issued 37,879 shares of common stock to an employee as part of their compensation. The Company agreed to issue $20,000 of stock, over a six- month period based on continual employment, based on the highest closing price of the Company’s common stock for the 5 days prior to employment, and accordingly recorded stock-based compensation of $1,250, included in Compensation and benefits in the consolidated statement of operations, included herein.

During the year ended December 31, 2018, the Company issued 53,325,2273,286,303,906 shares of common stock for partial conversion of $681,412 of principal and $40,954 of accrued interest, for a total of $722,366.interest.

 

Common Stock to be issued

 

As of December 31, 2018, the Company recorded 1,838,564 shares of common stock to be issued for the conversion of $100,000 of principal and $2,456 of accrued interest, for a total of $102,456. Shares have been issued during year ending December 31, 2019.

 

On October 13, 2018, the Company recorded 1,000,000 shares of restricted common stock to be issued to Erchonia (see Note 14).

 

On December 7, 2018, the Company recorded 3,125,000 shares of common stock to be issued pursuant to the Media Consulting Agreement (see Note 14).Agreement. 1,712,329 of common shares have been issued during the year ending December 31, 2019.

 

On December 31, 2018, the Company recorded 410,284 shares of common stock to be issued pursuant to the CSMA (see Note 14).CSMA. Shares have been issued during year ending December 31, 2019.

 

As of December 31, 2018,2020 and 2019, there are 6,373,848 share s2,415,671 shares of common stock to be issued.

F-22

NOTE 14 – RISKS AND UNCERTAINTIES

The Company's business and operations are sensitive to general business and economic conditions in the United States. A host of factors beyond the Company's control could cause fluctuations in these conditions. Adverse conditions may include recession, downturn or otherwise, local competition or changes in consumer taste. These adverse conditions could affect the Company's financial condition and the results of its operations.

In December 2020, a novel strain of coronavirus (COVID-19) was reported in Wuhan, China and has spread throughout the United States and the rest of the world. The World Health Organization has declared the outbreak to constitute a “Public Health Emergency of International Concern.” This contagious disease outbreak, which has not been contained, and is disrupting supply chains and affecting production and sales across a range of industries in United States and other companies as a result of quarantines, facility closures, and travel and logistics restrictions in connection with the outbreak, as well as the worldwide adverse effect to workforces, economies, and financial markets, leading to a global economic downturn. As a result, the Company experienced a negative impact to its operating results. Regarding future operations, the related financial impact and duration cannot be reasonably estimated at this time.

NOTE 15 – BUSINESS ACQUISITION

ASC Topic 805, "Business Combinations," requires that all business combinations be accounted for using the acquisition method and that certain identifiable intangible assets acquired in a business combination be recognized as assets apart from goodwill. ASC Topic 350, "Intangibles-Goodwill and Other" ("ASC 350"), requires goodwill and other identifiable intangible assets with indefinite useful lives not to be amortized, such as trade names, but instead tested at least annually for impairment and be written down if impaired. ASC 350 requires that goodwill be allocated to its respective reporting unit and that identifiable intangible assets with finite lives be amortized over their useful lives.

On November 22, 2021, the Company purchased Hearing Assist II, LLC. The Company acquired 100% interest in the entity for a total consideration of 591,209,963 common shares valued at $8,513,423 on the day of purchase. As part of the acquisition, the Company assumed assets in the amount of $15,713,000, consisting of trademarks, domains, customer lists, customer contracts, licenses, royalties, other contracts, and assumed liabilities in the amount of $7,199,678. This acquisition was accounted for using the acquisition method of accounting. The fair value of assets, liabilities and intangible assets and the purchase price allocation as of November 22, 2021 was as follows:

Allocation of Purchase Price
$
Assets
Cash44,850
Accounts Receivable789,009
Inventory2,243,947
Other assets83,163
Property and equipment93,632
Total assets3,254,601
Liabilities
Accounts payable4,303,622
Accrued expenses and other current liabilities2,460,785
Other current liabilities2,659,855
Long-term liabilities1,560,510
Total liabilities10,984,772
Net liabilities(7,730,171)
Intangible Asset: Hearing Aid3,000,000
Intangible Asset: Customer Database7,374,450
Intangible Asset: Loyalties5,338,550
Goodwill530,594
Total net assets acquired8,513,423

The purchase consideration of 591,209,963 of the Company’s common stock valued as detailed below:

Number of Common Stock  591,209,963 
Market price on the date of issuance  0.0144 
Purchase consideration $8,513,423 

The following unaudited pro forma consolidated statements of operations for the years ended December 31, 2020 present the Company’s results of operations as adjusted to give effect to the FYE 2021 Transaction as if it had occurred at the beginning of the period. The accompanying unaudited pro forma consolidated balance sheet as of December 31, 2020 presents the Company’s financial position as if the FYE Transaction had occurred on December 31, 2020.

F-23

The unaudited pro forma information below is provided for information purposes only and is not necessarily indicative of what the actual financial position or results of operations of the Company would have been had the transaction actually occurred on the dates indicated, nor does it purport to indicate the future financial position or results of operations of the Company. The pro forma adjustments are based upon available information and assumptions believed to be reasonable in the circumstances. There can be no assurance that such information and assumptions will not change from those reflected in the unaudited pro forma condensed financial statements and notes thereto.

         
INNERSCOPE HEARING TECHNOLOGIES, INC.
PRO FORMA CONSOLIDATED BALANCE SHEETS (Unaudited)
         
  Historical InnerScope Hearing Technologies, Inc. Acquisition    Pro forma combined
  As of December 31, 2020 of Hearing Assist II, LLC Pro forma adjustments As of December 31, 2020
ASSETS                
Current Assets:                
Cash $3,349  $177,834       $181,183 
Accounts receivable, allowance for doubtful accounts  12,429   1,832,042        1,844,471 
Employee advances  3,000             3,000 
Prepaid assets       103,190        103,190 
Inventory  4,671   2,242,409        2,247,080 
Total current assets  23,450   4,355,475        4,378,925 
               —   
Security deposits  4,863             4,863 
Domain name  3,000             3,000 
Other assets       63,260       63,260 
Intangible assets, net of accumulated amortization         (a) 4,410,947   4,410,947 
Property and equipment, net of accumulated depreciation  60,203   78,977        139,180 
Operating leases right-of-use assets, net  364,062             364,062 
Investment in undivided interest in real estate  1,227,733             1,227,733 
Total assets $1,683,311  $4,497,712  $4,410,947  $10,591,970 
                 
LIABILITIES AND STOCKHOLDERS' DEFICIT                
Current Liabilities:                
Bank overdraft  269             269 
Accounts payable and accrued expenses  1,841,302   5,828,561        7,669,863 
Accounts payable to related party  662,178             662,178 
Notes payable - stockholder  95,800             95,800 
Current portion of convertible notes payable, net of discounts  3,255,598             3,255,598 
Note payable, other & related party  118,786             118,786 
Customer deposits  10,925             10,925 
Other current liabilities                    
Current portion of note payable- undivided interest in real estate  22,150             22,150 
Derivative liabilities  4,046,401             4,046,401 
Operating lease liabilities, current portion  365,587             365,587 
Total current liabilities $10,418,996  $5,828,561  $    $16,247,557 
                 
EIDL loan       150,000        150,000 
Long term portion of note payable- undivided interest in real estate  938,003             938,003 
PPP loan  262,445             262,445 
Other long-term liabilities      11,528        11,528 
Long-term loan       1,844,020        1,844,020 
Operating lease liabilities, Less current portion  416,788             416,788 
Total liabilities $12,036,232  $7,834,109  $    $19,870,341 
                 
Commitments and contingencies                
Stockholders' Deficit:               
Members' Capital        4,112,476(a) (4,112,476)     
Preferred stock, $0.0001 par value; 25,000,000 shares authorized;             
Series A preferred stock, par value $0.0001, -0- (2020)  90             90 
Series B preferred stock, par value $0.0001, 900,000 (2020) shares authorized, and 900,000 (2020) shares issued and outstanding                    
Common stock, $0.0001 par value; 14,975,000,000 (2020) shares authorized and 3,628,422,042 (2020) shares issued and outstanding  362,846   —  (a) 59,121   421,967 
Common stock to be issued, $0.0001 par value, 2,412,671 (2020) shares  242             242 
Additional paid-in capital  8,534,062     (a) 8,454,302   16,988,364 
Accumulated deficit  (19,250,161)  (7,448,873)       (26,699,034)
Total stockholders' deficit  (10,352,921)  (3,336,397)  4,400,947   (9,288,371)
Total Liabilities and Shareholder Equity $1,683,311  $4,497,712  $4,400,947  $10,581,970 

F-24

         
INNERSCOPE HEARING TECHNOLOGIES, INC.
PRO FORMA CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
         
  Historical InnerScope Hearing Technologies, Inc. Acquisition   Pro forma combined
  As of December 31, 2020 of Hearing Assist II, LLC Pro forma adjustments As of December 31, 2020
Revenues:        
Revenues, other $166,111  $15,753,402  $    $15,919,513 
Total revenues  166,111   15,753,402        15,919,513 
                 
Cost of sales                
Cost of sales, other  68,768   7,781,088        7,849,856 
Total cost of sales  68,768   7,781,088        7,849,856 
               —   
Gross profit $97,343  $7,972,314  $    $8,069,657 
                 
Operating Expenses:                
Compensation and benefits  661,840   383,625        1,045,465 
Advertising and promotion  19,762   6,893,439        6,913,201 
R&D expense      276,926        276,926 
Professional fees  114,476   193,168        307,644 
Rent, including related party  322,879   129        323,008 
Investor relations  14,796             14,796 
Depreciation and Amortization expense  123,646   109,695        233,341 
Other general and administrative  69,188   765,795        834,983 
Total operating expenses $1,326,585  $8,622,777  $    $9,949,362 
                 
Loss from operations $(1,229,243) $(650,463) $    $(1,879,706)
                 
Other Income (Expense):                
Other income                
Derivative income (loss)  (1,066,904)            (1,066,904)
Gain (loss) on equity investment  30,646   6,889        37,535 
Amortization of debt discount  (1,222,965)            (1,222,965)
Gain/Loss on debt extinguishment       6,000        6,000 
Gain/Loss on lease termination  (201,283)            (201,283)
Other income (expenses)  181             181 
Loss on intangibles  (775,000)            (775,000)
Gain/Loss on assets disposal       (59,093)       (59,093)
Interest expense and finance charges  (489,123)  (448,678)       (937,801)
Total other income (expense), net $(3,724,447) $(494,882) $    $(4,219,329)
                 
Loss before income tax $(4,953,690) $(1,145,345) $    $(6,099,035)
               —   
Income tax provision                   
                 
Net Loss $(4,953,690) $(1,145,345) $    $(6,099,035)
                 
Basic and diluted income (loss) per share  (0.00)          (0.00)
                 
Weighted average number of common shares outstanding                
Basic and diluted  2,769,472,382           2,769,472,382 

The unaudited pro forma consolidated financial statements give effect to the following adjustment:

a.Adjustments to eliminate Hearing Assist II, LLC members’ capital and record issuance of an aggregate of approximately 591,209,963 shares of InnerScope common stock to the Hearing Assist II, LLC members, par value $0.001, in exchange for 100% of equity interests of Hearing Assist II, LLC held by the Hearing Assist II, LLC members in accordance with the Exchange Agreement dated November 22, 2021.

F-25

NOTE 1716 – SUBSEQUENT EVENTS

 

From January 1, 2019,2021, through April 15, 2019,June 30, 2022, the Company received conversion notices for the issuance of 24,010,6372,856,563,078 shares of common stock for conversion of $235,675$3,315,409 of principal and $17,864$992,743 of accrued interest on convertible notes. The Company also issued 870,826 to employees and consultants as well as 730,863 shares for additional consideration for notes previously converted.

From January 1, 2019,2021, through April 15, 2019,June 30, 2022, the Company issued 3,550,893 shares from52,124,378 as part of compensation for services based on the market price of the common stockstock on the date the Company agreed to beissue the shares.

From January 1, 2021, through June 30, 2022, the Company issued as65,000,000 for cash for a total value of December 31, 2018.$650,000.

From January 1, 2021, through June 30, 2022, the Company issued 127,653,805 to settle payables in the amount of $651,034.

 

On January 22, 2019,February 5, 2021, the Company issued to a third-party investor a convertible redeemable note (the “Note”"Note") with a face value of $122,500 and a back-end convertible redeemable note for $122,500.$195,000. The notes matureNote matures on January 22, 2020, haveFebruary 5, 2022, has a stated interest of 8%, and each note is convertible at any time following the funding of such noteNote into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The notes wereNote was funded on January 22, 2019,February 5, 2021, when the Company received proceeds of $220,000,$176,000 after disbursements for the lender’slender's transaction costs, fees, and expenses.

 

On January 29, 2019, the Company received proceeds of $83,333, after disbursements for the lender’s transaction costs, fees and expenses of the remaining balance due of the $280,500 back-end note dated December 24, 2018

On both February 12, 2019, and March 1, 2019, the Company received proceeds of $105,000, after disbursements for the lender’s transaction costs, fees and expenses of the $230,000 back-end note dated December 4, 2018

On February 22, 2019,25, 2021, the Company issued to a third-party investor a convertible redeemable note (the “Note”"Note") with a face value of $116,667.$165,000. The noteNote matures on February 22, 2020,25, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such noteNote into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The noteNote was funded on February 22, 2019,25, 2021, when the Company received proceeds of $100,000,$155,000 after disbursements for the lender’slender's transaction costs, fees, and expenses.

 

F-30

On March 8, 2019,April 6, 2021, the Company issued to a third-party investor a convertible redeemable note (the “Note”"Note") with a face value of $133,333.$165,000. The notes matureNote matures on March 8, 2020, haveApril 6, 2022, has a stated interest of 8%, and each note is convertible at any time following the funding of such noteNote into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The noteNote was funded on March 8, 2019,April 6, 2021, when the Company received proceeds of $114,000,$155,000 after disbursements for the lender’slender's transaction costs, fees, and expenses.

 

On March 20, 2019,July 7, 2021, the Company issued to a third-party investor a convertible redeemable note (the “Note”"Note") with a face value of $89,085 and a back-end convertible redeemable note for $89,085.$165,000. The notes matureNote matures on March 20, 2020, haveJuly 6, 2022, has a stated interest of 8%, and each note is convertible at any time following the funding of such noteNote into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The noteNote was funded on March 20, 2019,July 7, 2021, when the Company received proceeds of $79,875,$155,000 after disbursements for the lender’slender's transaction costs, fees, and expenses.

 

In addition, on March 20, 2019,On August 25, 2021, the Company issued to a third-party investor a convertible redeemable note (the “Note”"Note") with a face value of $89,085 and a back-end convertible redeemable note for $89,085.$165,000. The notes matureNote matures on March 20, 2020, haveAugust 25, 2022, has a stated interest of 8%, and each note is convertible at any time following the funding of such noteNote into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The noteNote was funded on March 20, 2019,August 25, 2021, when the Company received proceeds of $79,875,$155,000 after disbursements for the lender’slender's transaction costs, fees, and expenses.

The Notes issued by the Company accrue interest at a rate of 8% per annum with an increase to 24% in the event of a default and, mature on the one year anniversary of their respective issue date, subject to acceleration in the event of default. Principal and interest on the Notes are convertible into Common Stock of the Company at a price of 70% of the lowest closing bid price of the common stock as reported on the OTCQB exchange or any exchange upon which the Common Stock may be traded in the future, as calculated during the 15- trading day period just prior to the date of notice of conversion.

 

On March 29, 2019, the Company issued 625,000 shares of restricted common stock in settlement of $25,000 of accounts payable owed.

On April 3, 2019, the Company entered into a Consulting Agreement for marketing services pertaining to strategic marketing and public relations campaigns. Pursuant to the agreement the Company ahs agreed to issue 1,000,000 shares of restricted common stock.

On April 12, 2019,September 20, 2021, the Company issued to third party investors, twoa third-party investor a convertible redeemable notes, eachnote (the "Note") with a face value of $208,000.$165,000. The notes matureNote matures on April 12, 2020, haveSeptember 20, 2022, has a stated interest rate of 8%, and each note is convertible at any time following the funding of such noteNote into a variable number of shares of the Compnay’sCompany's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The notes wereNote was funded on April 12, 2019,October 13, 2021, when the Company received proceeds of $350,000 in the aggregate,$155,000 after disbursements for the lender’slender's transaction costs, fees, and expenses.

On October 13, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $330,000. The Note matures on October 13, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on October 13, 2021, when the Company received proceeds of $310,000 after disbursements for the lender's transaction costs, fees, and expenses.

On November 9, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $266,000. The Note matures on November 9, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on November 9, 2021, when the Company received proceeds of $250,000 after disbursements for the lender's transaction costs, fees, and expenses.

On November 15, 2021, the Company sold 30 million shares for aggregate proceeds of $300,000, of which a portion of the proceeds was utilized to pay principal and interest on an outstanding convertible loan in the aggregate amount of approximately $70,000.

On December 21, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $266,000. The Note matures on December 21, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on December 21, 2021, when the Company received proceeds of $200,000 after disbursements for the lender's transaction costs, fees, and expenses.

F-26

On January 13, 2022, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $158,000. The Note matures on January 13, 2023, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on January 13, 2021, when the Company received proceeds of $150,000 after disbursements for the lender's transaction costs, fees, and expenses. The loan was fully forgiven during period end March 31, 2022.

On January 28, 2022, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $262,000. The Note matures October 28, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note at a set price of $0.01 per shares. The Note was funded on January 28, 2022, when the Company received proceeds of $250,000 after disbursements for the lender's transaction costs, fees, and expenses.

On February 28, 2022, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $262,000. The Note matures November 18, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note at a set price of $0.01 per shares. The Note was funded on February 28, 2022,, when the Company received proceeds of $250,000 after disbursements for the lender's transaction costs, fees, and expenses.

On March 11, 2022, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $262,000. The Note matures December 11, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note at a set price of $0.01 per shares. The Note was funded on March 11, 2022, when the Company received proceeds of $250,000 after disbursements for the lender's transaction costs, fees, and expenses.

On March 30, 2022, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $262,000. The Note matures December 31, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note at a set price of $0.01 per shares. The Note was funded on March 30, 2022, when the Company received proceeds of $250,000 after disbursements for the lender's transaction costs, fees, and expenses.

On April 29, 2022, the Company issued to a third-party investor a conventional note payable(the "Note") with a face value of $262,000. The Note matures April 29, 2023, has a stated interest of 8% The Note was funded on April 29, 2022, when the Company received proceeds of $262,000 after disbursements for the lender's transaction costs, fees, and expenses.

On June 8, 2022, the Company issued to a third-party investor a conventional note payable(the "Note") with a face value of $162,500. The Note matures June 8, 2023, has a stated interest of 8%. The Note was funded on June 8, 2022, when the Company received proceeds of $150,000 after disbursements for the lender's transaction costs, fees, and expenses.

On June 13, 2022, the Company issued to a third-party investor a conventional note payable (the "Note") with a face value of $265,625. The Note matures June 13, 2023, has a stated interest of 8% The Note was funded on June 13, 2022, when the Company received proceeds of $255,000 after disbursements for the lender's transaction costs, fees, and expenses.

On June 21, 2022, the Company issued to a third-party investor a conventional note payable (the "Note") with a face value of $91,750. The Note matures June 21, 2023, has a stated interest of 8% The Note was funded on June 21, 2022, when the Company received proceeds of $85,000 after disbursements for the lender's transaction costs, fees, and expenses.

On June 23, 2022, the Company issued to a third-party investor a conventional note payable (the "Note") with a face value of $113,335. The Note matures June 23, 2023, has a stated interest of 8% The Note was funded on June 23, 2022, when the Company received proceeds of $105,000 after disbursements for the lender's transaction costs, fees, and expenses.

On May 24, 2022, the Company issued to a third-party investor a conventional note payable (the "Note") with a face value of $600,000. The Note matures May 24, 2023, has a stated interest of 10%. The Note was funded on May 24, 2022, when the Company received proceeds of $600,000. The note is secured by all company’s assets.

On May 24, 2022, the Company issued to a third-party investor a conventional note payable (the "Note") with a face value of $600,000. The Note matures May 24, 2023, has a stated interest of 10%. During period end June 30, 2022, Company received funds in the amount of $300,000. Second half of the note amount was received subsequently to period end. The note is secured by the real property.

On November 22, 2021, the Company purchased Hearing Assist II, LLC. The Company acquired 100% interest in the entity for a total consideration of 591,209,963 common shares valued at $8,513,423 on the day of purchase. As part of the acquisition, the Company assumed assets in the amount of $15,713,000, consisting of trademarks, domains, customer lists, customer contracts, licenses, royalties, other contracts, and liabilities in the amount of $7,199,678

On September 30, 2021, the Company entered into an Asset Purchase agreement with iHear Medical, Inc. pursuant to which the Company received a number of intangible assets, equipment, customer database and inventory for a total consideration of 400,000 preferred series C shares and $1,000,000 convertible note. Preferred shares valued at $666,667 on the day of purchase. As part of the acquisition, the Company assumed assets in the amount of $1,666,667, consisting of inventory, equipment, customer lists, patents and other technology-based intangibles.

 

The Company has evaluated subsequent events through the date the financial statements were issued and filed with the Securities and Exchange Commission. The Company has determined that there are no other such events that warrant disclosure or recognition in the financial statements, except as stated herein.

 

 

F-27

F-31